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ABSTRACT 
 
 
 
This dissertation introduces the development and scope of automated solution-phase 
oligosaccharide synthesis based on fluorous tags. Compared to previously developed solid-
phase and one-pot strategies, the new automated solution-phase methodology offers a more 
versatile platform for various solution-phase reaction conditions, with lower amounts of 
donor building blocks wasted. In addition, the fluorous-tag assisted solid-phase extraction 
was shown to be robust enough for automated purification steps to eliminate excess 
reagents. The optimization process that was required to be taken into account when designing 
a program to construct the complex oligosaccharide compounds is described in detail. The 
optimized protocols for automated oligosaccharide synthesis were then applied to the 
construction of oligosaccharides associated with anthrax and cholera infection. Chemistry 
was developed that allowed the simultaneous automated synthesis of both the anthrax- and 
cholera-associated oligosaccharides. Finally, a solution to solve limitations of a single 
fluorous tag strategy is presented. A di-tagged saccharide molecule was synthesized and 
tested under conventional bench-top conditions to obtain information on its robustness as 
applied to a glucosamine monosaccharide. This initial work was then extended to the 
automation platform and compared to the original mono-tagged strategy. For direct 
comparison, the two fluorous tags were incorporated into the initial rhamnose building block 
and were successfully made robotically. A second fluorous protecting group and new donor 
strategy were also introduced into the automated platform, thereby expanding the scope of 
the reactions and building block possibilities for future studies. By introducing the 
 vii 
development, application and alternative strategic examples, this dissertation offers a new 
convenient and robust synthetic method for oligosaccharide construction. 
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CHAPTER 1 
Review: Automated Solution-Phase Oligosaccharide Synthesis    
Portions of this chapter will be submitted to Advances in Carbohydrate Chemistry and 
Biochemistry 
Gisun Park and Nicola L. B. Pohl* 
 
General Introduction 
Dissertation organization 
 
This dissertation is divided into six chapters. The first chapter is a general literature 
review that is related to the chemistry discussed in chapters 2 through 5. Chapter 1 is a review 
of the development and scope of automated solution-phase oligosaccharide synthesis. The 
chapter compares the advantages and limitations of this new strategy with the previously 
developed solid-phase and one-pot strategies. Chapter 2 discusses the original process to 
develop the first automated solution-phase synthesis on an Automated Synthesis Workstation 
(ASW) 1000 robotics platform. This chapter describes the detailed optimization processes that 
were required to design a program to construct oligosaccharide compounds through iterative 
coupling/deprotection cycles using a single fluorous tag for fluorous solid-phase extractions 
(FSPE) between cycles. Chapter 3 demonstrates the application of the automated 
oligosaccharide synthesizer to the construction of biologically relevant molecules. Methods 
were developed to synthesize both the anthrax- and cholera-associated antigenic 
tetrasaccharides side by side on the platform simultaneously. Chapter 4 was published in The 
 2 
Journal of Fluorine Chemistry in 2008. This chapter follows up the previous chapters by 
introducing a solution to the occasional problem of purification issues related to incomplete 
reactions. A di-fluorous-tagged saccharide molecule was synthesized and tested under 
conventional bench-top conditions to obtain information about the robustness of FSPE-based 
separation of the di-fluorous-tagged molecule from mono- or untagged molecules. In chapter 
5, work to automate this new di-fluorous-tagged strategy is reported and compared to the 
original strategy discussed in chapter 2. Two fluorous tags were incorporated into a rhamnose 
building block for robotically-controlled synthesis. A second fluorous protecting group and a 
new donor strategy were also introduced into the automated platform, thereby expanding the 
scope of reactions and building block possibilities available for future work with this platform. 
Chapter 6 provides a summary and general conclusions for the entire dissertation. 
 
1. Introduction 
 
2. Challenges in the chemical synthesis of carbohydrates 
 
2-1.  Background 
 
Structure/function studies of carbohydrates have clearly lagged behind related studies 
of peptides and nucleic acids. Isolation of pure structurally well-defined oligosaccharides 
from natural sources is particularly challenging given the heterogeneity and diversity of this 
class of biomolecules. However, the growing recognition of the importance of carbohydrates 
in cell-cell interactions-between different cell types in the same organism and between two 
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organisms, such as a pathogen and its host, has spurred greater interest in the problems 
related to obtaining pure oligosaccharides of known composition. 
 
Chemical synthesis has proven to be a great solution to creating diverse structurally 
well-defined peptides and nucleic acids, especially as the stepwise iterative chemical 
synthesis of these biomolecules has been amenable to automation. Although oligosaccharides 
in their protected form rarely have the same aggregation problems that plague peptide 
synthesis, for example, oligosaccharides present their own set of special challenges. Unlike 
linkages between nucleic acid and amino acid building blocks, the linkages between sugars 
can be of two different stereochemical orientations that profoundly alter the shape and 
consequently also bioactivity of the resulting structures. In addition, sugars contain many 
identical functional groups, namely hydroxyls, which must be differentiated to control the 
regioselectivity of the linkages between monomers.  
 
Given the chemical challenges of linking monomeric sugar building blocks, the 
protecting (or masking) group strategy of each building block is a crucial part of 
oligosaccharide synthesis. Protecting groups can control the stereochemistry of the anomeric 
linkage during a glycosylation reaction through anchimeric assistance or conformational 
control and can tune the relative reactivity of a glycosyl donor or acceptor. In addition, 
protecting groups are the most reliable way to block the many hydroxyl groups and possibly 
other functional groups that constitute sugar building blocks to allow only the desired linkage 
to form. Some functional groups can be masked with groups that are only removed at the 
very end of the synthesis, whereas hydroxyl groups involved in interglycosidic linkages are 
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masked with a group that can be selectively removed prior to coupling. Although necessary 
given the very slight, if any, inherent reactivity differences between hydroxyl groups, the use 
of various protecting groups significantly lengthens the synthesis of each individual 
monomer unit. A monomer can require 5-14 linear steps to make, thereby making the 
building blocks particularly precious. 
 
Finally, the incredible diversity of naturally-occurring sugars further complicates their 
facile synthesis. Most proteins can be made from 23 canonical amino acids. Human 
oligosaccharides contain primarily only nine basic building blocks. However, the synthesis of 
bacterial, plant, and other oligosaccharides requires access to a much larger variety of 
monosaccharides. 
 
3. Automated oligosaccharide synthesis 
 
3-1.  One-pot method 
 
The first automated process for at least oligosaccharide synthesis design is called the 
one-pot method and was introduced by C.-H. Wong and coworkers [1, 2]. This method relies 
on the differential reactivity of carbohydrate building blocks provided by different protecting 
groups. The most reactive glycosyl acceptor building block reacts first with a glycosyl donor; 
then this newly formed disaccharide is activated for reaction with the next most reactive 
glycosyl acceptor. Data from empirical testing of dozens of protected building blocks, 
primarily those associated with mammalian glycosides, are now part of a computer program 
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that allows a user to quickly sort out the best building block combinations for a successful 
one-pot manual synthesis [3, 4]. Unfortunately, the challenges in providing building blocks 
with significant enough reactivity differences to avoid mixtures limits the method practically 
to the formation of two glycosidic linkages. This elegant approach does avoid the problems 
of requiring large excesses of donor building blocks required for biphasic processes. Future 
studies could possibly result in the development of an interface between this computerized 
oligosaccharide design program and a robotics platform to carry out the optimal synthesis. 
 
3-2.  Solid-phase oligosaccharide synthesis 
 
The first example of the robotically controlled synthesis of oligosaccharides 
comparable to automated nucleic acid and peptide synthesis was reported in 2001 by P. 
Seeberger and coworkers [5]. This process relies on the conversion of a conventional solid-
phase peptide synthesizer with the addition of a cooling unit required for some trickier 
glycosylation reactions. As in solid-phase peptide synthesis, a robot delivers soluble reagents 
and building blocks to a reactor containing the resin with the growing oligosaccharide chain 
and then rinses excess reagents from the resin. Unfortunately, the reported process calls for 
20 equivalents of building blocks at each coupling cycle. Therefore, even very efficient 
coupling yields would still generate 57 equivalents of wasted building blocks after only three 
cycles. In addition, the success of reactions cannot easily be monitored on the resin while a 
program runs. Even if mistakes are caught using solid-phase NMR spectrometry, the only 
options are to stop the run entirely or to continue to the end with the hope of purifying away 
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all the undesired sequences. The growing chain cannot be removed from the synthesizer, 
purified, and readily returned to the automation platform. 
 
4. Principles of automated solution-phase oligosaccharide synthesis 
 
4-1.  Automation platform 
 
Unlike polynucleotides [6] and peptides/proteins [7], oligosaccharides still lack a 
commercially available platform for their synthesis. The existing platforms for automation 
are based on the use of solid-phases, which provide robotic rinsing of resins. For the first 
automated solution-phase platform, we optimized a Chemspeed Automated Synthesis 
Workstation (ASW) 1000. The ASW consists of three main stations, the reactor block, SPE 
(solid-phase extraction) block and reagent racks (Fig. 1-1, Fig. 1-2). The reactor block 
contains the reactor vials that are made of double-jacked glassware and varies in size from 8 
mL (× 16) to 100 mL (× 4) in volume, even for gram scale syntheses. Between the double-
layered glassware flows the HTF (heat-transfer) oil that circulates around the reactor vials 
and connects to a unit that is capable of cooling the HTF to -20 oC or heating it to 250 oC for 
temperature-controlled reactions. A ceramic drawer opens/closes the reactor vials to air/inert 
gas/vacuum depending on the task that it is programmed to perform. The SPE (solid phase 
extraction) block was reengineered as described below in descriptions of the purification 
tool. 
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Figure 1-1.  Layout of the Automated Synthesis Workstation. 
 
 
 
Figure 1-2.  Schematic Design of the Automated Synthesis Workstation 1000  
 
5-2.  Purification tool 
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Although Bruce Merrifield used a solid-phase to prevent aggregation of growing 
peptide chains through spatial segregation, aggregation of growing oligosaccharide chains 
is rarely if ever a problem. The main use for a solid-phase resin then is for ease of isolation 
of the intermediates and removal of unreacted building blocks, decomposed building 
blocks, and excess reagents and their byproducts. Unfortunately, the resulting biphasic 
conditions then require an excess of not only reagents, but also the precious carbohydrate 
building blocks that often require up to ten or more steps to synthesize. In addition, the 
heterogeneity of reactive sites within the resins significantly complicates the translation of 
traditional solution-phase chemistry onto a solid-phase. For these reasons, a solution-phase 
approach is preferable. However, an appropriately robust alternative purification strategy is 
needed as well as a completely new type of automation platform. 
 
A fluorous synthesis approach has the potential to be such an alternative purification 
strategy. Fluorocarbon solvents can form a ‘third phase’ that usually is immiscible both 
with aqueous and conventional organic solvents [8]. Therefore, a standard liquid-liquid 
extraction can be used to isolate the fluorous molecules into a fluorocarbon layer, while 
other reagents and materials partition into aqueous or organic layers. Unfortunately, for 
reliable extraction into the fluorocarbon layer, organic molecules often have to be tagged 
with multiple fluorous tags, so-called heavy fluorous synthesis, thereby often rendering the 
molecules insoluble in standard organic reaction solvents. When this simple yet effective 
method is applied, the reaction mixtures can be purified without standard silica gel 
chromatography, which is a challenging step to have as an automated process. The fluorous 
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properties were demonstrated in many aspects and proved to be generally applicable to a 
wide range of synthetic conditions.  
 
Soluble fluorocarbon tags have been employed in the synthesis of a variety of 
carbohydrate molecules. A heavy fluorous tag could be incorporated into a protecting group 
to allow easy extraction or a light fluorous tag could be used to attract the tagged molecules 
by using a fluorinated silica gel in a solid-phase extraction process. [9] Although both 
heavy and light tags were developed for oligosaccharide synthesis, using heavy fluorous 
tags as protecting groups [10] was less attractive in our method, because of the necessity to 
include multiple fluorocarbon tails that results in a narrow solvent range for reaction 
conditions. On the other hand, using a single light fluorous tag was completely compatible 
with most of the oligosaccharide reaction conditions (Fig. 1-3). In addition, unlike other 
tagging methods that have been applied to carbohydrate chemistry, such as lipid or 
polyethylene glycol tags, [11-14] the fluorous tags are silent under standard characterization 
methods and orthogonal with different protecting group strategies. After simply loading the 
crude mixture from the reactor vials onto the FSPE cartridge, untagged molecules are eluted 
out and directed to the waste container, while the tagged molecules are directed to a vial 
placed underneath by changing the fluorophilicity of the solvent used. [15] Also a 2-carbon 
less C6F13 tag was tested to prove that it contained enough fluorous content to serve as a 
purification tool under identical procedures as the C8F17 [15].  
 
  As mentioned above, the SPE (solid phase extraction) block needed to be 
reengineered to hold the larger amount of fluorous silica gel required for fluorous solid-phase 
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extractions as opposed to normal silica gel-based solid-phase extractions. Commercially 
available 10 cc FSPE cartridges allow up to 200 - 300 mg of crude product to load for 
purification during the synthesis cycles. The question, however, was whether such a 
noncovalent fluorous interaction between tagged compounds and the fluorous silica gel 
would be reliably robust enough to find a single protocol for facile purification of the desired 
tagged compound from other reaction byproducts. Fortunately, we have now shown that even 
with a variety of saccharides, FSPE works successfully under automated conditions to retain 
fluorous-tagged compounds more strongly than the non-fluorous containing compounds. The 
FSPE task is important in that it offers an opportunity during the synthetic cycle to filter out 
any excess reagents or failed sequences to avoid accumulation of undesired byproducts in the 
solution mixture. This purification method then provides a convenient way to make a 
solution-phase approach in operating iterative cycles for oligosaccharide synthesis actually 
viable. 
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Figure 1-3.  Fluorous Solid-Phase Extraction. 
 
5-3.  Automated Synthesis of Poly α-(1→2)-L-Rhamnosides 
 
To further consider the variables for optimizing the reaction conditions on the 
automated platform, we started with our fluorocarbon tagged α-(1→2) rhamnoside building 
blocks 1 as initial substrates. After having the rhamnose building block activated as the 
trichloroacetimidate form 2, [16] it is attached to the fluorous-tagged acceptor 1 under 
acidic conditions. Ester functionality was required to be present at the O-2 position for 
stereochemical control of the anomeric center for glycosylation reactions. Having the first 
fluorous-tagged acceptor in hand, the synthetic cycle was built in a way for the activated 
donor to add on to the acceptor to elongate the saccharide chain (Fig. 1-4). Each synthetic 
cycle consists of three steps. The first step is to glycosylate using trimethylsilyl 
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trifluoromethanesulfonate (TMSOTf) to activate a trichloroacetimidate donor. Next is a 
deacetylation step with sodium methoxide in the same reactor vial. The automated solution-
phase approach is extremely attractive, because all the traditional manual solution phase 
chemistry could be directly transferred into the automated workstation without changes. 
Also, most importantly, the approach does not require a large excess of donor building 
blocks for the reactions. For example, for most of the glycosylation reactions, less than 3 
equivalents of donor building blocks were used. After the deprotection step, the crude 
reaction mixture is carried to the fluorous solid-phase extraction (FSPE) workstation, where 
the desired fluorinated compound and the non-fluorinated byproducts can be easily 
separated due to noncovalent fluorous-fluorous interaction between the fluorous-tagged 
oligosaccharide and the fluorinated silica gel [17]. Removal of the excess donor/byproducts 
is simply accomplished by washing the FSPE cartridge with an 80% methanol/water 
solution several times. Finally, the robotically-controlled needle pushes the FSPE block so 
that the cartridge is aligned directly above a vial to collect the eluted solution when the 
solvent is changed to 100% methanol. The eluted solution containing the desired tagged 
product is carried to a clean reactor vial for solvent removal, especially of water that could 
interfere with the following glycosylation reaction, and the chain-elongated glycosyl 
acceptor is ready for the next cycle.  
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Figure 1-4.  Automated solution phase synthesis of rhamnose pentasaccharide. 
 
For the rhamnose building block, after 4 cycles, pentamer 3 was obtained in 24 hours 
and 16% overall yield under automated conditions. For comparison, when made under 
conventional conditions, the entire scheme would take more then 30 hours; even more time 
would be required if conventional silica gel purification schemes had to be worked out after 
each reaction step. To make the acquisition general for a wide range of sugar substrates, the 
process required further optimization. For glycosylation conditions, toluene was substituted 
for 1,2-dichloromethane due to the heat generated during the machine run that resulted in 
partial evaporation of stock solutions that altered concentrations. In addition, toluene, in 
which water is somewhat miscible, was used as the reservoir rinsing solvent for rinsing the 
needle to eliminate any small quantities of water and impurities. One major remaining 
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concern was the observation that most of the loss in overall yields occurred because of 
incomplete transfer tasks. Therefore, to decrease the amount of dead volume during 
transfer, flat tip needles and canonically shaped sample vials were used. With these 
necessary changes made (Table 1-1), the method was able to produce an average of 
approximately 80% yield per reaction step consistently. 
 
Step Task Reagent/ Operation Operation 
Time 
1 
 
 
2 
3 
4 
5 
6 
7 
8 
9 
 
 
10 
11 
12 
13 
14 
15 
Glycosylation 
 
 
TLC sample 
Quenching 
Evaporation 
Deacetylation 
TLC sample 
Quenching 
Evaporation 
FSPE 
preparation 
Sample loading 
Wash 
Wash 
Transfer 
Evaporation 
Transfer 
Evaporation 
 
1.5 equivalent donor  (75 µmol) in 0.5 mL toluene, 
1 equivalent F-tagged acceptor (50 µmol) in 1 mL 
toluene; 0.3 equivalent TMSOTf, 0 oC 
30 µL of crude reaction mixture withdrawn 
0.5 mL TEA 
40 oC 
3 equivalent of NaOMe solution 
30 µL of crude reaction mixture withdrawn 
0.3 mL 0.5 M Acetic acid solution in MeOH 
50 oC 
 
0.4 mL DMF 
0.7 mL crude sample transferred to cartridge 
4.7 mL 80% methanol wash 
1.5 mL methanol wash (repeated 3 times) 
4.7 mL collected sample transferred to clean vial 
50 oC 
2 mL toluene added 
50 oC 
1-15 repeated for additional cycles 
45 min 
 
 
 
 
45 min 
3 h 
 
 
45 min 
 
 
 
 
 
 
45 min 
 
45 min 
 
Table 1-1. Description of Tasks Programmed in a Single Cycle. 
 
6. Examples of automated solution-phase oligosaccharide synthesis  
 
6-1.  1,2-Trans Glycosidic Linkages 
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a. Synthesis of Pentamannose 
 
With an initial solution-phase-based automation platform and basic robotics protocols 
for the requisite glycosylation/deprotection/purification steps in hand, the next challenge 
was testing the robustness of these protocols for the synthesis of a range of sugars. Since 
automation is adopted to save time, extensive reprogramming of the machine for each new 
oligosaccharide desired has to be avoided. To start, the automation protocol was applied to 
the simplest oligosaccharide synthesis problems, those in which neighboring group 
assistance can be used to easily control the synthesis of 1,2-trans-linkages. Once the 
original program was created and the general problems were solved, we started to apply the 
method to different oligosaccharide compounds. To begin with, we decided to construct α-
mannosides, which are substantially studied because of their occurrence in biological 
structures, such as glycolipids and N-linked glycoproteins. [18, 19] Having a neighboring 
group participant on the O-2 position will help achieve the desired 1,2-trans glycosidic 
linkage during the automated process. In addition, the initial building block should bear the 
fluorous tag on its reducing end for the chain extension/purification to occur. The α-
mannoside 4 (Fig. 1-5) is a perfect example to test the generality of the new method for its 
use for more complex molecules. 
 
 
O
BnO
BnO
BnO
O O
C8F17
4
4
O
BnO
BnO
AcOBnO
O
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Figure 1-5. α-Mannoside. 
 
With the appropriate protecting groups in place, the fluorous-tagged monomer was 
injected into the machine along with the trichloroacetimidate donor molecule. [20] After 3.5 
automation cycles, the desired pentasaccharide was synthesized within approximately 25 
hours in 11% yield. Each cycle only required 2 equiv. of donor molecules per glycosylation, 
rather than the 20 equiv reported for the solid-phase synthesis cycles of a mannose oligomer 
[5], and the excess donor was washed away during the FSPE step before starting a new 
cycle (Fig. 1-6). The initial program for the rhamnose oligosaccharide was directly applied 
and successfully produced the desired oligosaccharide compound. 
 
 
Figure 1-6. Automated synthesis of pentamannose. 
 
 
a. Synthesis of Cholera tetrasaccharide 
O
BnO
BnO
OHBnO
O O
C8F17
3.5 automation cycles
O
BnO
BnO
OAcBnO
O O
C8F17
5
Glycosylation (30 min)
Deacetylation (2 h)
Fluorous Solid Phase 
Extraction (FSPE)
O
BnO
BnO
OAc
O
BnO
CCl3
NH
6
5 4
Ac = Acetyl
Bn = Benzyl
TMSOTf = Trimethylsilyl trifluoromethanesulfonate
2 equiv.
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Cholera, a diarrheal disease caused by the gram-negative bacterium Vibrio cholerae is 
known to have a repeating terminal hexasaccharide of Ogawa lipopolysaccharide (LPS). 
[21] Interestingly, synthetic oligosaccharide antigens that were conjugated to BSA showed 
immunogenicity regardless of the number of saccharide monomers present. The minimum 
number of sugars tested were reported to be four. The tetrasaccharide version of the 
oligosaccharide unit was programmed to be synthesized under automated conditions. The 
repeating D-rhamnose building block contains a 4-amino functionality, which could be 
installed as a more stable azido group for the automated chain elongation process. Also, the 
1,2-trans glycosidic linkage requires a neighboring group participant for the 
stereoselectivity of the molecule.  
 
The initial acceptor molecule with the fluorous tag on the reducing end [22] was then 
injected into the automation workstation (Fig. 1-7). After 18 hours, the desired perosamine 
tetrasaccharide was synthesized in 2.5 cycles in 23% yield. 
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Figure 1-7. Automated synthesis of an antigenic cholera-associated tetrasaccharide. 
 
 
After careful silica gel purification, the resulting azido tetrasaccharide was subjected 
into AIBN, Bu3SnH conditions to reduce the azido groups to amines and was attached to 
the prepared side chains. After global deprotection, the target tetrasaccharide was 
completed. Conveniently, the mono-, di-, and tri- versions of the cholera oligosaccharide 
could be accomplished in one single machine run for further studies. The cholera 
tetrasaccharide was successfully synthesized by using the standard glycosylation protocols 
and conditions that were previously established requiring no additional setup time.  
 
c. Synthesis of anthrax tetrasaccharide 
 
Anthrax tetrasaccharide was also synthesized under automated conditions. Bacillus 
anthracis, which has spores called anthrax, is a well known cause of serious infections in 
2.5 automation cycles
Glycosylation (30 min)
Deacetylation (2 h)
Fluorous Solid Phase 
Extraction (FSPE)
Ac = Acetyl
Bn = Benzyl
TMSOTf = Trimethylsilyl trifluoromethane sulfonate
2 equiv.
O
BnO
OH
N3
O O
C8F17
O
BnO
OAc
N3
O CCl3
NH
8
O
BnO
OAc
N3
O O
C8F17
4
7 9
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cattle and other herbivores [23]. The structure of an antigenic surface oligosaccharide of the 
bacteria contains an exotic sugar called anthrose. This unusual terminal sugar is not found 
even in closely related species, which makes it an interesting target for carbohydrate-based 
vaccines and diagnostics for anthrax. A silyl protecting group was first introduced as a 
temporary protecting group to be used under automation. The tert-butyldimethylsilyl group 
was used to mask the O-3 position of the first donor and was deprotected under 
tetrabutylammonium fluoride conditions. Also the second donor was designed to bear a 
levulinate protecting group on the O-2 position to act as both a neighboring group 
participant and a temporary protecting group. For the deprotection of both new protecting 
groups, a TBAF solution in THF and the hydrazine acetate in methanol/dichloromethane 
were prepared in vials and placed at the reagent rack. After 35 hours, the desired 
tetrasaccharide 13 was synthesized in 18% overall yield. [22] Only 2 equivalents of donor 
was used for each glycosylation reaction (Fig. 1-8) and after careful standard silica gel 
purification, the obtained molecule was ready to be methylated, coupled to the side chain, 
and fully deprotected to give the anthrax tetrasaccharide. 
 
 
Figure 1-8. Automated synthesis of anthrax tetrasaccharide. 
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This was an excellent example where it shows that most of the solution-phase 
chemistry was easily transferrable to the automated solution-phase conditions. Silyl and 
levulinoyl groups proved to be good choices as temporary protecting groups to be 
unmasked in high yields to provide further chain elongation sites. 
 
6-2.  1,2-Cis Glycosidic linkages 
 
              a. Synthesis of Blood Group H  
 
1,2-Cis glycosidic linkages are well known to be challenging to synthesize in good 
yields, but are also often found in a range of naturally-occurring oligosaccharides [24]. To 
expand the utility of the automated platform, the next goal was to design a program to target 
1,2-cis linked carbohydrates. Blood group H was chosen as an ideal target because it 
contains both a 1,2-cis and a 1,2-trans-linkage. For the β-(1,4)-trans galactosidic linkage, a 
neighboring group strategy could be applied. For the cis-linked fucose, a nonparticipating 
protecting group at the 2-position hydroxyl and careful solvent choice could aid formation 
of this alpha-linkage. 
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Figure 1-9.  Automated Synthesis of Blood Group H. 
 
After careful design of the protecting group strategy for the three saccharide building 
blocks, each was synthesized from glucosamine hydrochloride, galactose or fucose [25]. 
With the building blocks in hand, the automated-solution-phase synthesis protocol was 
applied (Fig. 1-9). The α-fucosidic linkage was programmed to use 3 equivalents of donor 
molecule at -15 oC for 15 minutes. After 1.5 cycles and careful purification, the desired 
trisaccharide was obtained in 34% overall yield. The α-(1,2-cis) fucosidic configuration 
was supported by the small J1,2 coupling constant (J = 3.6 Hz) in the proton NMR spectra 
and the J1,2 coupling constant (J1,2 = 8.0 Hz) associated with the glucose building block 
demonstrated the β-(1,2-trans) glucosidic linkage. The anomeric proton on the galactose 
moiety overlaps with other protons and the anomeric configuration was determined by the 
one bond 13C-1H coupling constant (1JC1,H1 = 162 Hz). [26] The coupling constants from 
NMR experiments prove that the 1,2-cis glycosidic linkage was achieved under unattended 
matter by simply applying solvent effects into the reactor vial. 
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         b. Synthesis of Rhamnogalacturonan I  
 
Rhamnogalacturonans (RGs) are a group of closely related cell wall pectic 
polysaccharides that contain a backbone of a repeating disaccharide with alternating 1,2-cis 
and 1,2-trans glycosidic linkages throughout the structure of the oligosaccharide. Pectins 
have roles in plant growth, development and diseases resistance and are used as gelling 
agents in the food industry and coatings in medical devices. [27] Studies have revealed that 
the altering RG structure may have significant affects on plant growth and development. 
[28] However, little is known about the biosynthesis of RG1 and its specific molecular 
interactions as well-defined structures are difficult to isolate from heterogeneous natural 
sources and the RG compound itself has not been made by chemical synthesis. [29] 
 
To access specific molecular fragments for such studies, we have developed a flexible 
strategy to access a range of RG1 structures from five different rhamnose and galactose 
building blocks. An α-1,4-linked galacturonic acid and β-1,2-linked rhamnose units were 
prepared for the synthetic method. The rhamnose residues could be substituted at O-4 with 
linear and/or branched size-heterogeneous oligoglycosyl side chains composed of α-L-Araf 
and β-D-Galp residues. These building blocks served as inputs for a new fluorous-tag based 
automated protocol (Fig. 1-10) for the iterative solution-phase synthesis of a discrete library 
of rhamnogalacturonan 1 fragments. 
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Figure 1-10. Automated Synthesis of RG1 Backbone.  
 
             c. Synthesis of β-Mannosides  
 
The prevalence of β-mannoside residues in glycoconjugates and other naturally 
occurring compounds such as N-linked glycoproteins [30] and plant polysaccharides, [31] 
O-specific polysaccharides of Gram negative bacteria [32] has resulted in the development 
of a number of methodologies toward their synthesis. However, the synthesis of a β-
manoside linkage has been a challenge for a long time. This linkage is disfavored by the 
stereoelectronic effects of the n→σ* interaction between the nonbonding electrons of the 
ring oxygen and the antibonding orbitals of the anomeric substituent when it is in the α-
position. As a result, any generation of the carbonium ion tends to favor the α-mannoside. 
[33] 
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For the synthesis of this target, a new automated strategy had to be pursued (Fig. 1-
11). A glucose donor 22 was prepared instead of the mannose trichloroacetimidate donor. 
And after obtaining the β-anomer by using a neighboring group participant, the O-2 
position went through an oxidation/reduction step to invert the stereochemistry for 
achieving an axial hydroxyl group, thereby resulting in a β-mannoside linkage. [34] 
           
Figure 1-11. Automated Synthesis of β-Mannosides: Oxidation/Reduction Strategy  
 
However, unlike other cases in which only a single FSPE is required at the end of 
each cycle, a single cycle here required two additional purification tasks. These additional 
transfer steps resulted in a substantial amount of material loss even when programmed to go 
through only two cycles. The automated oxidation/reduction protocol proved to be 
successful under similar automated conditions as previous molecules, but would not be as 
efficient when building saccharide chains containing multiple β-mannosidic-linkages.  
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To improve the product yields while achieving the difficult 1,2-cis linkage, an 
alternative attempt was pursued. It was shown that glycosylations of mannuronic ester 
donors resulted in high α stereoselectivity producing the 1,2-cis linkages [35] by a remote 
stereodirecting effect of the C-5 carboxylate group. Therefore, after synthesis of the 
requisite mannuronic acid building block, similar reaction conditions were applied to the 
mannuronic ester donor and successfully produced the desired β-di-mannuronic ester 
compound in moderate yields (Fig. 1-12). The resulting disaccharide 27 was then reduced at 
the C-6 position to give the β-di-mannoside compound. The design and implementation of 
these different strategies to make the beta-mannosides shows the range of reactions that can 
be readily accessible on a solution-phase automation platform. 
 
 
 
Figure 1-12. Alternative Scheme for Automated Synthesis of β-Mannosides  
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6-3. Branched Sugars 
 
a. Synthesis of β-Glucans 
  
An orthogonal protecting group strategy is especially important if there are specific 
positions that need to be unmasked for further chain elongations. In addition to linear 
oligosaccharide targets, a branched β-glucan fragment was selected as a target molecule. By 
synthesizing a tetrasaccharide version of the β-glucan fragment, we envisioned that this 
would allow us to demonstrate the ability to extend two sugar chains independently from a 
single branch point sugar unit. The β-glucan tetrasaccharide consists of 1,2-trans glycosidic 
linkages among the structure requiring a neighboring group participant as O-2 position 
protecting groups, as well as temporary protecting groups that are orthogonal to the rest of 
the masked positions on the branch point sugar molecule. The levulinate protecting group 
was introduced for use as a temporary protecting group for the synthesizer. The required 
deprotection conditions are mild and orthogonal to the rest of the molecule and indeed 
proved to be amenable to automation.  
 
With the requisite building blocks in hand the automated synthesis of 32 was 
undertaken (Fig. 1-13). The target molecule 32 was obtained in 9.4% overall yield [36] over 
five chemical steps in seventeen hours. 
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Figure 1-13. Automated Synthesis of β-Glucans. 
 
b. Synthesis of streptococcus 
 
Group A streptococcus (GAS) and Staphylococcus aureus are known causes of 
cellulitis, a poorly treatable skin disease. There is no known vaccine for the treatment of the 
disease, and in order to develop any against these bacterial infections, the key cell wall 
oligosaccharide 33 [37] was synthesized under automated conditions (Fig. 1-15).   
 
 
Figure 1-14. Automated synthesis of a streptococcus-associated oligosaccharide. 
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The polysaccharide contains a dirhamnose/glucosamine repeating unit. The core 
trisaccharide unit (tetrasaccharide unit shown in Fig. 1-14) was designed to be synthesized 
with the initial fluorous tagged-rhamnose building block. The second rhamnose and the 
glucosamine building blocks were then incorporated to build up the growing saccharide 
chain. The second rhamnose unit also acts as the potential branch point for further 
glycosylations to occur to access other naturally-occurring polysaccharide fragments. 
 
 
Figure 1-15. Automated synthesis of a streptococcus-associated oligosaccharide. 
 
6-4.  Purification Strategies and Limitations 
 
a. Synthesis of Glucosamine oligomers: a ditagging strategy 
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The fluorous tag is a crucial tool in this whole process of constructing various 
oligosaccharides. However, one drawback is that there are failed acceptor molecules that 
are carried along with the desired molecule that results in by-product build up during the 
process. Therefore, at the end of the programmed acquisition, the failed sequences are 
collected along with the desired product. Although often these failed sequences can be 
readily removed at the end of the synthesizer run, sometimes the purification is not trivial.  
 
To solve this problem, we tested how the property of the sugar molecule would 
change if there were a second fluorous tag present. [38] A glucosamine molecule was 
prepared with an ester derived fluorous protecting group on the O-4 position. The newly 
prepared glucosamine donor was activated and attached to the allyl-fluorous tag. The crude 
mixture was then carried to the 2 cc FSPE cartridge to test its activity (Fig. 1-16). After 
several trials it was shown that the additional tag indeed provided a strong enough 
interaction with the fluorinated silica gel compared to the singly tagged molecule. When 
90% methanol/water solvent was used, the singly-tagged excess donor and failed acceptor 
eluted out.  
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Figure 1-16.  Separation of a di-fluorous tagged saccharide. 
 
b. Automated synthesis of a di-tagged rhamnose pentasaccharide 
 
With the preliminary results in hand with the di-tagged glucosamine molecules, we 
next decided to transfer the conditions for automation (Fig. 1-17). The rhamnose donor 1 
that was initially used for optimizing the automated conditions was used again for 
comparison. Instead of the acetate protecting group that was placed on the O-2 position, the 
ester derived C8F17 group was installed. Unlike the initial reaction programs that were 
applied to the other molecules, the FSPE step was programmed to occur right after the 
glycosylation step to filter out the acceptor that has failed to react as well as the excess 
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donor. The HPLC traces for the crude final compound from the synthesizer appeared to be 
pure compared to the singly-tagged saccharide compounds.  
 
 
Figure 1-17. Automated synthesis of di-fluorous tagged rhamnose pentasaccharide. 
 
c. Synthesis of 16mer oligosaccharide 
 
To date, the fluorous tail has been compatible with most of the conditions including 
building block synthesis and glycosylation/deprotection conditions. The FSPE step acted as 
a convenient tool to purify the desired oligosaccharides from the non-fluorinated reagents 
and by-products. However, a question remained as to the size of the sugar chain that could 
be made without problems with purification and transfer steps. Once the oligosaccharide 
molecule exceeds the pentasaccharide scale, the solubility and separation within the FSPE 
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To test the feasibility and possibility of pursuing the fluorous tail strategy to make 
larger oligosaccharide compounds, a known tetrasaccharide donor was used. [39] The 
repeating tetrasaccharide is found in the O-specific polysaccharide of Shigella dysenteriae 
type 1.  Under automated conditions, the molecule is programmed to go through the 
identical coupling/deprotection steps to produce a hexadecasaccharide compound. Also, the 
introduction of the deprotection of the temporary protecting chloroacetyl group via 
thioacetate conditions expands the scope of the protecting groups that could be used.  
 
By increasing the reaction time and equivalents of donors used, the desired 
hexadecasaccharide 44 was synthesized successfully in an overall 14% yield (Fig. 1-18). 
The higher-membered oligosaccharide fluorous tagged intermediates behaved as 
consistently as the small saccharide compounds and good separations resulted during the 
FSPE steps-an important finding for the future synthesis of larger molecules.  
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Figure 1-18. Automated synthesis of 16mer oligosaccharide. 
 
6-5.  Tag modification/removal 
 
The allyl-C8F17 fluorous tag has proved to be a convenient tool for synthesizing larger 
oligosaccharide compounds not only by conventional means [40], but also under unattended 
automated conditions by taking advantage of the fluorous-fluorous interactions. The tag 
was able to survive a wide range of synthetic conditions, making it useful for the 
glycosylation/deprotection cycles. However, after developing the general procedure for 
synthesizing various oligosaccharides with protecting groups, demonstrating the removal 
and modification of the fluorous tag was necessary. For the automated process to be an 
attractive method, the removal of the fluorous tag should be a mild conditioned and highly 
converted process. The fluorous allyl tag is designed to be a flawless group to be used 
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because its versatility allows it to be converted to different functional groups for various 
future applications. The alkene functionality offers a versatile route for the final 
oligosaccharide to be functionalized for any future applications. The automatically 
synthesized rhamnose pentasaccharide 3 was carried out under olefin cross-metathesis 
conditions [41] to give the resulting allyl pentasaccharide 45 in 72% yield as shown in 
Figure 1-19. The anomeric allyl group is a common protecting group that is used in 
oligosaccharide synthesis. The further removal of the anomeric allyl group could be 
accomplished by using palladium reagents [42] or an iridium catalyst [43], followed by 
either iodine or mercury conditions. [44] 
 
 
 
Figure 1-19. Deprotection of the fluorous tag of an automatically synthesized 
rhamnose pentasaccharide under cross metathesis conditions. 
 
The allyl fluorous-tagged molecules can also directly be introduced to ozonolysis 
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product. The aldehyde could then be further oxidized to a carboxylic acid to be coupled to a 
carrier of interest, which makes it convenient in many applications. 
 
 
 
Figure 1-20. Modification of the fluorous tag of rhamnose under ozonolysis 
conditions. 
 
For microarraying purposes, the fluorous tail is crucial for immobilizing the sugar 
molecules on the fluorinated glass slide. The final product from the automated synthesizer 
will be purified and introduced to a series of global deprotection conditions to result in a 
fully deprotected oligosaccharide 50 with a fluorous tail as shown in Figure 1-21. 
 
 
Figure 1-21. Deprotection of Automatically Synthesized BGH 
 
O3, DCM, -78 
oC - rt,
     10 mins
O
BnO
BnO
OAc
O O
C8F17
O
BnO
BnO
OAc
O
O
O
C8F17
H +
O
H
46 47 48
1. n-BuOH/ethylene diamine
2. Ac2O/Et3N/MeOH
O
BnO
O
O
OBn
BnO
O
BnO
NHAc
OBn
O
OH
OH
OBn
10% Pd/C, H2
75%
98%
49
O
HO
O
O
OH
O
HO
NHAc
OH
O
OH
OH
OH
50
HO
O
OBn
O
BnO
NPhth
O
BnO
BnO
OBn
O
O OBn
OAc
OAc
O O
C8F17
17
O O
C8F17
O O
C8F17
 36 
7.  From automation synthesis to microarray fabrication 
 
7-1.  Background 
 
Microarrays are known to be one of the most highly efficient tools for unmasking 
biomolecular interactions. With the minimum amount of sample, the screening process is 
fast and reliable. For instance, DNA chips have been particularly successful and produced 
several practical assays using glass slides for immobilization. [46] However, for cases such 
as small molecules, like carbohydrates, the immobilization process generally requires 
certain functionalities of the small molecule for covalent bond formation, creating multiple 
chemical manipulation processes. It has been reported previously from our group utilizing 
the fluorous tag as an affinity tag for immobilizing the target saccharide molecules on the 
fluorinated glass slide. [47] A single C8F17 tag proved to be efficient enough to have a 
stable binding with the fluorinated glass slide to tolerate repetitive incubation and rinsing 
steps for testing specific interactions with a certain protein. In addition, larger saccharide 
molecules and charged sugars were also compatible with the designed strategy. [48] Not 
only does this approach simplify the arraying techniques for highly functionalized 
hydrophilic carbohydrate molecules, but it also was proved to be equally sufficient for 
hydrophobic druglike molecules. [49]  
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Figure 1-22. Strategy for the synthesis of carbohydrates and direct formation of 
fluorous-based carbohydrate microarrays. 
 
To first test the feasibility of the surface patterning, several sugars were prepared with 
the fluorous-tagged allyl linker. After multiple chemical manipulation, the requisite 
fluorous-tagged monosaccharides were spotted on a C8F17-derivatized glass slide using a 
standard robot that is also used for DNA arraying. The spotted slide was then washed to 
eliminate any unbound excess molecules and was incubated with a solution of fluorescein 
isothiocyanate-labeled concanavalin A (FITC-ConA) for 20 minutes. As was hypothesized, 
the fluorous tag offered as a sturdy handle even when exposed to continuous rinsing steps 
with buffer and distilled water. And the detection of the incubated slide showed specific 
binding to only mannose-containing spots.  
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Figure 1-23. Fluorous-tagged carbohydrates synthesized for microarray formation 
                  
 
Figure 1-24. Fluorescence images of arrayed carbohydrates probed with FITC-labeled 
lectins. Columns of 4 spots each of 2, 1, 0.5, 0.1 mM carbohydrates were incubated 
for 20 min with FITC-ConA (top) or FITC-ECA with 1% TWEEN-20 detergent 
(bottom) with BSA. (reproduced with permission from reference 51. Copyright 2005 
American Chemical Society.) 
 
 
The feasibility of fluorous tags capped with an aminooxy functionality was also tested 
under similar conditions. The advantage of this approach is to introduce a robust tool that 
allows the incorporation of the reducing sugars directly onto a fluorous-based microarray. 
[50] With the new fluorous glycosylation method, the reducing oligosaccharides from 
natural sources can be tagged without activation of the anomeric center in a few number of 
steps. Due to its accessibility and high yield, the process is envisioned to be an attractive 
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assay for the area of glycobiology. Although it requires more study to fully understand its 
strength and limitation, the noncovalent forces that the fluorous-tags offer are reliable and 
generally applicable to many small molecule assays.  
 
7-2.  Examples 
 
Synthesis of a Brucella-associated pentasaccharide 
 
Brucella, which is known to be the cause of brucellosis, is transmitted by ingesting 
infected food, direct contact with an infected animal, or inhalation of aerosols but not by 
human-to-human transmission. The economical impacts are mostly in North America and 
developing countries and the protection and detection of the disease is highly desirable. [52] 
Although structurally distinct, the O-antigenic polysaccharides of Brucella abortus and 
Brucella melitenis both contain 2-O-linked 4,6-dideoxy-4-formamido-α-D-mannopyranosyl 
residues. For microarraying purposes, we have attempted to synthesize multiple fragments 
of the brucella oligosaccharide (Fig. 1-25) for diagnosis and its future possibility as 
carbohydrate-based vaccines. 
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Figure 1-25. Automated synthesis of Brucella pentasaccharide for use in fluorous 
microarrays. 
 
The initial acceptor monosaccharide was prepared from mannose with an azido group 
in the O-4 position. Two donors were prepared to be attached onto the molecule. After 3.5 
cycles, the Brucella pentasaccharide was synthesized in moderate yields. The resulting 
compound was deprotected and arrayed on a fluorous surface for screening with infected 
animal sera. Antibodies in infected, but not in uninfected unvaccinated cattle, readily bound 
to the synthetic sugars to allow diagnosis of exposure to Brucella. These results open the 
possibility of diagnostics based on sugars made by automated synthesis. 
 
8. Summary and future directions 
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Although known to be one of the three most important biomolecules, it is surprising 
how far behind studies of carbohydrates are compared to those of peptides and 
oligonucletides. The development of the customized automated solution-phase synthesizer 
has opened up the possibility of providing structurally well-defined complex 
oligosaccharide compounds conveniently. Since the automated solution-phase synthesizer 
using fluorous solid-phase extraction steps for purification of intermediates has proven to 
possess the ability to construct a range of saccharide compounds, the possibility of 
combinatorial carbohydrate libraries is now open. 
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Automated Solution-Phase Synthesis of Oligosaccharides 
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Abstract 
 
Automated solid-phase synthesis has allowed the commercial production of nucleic 
acid and peptide strands that drive genomics and proteomics studies. However, the synthesis 
of building blocks for linear and branched oligosaccharides is more complex than what is 
required for nucleic acid and peptide strands and therefore the solid-phase approach to 
oligosaccharide synthesis is more difficult and expensive. We here present an alternative 
automated iterative solution-phase approach to oligosaccharide synthesis and demonstrate the 
reliability of automated separations based on fluorous solid-phase extraction (FSPE). 
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Introduction 
 
 Automated chemical synthesis has allowed the commercial production of nucleic acid 
and peptide strands that help drive genomics and proteomics studies. These automated 
processes rely on a solid-phase matrix for covalent attachment of the growing biopolymer 
chain for simple purification of intermediates [1]. This solid-phase can be robotically rinsed 
with reagents and solvents as needed to iteratively attach building blocks and remove 
temporary protecting groups from the attached blocks to unmask the next reactive functional 
group. Bruce Merrifield outlined the advantages of this approach in his 1984 speech for the 
Nobel Prize in Chemistry [2, 3]: excesses of reagents could be used to drive reactions to 
completion and then could be rinsed from the solid-phase. Since his initial development of 
solid-phase chemistry, Merrifield's idea has been applied in a range of settings including 
nucleic acid synthesis [4, 5], oligosaccharide synthesis [6, 7], and the combinatorial synthesis 
of drug-like molecules [8]. Unfortunately, solid-phase reactions cannot be directly translated 
from traditional solution-phase reactions, thereby lengthening development times and 
effectively limiting the range of reactions that can be easily carried out in this manner [9]. 
The requirement for excesses of reagents also limits the effective range of this process 
despite the relative ease of automating solid-phase-based reaction sequences. 
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Results and discussion 
 
Solution-phase-based Automated Synthesis 
 
Given the limitations of solid-phase chemistry, soluble tags [10] to simplify the 
purification of soluble intermediates in iterative synthesis cycles have been explored. The 
unique physical properties of these tags can be used for precipitation, extraction into a liquid 
phase, or affinity purification/solid-phase extraction. We found that precipitation and liquid-
phase extractions are too variable for reliable automation of the process. However, solid-
phase extractions—a form of affinity chromatography—held promise. The required tags had 
to be relatively chemically inert and therefore hydrocarbon and fluorocarbon tags were 
investigated [11].  
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Figure 2-1. Automated Synthesis Workstation. 
 
  A key question for the success of an automated process based on fluorous tags is the 
robustness of these fluorous-based interactions [12, 13] between the soluble fluorous tag and 
the solid support during the purification step. Covalent attachment of a growing chain on a 
solid-support has the distinct advantage of dependable partition of the product regardless of 
its chemical nature from solvents even if reagents can be trapped by the supports themselves. 
In contrast, compounds containing a lipophilic tag [14, 15] usually require two 12 to 18-
carbon hydrocarbon chains for reliable separation on C18-modified supports and separation 
times will vary based on the lipophilicity of the other portion of the molecule and its 
protecting groups. Given that traditional protecting groups are lipophilic but nonfluorous, we 
reasoned that a fluorous-based strategy would present less variability in the separation steps 
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such that an automated process would be feasible without reprogramming of the purification 
protocols for each new molecule. Carbohydrates, even in their protected form, contain so 
many atoms that can form hydrogen bonds with the water necessary for fluorous-based solid-
phase extractions that they present a particularly good target for an alternative to automated 
solid-phase synthesis. In addition, an appreciation of the importance of carbohydrates in 
cancer, development, and immune recognition processes has been steadily growing, although 
work is still limited in part by the lack of ready availability of a range of oligosaccharides for 
structure/function studies [16].  
 
To test the feasibility of an automated approach to oligosaccharide synthesis based on 
fluorous-solid-phase-extraction (FSPE), we needed to create an appropriate robotics 
platform. In addition to the liquid handling and temperature control functions of a solid-phase 
synthesis platform, our platform would have to carry out reaction mixing, fluorous-solid-
phase extractions, and solvent evaporation functions reliably. Although many automation 
platforms for solid-phase iterative synthesis are now commercially available, commercial 
automation platforms for solution-phase chemistry tend to break apart functions and thereby 
require, for example, a machine to carry out the reaction, another one for the purification 
step, and a third for removal of solvents and volatile reagents. In the end, we machined a 
commercial Chemspeed ASW (Automated Synthesis Workstation) 1000 (figure 2-1) to carry 
out all the necessary individual steps. A crucial issue was the reengineering of the solid-
phase extraction block to carry cartridges large enough to handle the larger quantities of 
fluorous-modified silica gel needed for separation of 200-300 milligrams of fluorous-tagged 
intermediates.  
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Once the physical platform was in place, programming of the automation cycles 
commenced. Building block 2 (Fig. 2-2) [17], useful for the synthesis of polyα-(1→2) 
rhamnosides, was chosen as an initial test substrate. Polyrhamnose is part of the coating of 
streptococcal group A and C bacteria [18]. This basic building block can now be made in 6 
steps and 2 days and contains an acetyl group at the C2-position for neighboring group 
assistance in setting the stereochemistry of the glycosidic linkage. The block is activated as a 
trichloroacetimidate for ready activation by acids amenable to liquid handling such as 
trimethylsilyl trifluoromethanesulfonate (TMSOTf) [19]. A fluorous tag was chosen to 
contain an alkene handle for either later removal, for functionalization to attach the 
oligosaccharide to, for instance, fluorescent reporter groups, or for reduction of the tag for 
fluorous-based microarray formation [20-24]. This tag was added by acid-catalyzed 
glycosylation to form the initial rhamnoside 1 to test various reaction and purification 
conditions.  
 
Each synthetic cycle to add a new building block consists of three steps: 
glycosylation for addition of the next unit to the growing chain, protecting group removal to 
unmask the next reactive hydroxyl for chain extension, and purification by FSPE. The 
automated solution-phase approach is extremely attractive because we found that general 
solution-phase reaction protocols could be directly transferred onto the automated 
workstation. In addition, the platform could be programmed to remove an aliquot at various 
times in the automation cycle in order to readily troubleshoot steps at the end of a 
programmed run by thin layer chromatography (tlc). The ability to quickly pinpoint problem 
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steps made development of this process much faster than a solid-phase-based process. Most 
importantly, the automated solution-phase chemistry did not require the 5- to 20-fold 
excesses [7] of activated donor building blocks required for solid-phase oligosaccharide 
synthesis. For most of the glycosylation reactions, less than 2 equivalents of donor building 
blocks were used for each nucleophilic acceptor attached to a fluorous tag. 
 
 After glycosylation, the crude reaction mixture was quenched with triethylamine as a 
base and then carried to the fluorous solid phase extraction (FSPE) workstation for column 
loading. Removal of the excess donor from the mixture generates the second acceptor ready 
for the next cycle after deprotection. After initial failures evident by tlc in retention of the 
fluorous-tagged material on the fluorous silica gel, we found automation conditions that 
readily retained fluorous-tagged compounds on the column while only non-fluorous 
compounds eluted. Switching to a nonaqueous solvent allowed subsequent complete removal 
of the fluorous-tagged material. Because the same FSPE column is conveniently used 
throughout the iterative cycles, complete removal of the tagged compounds is necessary. 
Further optimization showed that deprotection with sodium methoxide of the acetyl group for 
chain extension could be carried out directly after the glycosylation cycle, thereby saving the 
time of a purification cycle. Solvent removal steps also required careful programming to 
avoid splashing of material to the top of the reaction vial and thereby loss of that material to 
the next reaction step. In a final iteration of the new protocols, after 4 cycles with rhamnose 
building block 2, pentasaccharide 3 was obtained in 24 unattended hours and 16% overall 
isolated yield under automated conditions (Fig. 2-2). For comparison, conventional manual 
synthesis with normal silica gel chromatography between steps would require at least 3 days 
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for generation of this pentamer. Proton and carbon nuclear magnetic resonance (NMR) 
spectra showed that only alpha-anomers were produced. 
 
 
A 
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C 
Step Task Reagent/ Operation Operation 
Time 
1 
 
 
2 
3 
4 
5 
6 
7 
8 
9 
 
 
10 
11 
12 
13 
14 
 
15 
Glycosylation 
 
 
TLC sample 
Quenching 
Evaporation 
Deacetylation 
TLC sample 
Quenching 
Evaporation 
FSPE 
preparation 
Sample 
loading 
       Wash 
Wash 
Transfer 
Evaporation 
Transfer 
Evaporation 
 
     1.5 equivalent donor  (75 µmol) in 0.5 mL    
                                   toluene,  
1 equivalent F-tagged acceptor (50 µmol) in 1 mL 
toluene; 0.3 equivalent TMSOTf, 0 oC 
30 µL of crude reaction mixture withdrawn 
0.5 mL TEA 
40 oC 
3 equivalent of NaOMe solution 
30 µL of crude reaction mixture withdrawn 
0.3 mL 0.5 M acetic acid solution in MeOH 
50 oC 
 
0.4 mL DMF 
0.7 mL crude sample transferred to cartridge 
4.7 mL 80% methanol wash 
1.5 mL methanol wash (repeated 3 times) 
4.7 mL collected sample transferred to clean vial 
50 oC 
2 mL toluene added 
50 oC 
1-15 repeated 
45 min 
 
 
 
 
45 min 
3 h 
 
 
45 min 
 
 
 
 
 
 
45 min 
 
45 min 
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D 
 
 
Figure 2-2. (A) ASW Automated Synthesizer layout (B) Schematic of the Automated 
Solution-Phase Synthesis of Rhamnose Pentasaccharide (C) Description of the tasks 
performed (D) Analytical HPLC chromatogram of Rhamnose pentamer synthesis (1 mL/min 
flowrate, 20% Ethyl acetate/Hexane, 10 minute run). 
 
Of course, the utility of the process depends on its dependability using a range of 
monomers without reprogramming. For this, further optimization of the protocols and their 
application to a variety of monomers was required. For glycosylation reactions, toluene was 
substituted for 1,2-dichloroethane or dichloromethane to prevent evaporation of stock 
solutions from heat generated during the machine run. Toluene, which forms an azeotrope 
with water, was also used to rinse the needle used for transfers to eliminate any small 
quantities of water that might interfere with the glycosylation yields. At this point, most of 
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the loss in yields occurred during the transfer tasks. Therefore, a flat tip needle and conically-
shaped sample vial was used to decrease the amount of dead volume during transfer. 
 
Depending on the complexity of the structure of the desired oligosaccharide, various 
compounds were made under similar or slightly modified automated conditions. The 
automated synthesis of oligomannose, branched β-glucan fragment, blood group H (BGH) 
trisaccharide are discussed elsewhere [25].  
 
 
Figure 2-6. Example of further modifications of the fluorous tag  
 
 The alkene functionality of the fluorous tag also offers a versatile route for the final 
oligosaccharide to be functionalized for any future applications. For example, rhamnose 
pentasaccharide 3 was subjected to olefin cross-metathesis conditions [26] to give the 
resulting allyl pentasaccharide in 72% yield (Fig. 2-6). Also any fluorous-tagged compound 
obtained from the new automation platform can be subjected to ozonolysis conditions to 
obtain the aldehyde functionality for further conjugation or other reactions. Also the fully 
deprotected fluorous-tagged oligosaccharides could be used directly for arraying purposes 
[20-24]. 
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Conclusion 
 
In conclusion, this work [27] illustrates that noncovalent fluorous interactions are 
strong enough to support automated iterative synthetic protocols that reliably separate a 
growing carbohydrate chain from undesired by-products in a process that mimics solid-phase 
protocols that rely on covalent interactions. Such a solution-phase automation process 
requires 2 to 10-fold fewer equivalents of building blocks than equivalent processes based on 
solid-phase chemistry and allows greater flexibility to interrupt the synthetic process. 
Traditional solution-phase methods can be directly translated into this automation strategy 
without the significant optimization times required for the development of solid-phase 
synthetic strategies. In addition, the fluorous tag itself can be used to not only aid compound 
purification, but also be used to directly attach the compounds to microarrays for screening. 
These significant differences should greatly accelerate the synthesis of well-defined 
oligosaccharide structures to drive the field of glycobiology and particularly immunology. 
Finally, this new approach to automated iterative synthesis is not only an important leap to 
accelerate oligosaccharide synthesis, but should also aid in the automated iterative synthesis 
of other molecules that have been difficult to obtain by solid-phase automation strategies. 
 
Experimental section 
 
General methods 
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All commercial reagents and solvents were used as received without further 
purification unless indicated. Reaction solvents were distilled from calcium hydride for 
dichloromethane and from sodium metal and benzophenone for diethyl ether. Amberlyst 15 
ion-exchange resin was washed repeatedly with methanol before use. The reactions were 
monitored and the Rf values determined using analytical thin layer chromatography (tlc) with 
0.25 mm EM Science silica gel plates (60F - 254). The developed tlc plates were visualized 
by immersion in p-anisaldehyde solution, followed by heating on a hot plate. Silica gel flash 
chromatography was performed with Selecto Scientific silica gel, 32-63 mm particle size. 
Fluorous phase chromatography was performed using fluorous solid-phase extraction 
cartridges containing silica gel bonded with perfluorooctylethylsilyl chains (Fluorous 
Technologies, Inc.; Pittsburgh, PA). All other fluorous reagents were also obtained from 
Fluorous Technologies, Inc. All moisture sensitive reactions were performed in flame- or 
oven-dried glassware under nitrogen atmosphere. Bath temperatures were used to record the 
reaction temperature in all cases run without microwave irradiation. All reactions were 
stirred magnetically at ambient temperature unless otherwise indicated. 1H NMR and 13C 
NMR spectra were obtained with a Bruker DRX400 at 400 MHz and 162 MHz, Varian400 at 
400 MHz and 100 MHz or Varian300 at 300 MHz and 75 MHz respectively. 1H NMR 
spectra were reported in parts per million (δ) relative to CDCl3 (7.27 ppm) as an internal 
reference. 13C NMR spectra were reported in parts per million (δ) relative to CDCl3 (77.23 
ppm) or CD3OD (49.15 ppm). HPLC traces were obtained from a Varian Inc. HPLC system 
using a Waters Nova-pak 4 µL 3.9 ×150 mm silica column. High-resolution mass 
spectrometry was obtained with Applied Biosystems QSTAR XL Hybrid System from the 
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W. M. Keck Metabolomics Research Laboratory or Applied Biosystems DE-Pro MALDI 
mass analyzer from the protein facility at Iowa State University. 
 
General procedure for automated synthetic cycles using ASW 1000 with polyrhamnose 
 
1. Sample Preparation 
 
Donor molecule (265.4 mg, 500 µmol) was dissolved with dried toluene (2.5 mL) in 
the 13 mL vial and placed at the stock solution rack (Donor 1) under argon. 0.27 M 
trimethylsilyltrifluoromethanesulfonate (TMSOTf, 1.05 mL) solution in toluene was 
prepared in the 8 mL vial and placed as indicated on the stock solution rack under argon. 
Dried toluene (1 L) was placed in the stock solution bottle and placed at the reservoir bottle 
rack with tubing as reservoir solution for rinsing. Methanol (100 mL), 80% methanol/water 
(100 mL), triethylamine (8 mL) were prepared in stock solution bottles and connected to the 
transfer ports. Acceptor molecule (43.7 mg, 50 µmol) was dissolved with dried toluene (0.5 
mL) in a Wheaton 8 mL E-Z extraction vial (conically- bottomed) capped with pre-punctured 
septa and placed at the reagent rack where indicated (F-tagged OH).  
 
0.5 M Sodium methoxide solution in methanol (5 mL) was prepared in 8 mL vial 
capped with pre-punctured septa and placed at the reagent rack. 0.2 M acetic acid solution in 
methanol (5 mL) was prepared in 8 mL vial capped with pre-punctured septa and placed at 
the reagent rack where indicated. N, N-dimethylformamide (DMF, 5 mL) directly from Fluka 
was transferred in 8 mL vial capped with pre-punctured septa and placed at the reagent rack 
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where indicated. Fluorous solid phase extraction (FSPE) cartridge (2 g, 10 cc) was 
preconditioned with 80% methanol(/water) and placed at machined SPE block. An empty 
Wheaton 8 mL E-Z extraction vial was placed under the FSPE cartridge.  
 
2. Cleaning Cycle 
 
Prior to introduction of reagents, the ASW1000 reactor vials were cleaned, dried and 
purged with argon by running the cleaning cycle. During the cleaning cycle each of the 16 
reactor vials (13 mL) were rinsed with 8 mL toluene and 8 mL methanol 3 times each. After 
the solvents were completely removed, the reactor vials were dried under vacuum and purged 
with argon for 45 minutes. Reagent solutions were prepared by azeotroping the building 
blocks individually with toluene and dried under high vacuum. After the cleaning cycles 
were done, the reagents were transferred into the reagent vials respectively, which were then 
placed on the inert condition reagent rack and general atmosphere reagent rack.   
 
3. Method Run 
 
3.1. Glycosylation 
 
Reactor vials were cooled to 0 oC during the 5 minutes wait time by the heat transfer 
oil. Then the flat-tipped open vial needle transferred the acceptor molecule (F-tagged OH) 
solution (0.6 mL) to the reaction vial 1, followed by the transfer of the acceptor molecule 
solution (0.5 mL) and the TMSOTf solution (56 µL). After each individual transfer, the 
needle was rinsed by 2 mL of toluene inside and out before operating the next task. The 
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reaction mixture was vortexed at 800 rpm for 30 minutes at 0 oC under inert gas.  After the 
reaction time the needle withdrew 30 µL of the solution from the reaction mixture and placed 
it into the first well of the microtiterplate for thin layer chromatography monitoring. 
Triethylamine (0.5 mL) was added to the solution for quenching and solvent evaporated 
under reduced pressure.   
 
3.2. Deacetylation 
 
To the dried residue, methanol (0.5 mL) was added to the reactor vial followed by 
sodium methoxide solution (0.4 mL). The reaction mixture was vortexed at 800 rpm for 3 
hours at room temperature. After the reaction time the needle withdrew 30 µL from the 
reaction mixture and placed it into the second well of the microtiterplate for thin layer 
chromatography monitoring. Acetic acid (0.75 mL) solution was added to the reactor vial for 
quenching, followed by the addition of toluene (1 mL) and the solvent was evaporated under 
reduced pressure.   
 
3.3. FSPE 
 
DMF (0.4 mL) was added to dissolve the crude mixture and the vials were vortexed at 
100 rpm for 5 minutes. The reaction mixture (0.7 mL) was carried to the FSPE cartridge at 
the SPE rack dispensed at a speed of 20 mL/s via the 10 mL syringe. Then 80% methanol 
(4.5 mL) was used to rinse the empty reactor vial. 80% Methanol solvent was removed from 
the reactor vial each time (1.7 mL, 1.5 mL, 1.5 mL) and delivered to the FSPE cartridge. An 
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additional 80 % methanol solution (1 mL) was used to rinse the FSPE cartridge. During the 
80% methanol rinse, the cartridge was positioned at ‘SPE waste’ for the eluted mixture to be 
disposed. Methanol (1.5 mL, repeated 3 times) was used to wash the FSPE cartridge for 
eluting the desired compound. During the task, the FSPE cartridge was positioned as ‘SPE 
collect’ to be placed right above the 8 mL vial for collection of the sample. After the task, the 
position of the SPE rack was changed into ‘SPE direct’ for the needle to withdraw the 
collected sample from the vial and deliver it to the clean reactor vial for the next reaction. 
Toluene (1 mL) was added to the solution and the solvent was evaporated under reduced 
pressure. After the evaporation cycle, once again toluene (1 mL) was added and removed 
under reduced pressure for complete dryness. 
 
Synthetic Procedures 
 
1, 2, 3, 4-Tetra-O-acetyl-α-L-rhamnopyranosde.  
 
α/β-L-(+)-Rhamnose monohydrate (2.00 g, 10.98 mmol) was dissolved in 10 mL of 
pyridine/acetic anhydride (1:1). The reaction mixture was stirred at room temperature 
overnight. TLC confirmed the complete conversion of the starting material. The reaction 
mixture was diluted with ethyl acetate (50 mL) and washed with water (3 × 50 mL), and 
brine (3 × 50 mL). The organic layer was collected and dried over MgSO4. The solvent was 
O
AcO
AcO
OAc
OAc
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removed under reduced pressure to obtain the title compound (3.57 g, 10.76 mmol, 98%) as a 
colorless oil.  
 
Rf (ethyl acetate/hexane): 0.57 (2/3).  
1H NMR (CDCl3, 400 MHz): δ (ppm) 5.99 (d, J = 1.6 Hz, 1H, H-1), 5.29 (dd, J = 10.0 Hz, 
3.6 Hz, 1H, H-3), 5.23 (dd, J = 3.6 Hz, 1.6 Hz, 1H, H-2), 5.12 (t, J = 10.0 Hz, 1H, H-4), 3.91 
(m, 1H, H-5), 2.15 (s, 3H, OAc), 2.14 (s, 3H, OAc), 2.04 (s, 3H, OAc), 1.98 (s, 3H, OAc), 
1.22 (d, J = 6.0 Hz, 3H, H-6). 
13C NMR (CDCl3, 100 MHz): δ (ppm) 170.2, 170.0, 169.9, 168.5, 90.7, 70.6, 68.9, 68.7, 
68.6, 21.1, 21.0, 20.9, 20.8, 17.6. 
HRMS-MALDI (m/z): [M+Na]+ Calcd: 355.1005; Found: 355.1566.  
 
 
1-Bromo-2, 3, 4-tri-O-acetyl-α-L-rhamnopyranoside.  
 
To a solution of 1, 2, 3, 4-tetra-O-acetyl-α-L-rhamnopyranoside (3.56 g, 10.7 mmol) in 
anhydrous dichloromethane (40 mL) was added 30% hydrobromic acid in acetic acid (25 
mL) dropwise in a 0 oC ice bath. The reaction mixture was stirred at room for 5 hours. TLC 
confirmed the complete conversion of the starting material. The reaction mixture was diluted 
with dichloromethane (30 mL) and washed with ice water (3 × 50 mL), 2 N hydrochloric 
acid (3 × 50 mL) and brine (3 × 50 mL). The organic layer was collected and dried over 
O
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MgSO4. The solvent was removed under reduced pressure to obtain the title compound (3.35 
g, 9.50 mmol, 89%) as a colorless oil.  
 
Rf (ethyl acetate/hexane): 0.83 (2/3).  
1H NMR (CDCl3, 400 MHz): δ (ppm) 6.25 (d, J = 0.8 Hz, 1H, H-1), 5.67 (dd, J = 10.4 Hz, 
3.6 Hz, 1H, H-3), 5.43 (dd, J = 3.6 Hz, 1.6 Hz, 1H, H-2), 5.17 (t, J = 10.0 Hz, 1H, H-4), 4.08 
(m, 1H, H-5), 2.15 (s, 3H, OAc), 2.07 (s, 3H, OAc), 1.99 (s, 3H, OAc), 1.28 (d, J = 6.0 Hz, 
3H, H-6). 
13C NMR (CDCl3, 100 MHz): δ (ppm) 169.9, 169.8, 169.7, 83.7, 72.4, 71.1, 70.3, 68.4, 
20.8, 20.7, 20.6, 17.0. 
HRMS-MALDI (m/z): [M+Na]+ Calcd: 325.0055; Found: 325.0921.  
 
 
 
3, 4-O-Di-acetyl-1,2-O-methoxyethylidene-β-L-rhamnopyranose. [28] 
 
To a solution of 1-bromo-2, 3, 4-tri-O-acetyl-α-L-rhamnopyranoside (2.80 g, 7.95 mmol) in 
anhydrous dichloromethane (20 mL) was added tetrabutylammonium bromide (3.8 g, 11.9 
mmol) and 94% N,N-dimethylformamide dimethyl acetal (1.96 mL, 11.9 mmol). The 
reaction mixture was refluxed for 5 hours. TLC confirmed the complete conversion of the 
starting material. The reaction mixture was diluted with dichloromethane (30 mL) and 
washed with water (3 × 50 mL) and brine (3 × 50 mL). The organic layer was collected and 
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dried over MgSO4. The crude product was purified by silica column chromatography (ethyl 
acetate/hexane, 1/4, v/v) to afford the title compound title compound (2.10 g, 6.92 mmol, 
87%) as a white solid.  
 
Rf (ethyl acetate/hexane): 0.57 (2/3).  
1H NMR (CD3OD, 400 MHz): δ (ppm) 5.67 (d, J = 2.0 Hz, 1H, H-1), 5.35 (dd, J = 10.0 Hz, 
4.0 Hz, 1H, H-3), 5.12 (t, J = 9.6 Hz, 1H, H-4), 4.78 (dd, J = 4.4 Hz, 2.4 Hz, 1H, H-2), 3.82 
(m, 1H, H-5), 3.39 (s, 3H, OCH3), 2.23 (s, 3H, CH3), 2.21 (s, 3H, CH3), 1.80 (s, 3H, CH3), 
1.34 (d, J = 6.4 Hz, 3H, H-6). 
13C NMR (CD3OD, 100 MHz): δ (ppm) 170.4, 170.4, 124.1, 97.4, 77.4, 70.8, 70.6, 68.4, 
50.0, 25.7, 20.9, 20.8, 17.0.  
HRMS-MALDI (m/z): [M+Na]+ Calcd: 327.1056; Found: 327.2201.  
 
 
1,2-O-Methoxyethylidene-β-L-rhamnopyranose. 
 
To a solution of 3,4-O-di-acetyl-1,2-O-methoxyethylidene-β-L-rhamnopyranose (2.00 g, 6.58 
mmol) in methanol (20 mL) was added small pieces of sodium. The reaction mixture was 
stirred at room temperature for 5 hours. TLC confirmed the complete conversion of the 
starting material. The reaction mixture was concentrated under reduced pressure and loaded 
onto silica gel for column chromatography (ethyl acetate/hexane, 9/1, v/v) purification to 
O
HO
HO
O
O
OMe
 67 
afford the title compound. The solvent was removed under reduced pressure to obtain the 
title compound (1.39 g, 6.32 mmol, 96%) as a white solid. 
 
Rf (chloroform/methanol): 0.67 (4/1).  
1H NMR (CD3OD, 400 MHz): δ (ppm) 5.48 (d, J = 2.4 Hz, 1H, H-1), 4.52 (dd, J = 4.0 Hz, 
2.0 Hz, 1H, H-2), 3.72 (dd, J = 8.8 Hz, 4.4 Hz, 1H, H-3), 3.34-3.29 (m, 5H), 1.67 (s, 3H, 
CH3), 1.34 (d, J = 6.0 Hz, 3H, H-6). 
13C NMR (CD3OD, 100 MHz): δ (ppm) 125.0, 98.9, 81.6, 73.5, 73.1, 72.0, 49.8, 25.8, 18.1. 
HRMS-MALDI (m/z): [M+Na]+ Calcd: 243.0845; Found: 243.3398.  
 
 
 
3,4-Di-O-benzyl-1,2-O-methoxyethylidene-β-L-rhamnopyranose.  
 
To a solution of 1,2-O-methoxyethylidene-β-L-rhamnopyranose (1.20 g, 5.45 mmol) in 
anhydrous N, N - dimetylformamide (30 mL) was added 60% NaH (458 mg, 11.5 mmol) and 
BnBr (1.36 mL, 11.5 mmol). The reaction mixture was stirred at room temperature for 2 
hours. TLC confirmed the complete conversion of the starting material. The reaction mixture 
was diluted with dichloromethane (50 mL) and washed with water (3 × 50 mL), and brine (3 
× 50 mL). The organic layer was collected and dried over MgSO4. The crude product was 
purified by silica column chromatography (ethyl acetate/hexane, 1/4, v/v) to afford the title 
compound (1.98 g, 4.96 mmol, 91%) as a colorless oil. 
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Rf (ethyl acetate/hexane): 0.74 (2/3).  
1H NMR (CD3OD, 400 MHz): δ (ppm) 7.53-7.27 (m, 10H), 5.37 (d, J = 2.0 Hz, 1H), 4.90 
(d, J = 10.4 Hz, 1H), 4.79 (d, J = 11.6 Hz, 1H), 4.70 (d, J = 10.0 Hz, 1H), 4.68 (d, J = 9.2 Hz, 
1H), 4.57 (dd, J = 4.0 Hz, 2.4 Hz, 1H), 3.85 (dd, J = 8.8 Hz, 4.0 Hz, 1H), 3.38 (m, 1H), 3.27 
(s, 3H, CH3), 1.64 (s, 3H, CH3), 1.29 (d, J = 6.0 Hz, 3H, H-6). 
13C NMR (CD3OD, 100 MHz): δ (ppm) 140.0, 139.7, 129.6, 129.5, 129.3, 129.3, 129.0, 
128.9, 125.2, 99.1, 81.0, 80.1, 78.9, 76.3, 73.0, 71.3, 50.0, 25.7, 18.4. 
HRMS-MALDI (m/z): [M+Na]+ Calcd: 423.1784; Found: 423.1708. 
 
 
 
2-O-Acetyl-3,4-di-O-benzyl-α/β-L-rhamnopyranose.  
 
To a solution of 3,4-di-O-benzyl-1,2-O-methoxyethylidene-β-L-rhamnopyranose (1.0 g, 2.50 
mmol) 80% AcOH/water solution (30 mL) was added and then stirred at room temperature 
for 1 hour. TLC confirmed the complete conversion of the starting material. The reaction 
mixture was diluted with dichloromethane (50 mL) and washed with water (3 × 50 mL), and 
brine (3 × 50 mL). The organic layer was collected and dried over MgSO4. The crude product 
was purified by silica column chromatography (ethyl acetate/hexane, 1/4, v/v) to afford the 
title compound (0.87 g, 2.25 mmol, 90%) as a colorless oil. 
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Rf (ethyl acetate/hexane): 0.74 (2/3).  
1H NMR (CD3OD, 400 MHz): δ (ppm) 7.34-7.22 (m, 10 H), 5.43 (dd, J = 3.2 Hz, 1.6 Hz, 
1H, H-2), 4.86 (d, J = 11.2 Hz, 1H), 4.68 (d, J = 11.2 Hz, 1H), 4.63 (d, J = 10.8 Hz, 1H), 4.60 
(d, J = 2.0 Hz, 1H), 4.50 (d, J = 11.2 Hz, 1H), 3.87 (dd, J = 9.2 Hz, 3.2 Hz, 1H), 3.66 (m, 
1H), 3.42 (t, J = 9.2 Hz, 1H), 3.34 (s, 3H, CH3), 2.09 (s, 3H, CH3), 1.20 (d, J = 6.0 Hz, 3H, 
H-6). 
13C NMR (CD3OD, 100 MHz): δ (ppm) 172.0, 140.0, 139.5, 129.5, 129.5, 129.4, 129.2, 
129.0, 128.9, 100.1, 81.3, 79.4, 72.9, 70.3, 68.9, 55.4, 21.0, 18.4. 
HRMS-MALDI (m/z): [M+Na]+ Calcd: 409.1627; Found: 409.8701.  
 
 
 
2-O-Acetyl-3,4-di-O-benzyl-α/β-L-rhamnopyranoside trichloroacetimidate (2) 
 
To a solution of 2-O-acetyl-3,4-di-O-benzyl-α/β-L-rhamnopyranose (260 mg, 0.702 mmol) 
in anhydrous dichloromethane (10 mL) was added anhydrous trichloroacetonitrile (0.35 mL, 
3.51 mmol) and cesium carbonate (595 mg, 1.76 mmol). The reaction mixture was stirred at 
room temperature for 1 hour. TLC confirmed the complete conversion of the starting 
material. The reaction mixture was filtered over Celite and loaded onto silica gel for column 
O
BnO
BnO
OAc
O CCl3
NH
 70 
chromatography (ethyl acetate/hexane, 1/9, v/v) purification to afford the title compound 
(335 g, 0.632 mmol, 90%) as a colorless oil. 
 
Rf (ethyl acetate/hexane): 0.67 (3/7).  
1H NMR (CDCl3, 400 MHz): δ (ppm) 8.68 (s, 1H, NH), 7.39-7.20 (m, 10H), 6.21 (d, J = 2.0 
Hz, 1H, H-1), 5.58 (dd, J = 3.2 Hz, 2.4 Hz, 1H, H-2), 4.98 (d, J = 10.8 Hz, 1H), 4.78 (d, J = 
11.2 Hz, 1H), 4.68 (d, J = 10.8 Hz, 1H), 4.62 (d, J = 11.2 Hz, 1H), 4.04 (dd, J = 9.6 Hz, 3.6 
Hz, 1H, H-3), 3.98 (m, 1H, H-5), 3.58 (t, J = 9.6 Hz, 1H, H-3), 2.22 (s, 3H), 1.40 (d, J = 6.4 
Hz, 3H, H-6). 
13C NMR (CDCl3, 100 MHz): δ (ppm) 170.2, 160.3, 138.3, 137.7, 129.2, 128.6, 128.6, 
128.5, 128.4, 128.3, 95.4, 91.0, 79.5, 77.3, 75.8, 72.2, 70.9, 67.7, 21.6, 21.2, 18.2. 
HRMS-MALDI (m/z): [M+Na]+ Calcd: 552.0723; Found: 552.6624.  
 
 
                                                                                                                              
cis-4-(1H, 1H, 2H, 2H,3H, 3H-Perfluoroundecyloxy)-2-butenyl-2-O-acetyl-3,4-O-dibenzyl-
α-L-rhamnopyranoside.  
 
To a solution of 2-O-acetyl-3, 4-di-O-benzyl-α-L-rhamnopyranosyl tricholoroacetimidate (2) 
(0.20 g, 0.46 mmol) and 3-(perfluorooctyl)propanyloxybutenyl alcohol (0.13 g, 0.23 mmol) 
in dry toluene (5 mL) was added TMSOTf (0.02 mL, 0.11 mmol) at 0 oC. The reaction 
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mixture was stirred at room temperature for 30 min. The reaction was quenched with 
triethylamine (0.5 mL) and concentrated. The crude product was purified by solid phase 
extraction using a fluoro flash column. Nonfluorous compounds were eluted with 5 mL 80% 
MeOH/water and the desired product was eluted by 5 mL 100% MeOH. The solvent was 
removed under reduced pressure to obtain the title compound (0.15 g, 0.175 mmol, 76%) as a 
colorless oil.  
 
Rf (ethyl acetate/hexane): 0.83 (2/3).  
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.31-7.24 (m, 10H, PhH), 5.80-5.15 (m, 2H, CH=), 
5.37 (dd, J = 3.2 Hz, 1.6 Hz, 1H, H-2), 4.93 (d, J = 8.1 Hz, 1H, CH2Ph), 4.76 (s, 1H, H-1), 
4.71 (d, J = 8.4 Hz, 1H, CH2Ph), 4.62 (d, J = 7.8 Hz, 1H, CH2Ph), 4.5 (d, J = 8.4 Hz, 1H, 
CH2Ph), 4.19-4.15 (dd, J = 9.3 Hz, 4.5 Hz, 1H, =CHCH2O), 4.10-4.06 (dd, J = 9.6 Hz, 5.1 
Hz, 1H, =CHCH2O), 4.04 (d, J = 3.9 Hz, 2H, =CHCH2O), 3.95-3.92 (dd, J = 6.9 Hz, 2.4 Hz, 
1H, H-3), 3,79-3,72 (m, 1H, H-5), 3.5 (t, J = 5.1 Hz, 2H, CH2O), 3.44 (t, J = 9 Hz, 1H, H-4), 
2.30-2.14 (m, 5H, C8F17CH2CH2CH2O, OAc), 1.95-1.80 (m, 2H, C8F17CH2CH2CH2O), 1.45 
(d, J = 6.0 Hz, 3H, H-6).  
13C NMR (CDCl3, 100 MHz): δ (ppm) 170.6 (OAc), 139.1, 138.2 (2 × CH=), 131.0, 129.1, 
128.9, 128.8, 128.2 (8 × CAr), 98.2 (C-1), 80.2 (C-3), 78.34 (C-2), 75.5 (C-4), 72.01 (C-5), 
69.3, 69.0 (2 × CH2Ph), 68.4 (C8F17CH2CH2CH2O), 66.8 (CH2O), 62.98 (CH2O), 21.2 
(C8F17CH2), 20.8 (C8F17CH2CH2), 18.0 (C-6).  
HRMS-ESI (m/z): [M+Na]+ Calcd.: 939.2166; Found: 939.2122.  
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cis-4-(1H, 1H, 2H, 2H, 3H, 3H-Perfluoroundecyloxy)-2-butenyl-2-O-hydroxyl-3,4-O-
dibenzyl- α-L-rhamnopyranoside (1) 
 
To a solution of cis-4-(1H, 1H, 2H, 2H, 3H, 3H-perfluoroundecyloxy)-2-butenyl-2-O-acetyl-
3,4-O-dibenzyl-α-L-rhamnopyranoside (315 mg, 0.343 mmol) in methanol (2 mL) was added 
0.5 M NaOMe (0.67 mL, 0.34 mmol) and the reaction mixture was stirred at ambient 
temperature for 20 min. The solution was neutralized with Amberlyst acidic resin. The 
mixture was filtered and washed with MeOH (10 mL) and then concentrated in vacuo. The 
crude product was purified by solid-phase extraction by using a fluorous solid-phase 
extraction (FSPE) cartridge. Non-fluorous compounds were eluted with 80% MeOH/H2O 
and the desired product was eluted by 100% MeOH. The solvent was removed under reduced 
pressure to obtain deacetylated rhamnose 1 (273 mg, 0.312 mmol, 91%) as a colorless oil.  
 
Rf (ethyl acetate/hexane): 0.7 (2/3). 
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.31-7.24 (m, 10H, PhH), 5.73-5.66 (m, 2H, CH=), 
4.92 (d, J = 11.2 Hz, 1H, CH2Ph), 4.85 (s, 1H, H-1), 4.71 (s, 2H, CH2Ph), 4.67-4.65 (d, J = 
10.8 Hz, 1H, CH2Ph), 4.22-4.17 (dd, J = 12.4 Hz, 5.2 Hz, 1H, =CHCH2O), 4.12-4.05 (m, 4H, 
=CHCH2O, H-2), 3.88-3.85 (dd, J = 9.2 Hz, 3.2 Hz, 1H, H-3), 3.79-3.72 (m, 1H, H-5), 3.51-
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3.46 (m, 3H, CH2O, H-4), 3.46 (s, 1H, OH), 2.57-2.16 (m, 2H, C8F17CH2CH2CH2O), 1.95-
1.80 (m, 2H, C8F17CH2CH2CH2O), 1.45 (d, J = 6 Hz, 3H, H-6). 
 13C NMR (CDCl3, 100 MHz): δ (ppm) 138.5, 138.2 (2 × CH=), 130.1, 128.9, 128.7, 128.5, 
128.3, 128.3, 128.0, 127.9 (8 × CAr), 98.2 (C-1), 80.2 (C-3), 80.2 (C-2), 75.5 (C-4), 72.3 (C-
5), 68.9, 68.7 (2 × CH2Ph), 67.5 (C8F17CH2CH2CH2O), 66.4 (CH2O), 62.6 (CH2O), 28.0 
(C8F17CH2), 20.8 (C8F17CH2CH2), 18.0 (C-6). 
HRMS-ESI (m/z): [M+Na]+Calcd.: 897.2060; Found: 897.1884. 
 
 
                                                                                                                      
cis-4-(1H, 1H, 2H, 2H, 3H, 3H-Perfluoroundecyloxy)-2-butenyl 2-O-acetyl-3,4-di-O-benzyl-
α-L-rhamnopyranosyl-(1→2)-3,4-di-O-benzyl-α-L-rhamnopyranosyl-(1→2)-3,4-di-O-
benzyl-α-L-rhamnopyranosyl-(1→2)-3,4-di-O-benzyl-α-L-rhamnopyranosyl-(1→2)-3,4-di-
O-benzyl-α-L-rhamnopyranoside (3) 
               
Synthesis of rhamnose pentamer-ASW rhamnose pentamer method run (3.5 cycles) 
After the 4th FSPE, the methanol elution collected in the 8 mL vial was removed from the 
instrument and concentrated. The solvent was removed under reduced pressure to obtain the 
crude title compound (13 mg) as a colorless oil. After purification, 9 mg of the titled 
compound was obtained (16% overall yield).  
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Rf (ethyl acetate/haxane):  0.51 (20/80).  
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.40-7.15 (m, 50H), 5.80-5.60 (m, 2H), 5.67 (d, J = 
3.2 Hz, 1.6 Hz, 1H), 5.28-4.54 (m, 25H), 4.13 (m, 18H), 3.49-3.31 (m, 7H), 2.30-2.14 (m, 
5H), 1.95-1.80 (m, 2H), 1.45 (m, 15H).  
13C NMR (CDCl3, 100 MHz): δ (ppm) 170.3, 138.7, 138.6, 138.6, 138.6, 138.5, 138.5, 
138.5, 138.4, 138.4, 138.3, 129.9, 129.9, 128.6, 128.6, 128.6, 128.6, 128.5, 128.5, 128.4, 
128.3, 128.2, 128.2, 128.2, 128.1, 127.9, 127.9, 127.9, 127.7, 100.8, 100.5, 99.3, 98.2, 80.6, 
80.5, 80.4, 80.4, 80.3, 80.3, 80.3, 79.6, 79.1, 78.0, 78.0, 77.9, 77.4, 75.7, 75.6, 74.9, 74.8, 
74.77, 72.4, 72.3, 72.2, 72.1, 72.0, 69.1, 69.0, 68.7, 68.5, 68.2, 66.7, 62.7, 28.2, 21.4, 21.0, 
18.2, 18.2.  
HRMS-ESI (m/z): [M+Na]+Calcd.: 2243.8238; Found: 2243.8886. 
 
 
Allyl 2-O-acetyl-3,4-di-O-benzyl-α-L-rhamnopyranosyl-(1→2)-3,4-di-O-benzyl-α-L-
rhamnopyranosyl-(1→2)-3,4-di-O-benzyl-α-L-rhamnopyranosyl-(1→2)-3,4-di-O-benzyl-α-
L-rhamnopyranosyl-(1→2)- 3,4-di-O-benzyl-α-L-rhamnopyranoside (4) 
 
To a solution of fluorous-tagged rhamnose pentasaccharide (25 mg, 0.011 mmol) in dry 
CH2Cl2 (2 mL), 2
nd generation Grubbs’ catalyst (1.8 mg, 2.10 µmol) was added. The 
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suspension was degassed by bubbling in ethylene gas for 30 minutes. Then after evacuating 
air under reduced pressure, an ethylene balloon was attached. The reaction flask was stirred 
at room temperature for 48 hours under an ethylene atmosphere. The suspension was filtered 
over a short pad of celite and silica, then concentrated. Purification by flash silica 
chromatography yielded the allyl saccharide (14 mg, 8.08 mmol, 71.8%).  
 
Rf (ethyl acetate/haxane): 0.51 (20/80).  
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.41-7.16 (m, 50 H), 5.92-5.82 (m, 1H), 5.62 (d, J = 
3.2 Hz, 1.6 Hz, 1H), 5.30-4.59 (m, 27H), 4.18-3.33 (m, 22H), 2.17 (s, 3H), 1.30-1.22 (m, 
15H). 
13C NMR (CDCl3, 100 MHz): δ (ppm) 170.3, 138.7, 138.6, 138.6, 138.5, 138.4, 138.4, 
138.2, 138.0, 137.9, 133.9, 129.2, 128.9, 128.8, 128.7, 128.7, 128.6, 128.5, 128.5, 128.4, 
128.4, 128.3, 128.3, 128.2, 128.2, 128.2, 128.1, 128.1, 128.0, 127.9, 127.8, 127.8, 127.7, 
127.7, 127.6, 127.3, 125.5, 117.3, 100.8, 100.7, 100.4, 99.3, 98.1, 80.4, 80.4, 80.3, 80.0, 79.8, 
79.5, 79.4, 79.2, 78.9, 78.6, 78.3, 78.2, 78.0, 77.4, 75.7, 75.5, 74.8, 74.2, 72.4, 72.3, 72.0, 
71.7, 69.6, 69.1, 68.8, 68.7, 68.6, 68.5, 68.3, 68.1, 67.8, 67.3, 21.3, 18.2, 18.1. 
HRMS-MALDI (m/z): [M+H]+ Calcd.: 1731.8193; Found: 1731.8204. 
 
Additional Information: Experimental details, including copies of the 1H NMR spectra, for 
the synthesis are found in the Appendix at the end of this dissertation. 
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CHAPTER 3 
Automated Solution-Phase Synthesis of Anthrax- and Cholera- 
Associated Antigenic Tetrasaccharides  
Portions of this chapter will be submitted to The Journal of the American Chemical Society 
Gisun Park and Nicola L. B. Pohl* 
 
Abstract 
 
The first automated solution-phase syntheses of two key antigenic tetrasaccharides associated 
with anthrax and cholera is reported. Two protecting group strategies were newly introduced 
into an automated strategy that relies on robotic fluorous solid-phase extractions (FSPE) for 
purification of intermediates and both groups proved to be good masking entities under 
automated conditions. After careful design of the automated synthetic protocol, both 
tetrasaccharides were successfully synthesized side by side simultaneously. In addition to 
providing two important antigenic saccharides for possible antibody screening, these results 
lend credence to the prospect of using this platform for the synthesis of carbohydrate 
libraries. 
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Introduction 
 
 To extend the scope of the automated solution-phase oligosaccharide synthesis 
platform [1, 2], two new oligosaccharides were tested to investigate the general applicability 
of the methods. Bacillus anthracis, which has spores called anthrax, is a well known cause of 
serious infections in cattle and other herbivores [3]. The structure of an antigenic surface 
oligosaccharide of the bacteria contains an exotic sugar called anthrose. This unusual 
terminal sugar is not found even in closely related species, which makes it an interesting 
target for carbohydrate-based vaccines and diagnostics for anthrax. During its synthesis [4], 
an intermediate from the anthrose building block resembles the repeating building block of 
perosamine that causes cholera [5]. Herein, we report the linear automated synthesis of 
anthrax (1) and cholera (2) tetrasaccharide by a divergent synthetic strategy targeting both 
building blocks. Key steps in our synthetic strategy for making the oligosaccharide include 
the selective inversion of the 6-deoxygenated D-galactose, microwave-accelerated reactions, 
and fluorous-tail assisted separation via fluorous column.  
 
Figure 3-1. Structures of the anthrax- and cholera-associated antigenic tetrasaccharide 
targets. 
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Results and discussion 
 
 
 Figure 3-2. Retrosynthetic analysis of the anthrax-associated tetrasaccharide target. 
 
Our synthetic scheme was designed to have a linear approach for both the anthrax- 
and cholera-antigenic tetrasaccharides and thereby mimic the biosynthetic pathway for these 
oligosaccharide compounds (Figure 3-2). The anthrax tetrasaccharide was started by 
synthesizing the first three building blocks from L-rhamnose (Figure 3-3). The 1,2- and 1,3- 
glycosidic linked building blocks were both made starting from the known 1,2-ortho ester-
rhamnose pyranoside [6]. Treating compound 6 with 1.3 equiv. benzyl bromide and sodium 
hydride provided not only the dibenzylated compound 7 but also the desired mono-
benzylated compound 8 in a 1:1.4 ratio. For the synthesis of the anthrax teterasaccharide, 
donors 9 and 4 are required in a 1:2 ratio. Therefore, these reaction conditions conveniently 
provided both donors [7]. The mono-benzylated compound was then protected at the 3-
position with a silyl group and further activated, after in situ opening of the orthoester to 
reveal a free anomeric hydroxyl, to give the desired trichloroacetimidate 4. Compound 7 was 
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directly activated in a similar manner to give the imidate compound 9, which was activated 
and then glycosylated to a fluorous tail [8] acceptor to provide (3). The fluorous tail at the 
anomeric position of the reducing end of the initial rhamnose building block will serve as a 
purification handle during the automation process. 
 
Figure 3-3. Synthetic strategy for the rhamnose building block.  
 
 
Figure 3-4. Synthetic strategy for the anthrose/perosamine building block from D-galactose  
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The anthrose/perosamine building block was started from D-galactose to give 
compound 10 in 4 steps. The D-fucose molecule was achieved by iodination followed by 
hydrogenation over Pd/C conditions. And after the 2 position was selectively protected and 
acetonide group removed, compound 14 was synthesized. To introduce the equatorial azide 
functionality 14 was introduced to a series of reaction conditions. After the triflate addition 
on the 4-position of the fucose derivative, the inversion step was conducted under microwave 
conditions with sodium azide to give compound 15 in 1 h. Under well-known procedures [9], 
the p-methoxyphenol(OMP) group was removed, and the building block was completed after 
activation to the trichloroacetimidate to give compound 5 for the anthrose building block. 
From the common intermediate 15, the perosamine building block was made by unmasking 
the levulinic ester group and performing a second inversion under microwave conditions. 
Triflate addition followed by inversion using tetra butyl ammonium acetate under microwave 
conditions ultimately provided compound 16. Finally, removal of the OMP group provided 
the anomeric alcohol and after activation to the trichloroacetimidate, the perosamine building 
block 17 was in hand. In order to provide the handle for automated purification in our 
solition-phase synthesis platform, a fluorous allyl alcohol was attached at the anomeric center 
of the reducing end of the molecule. Deacetylation of the fluorous-tagged monomer gave 18 
as the initial molecule to extend the chain under automation. 
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Figure 3-5. Divergent synthetic strategy for the anthrose and perosamine building block. 
 
With the initial acceptor monomers and donors in hand, programming of the 
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hours in 22% overall isolated yield. The anthrax tetrassaccharide automation protocol was 
necessarily different from the initial rhamnose pentasaccharide study because silyl and 
levulinate protecting groups were introduced. Due to the position of the protecting group (the 
O-3 position), longer than expected reaction times were required using 
tetrabutylammoniumfluoride (TBAF)/tetrahydrofuran (THF) for the desilylation conditions. 
However, the both deprotection conditions ultimately proved to be amenable to automation 
and thereby provided options in designing an orthogonal protecting group strategy in the 
future. The newly programmed deprotection conditions also resulted in high yields of the 
deprotected intermediate. The HPLC traces of the crude product from the robotics platform 
showed only one major product that was later characterized to be the desired tetrasaccahride 
compound. The robotics platform succesfully synthesized the anthrax-associated 
tetrasaccharide from two different donors and with two different deprotection protocols.  
 
After careful purification of the product collected from the synthesizer, 
tetrasaccharide 19 was further elaborated manually to provide the final compound ready for 
incorporation into fluorous-based microarrays [10] (Figure 3-6). First, the methylation was 
accomplished under silver oxide conditions with refluxing methyl iodide as solvent itself. 
Other conditions using various solvents instead of neat condition were reported to be 
inefficient to provide moderate yield [4]. The 4-azido group was then reduced to an amide for 
side chain attachment. The side chain synthesis was completed in 2 steps starting with ethyl 
bromoacetate (20) (Figure 3-7). Surprisingly, under microwave conditions, the Reformatsky 
reaction [11] was completed within 10 minutes even with unactivated zinc to give the desired 
compound 21. Following the completion of these studies on the side chain synthesis, another 
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group published experiments that show similar microwave-acceleration of the Reformatsky 
reaction [11]. Following purification of the Reformatsky product, the compound was 
oxidized to give the corresponding acid.  
 
 
Figure 3-6. Automated synthesis of the anthrax-associated tetrasaccharide and post-
automation modifications. 
 
 
 
Figure 3-7. Side chain synthesis of the anthrax tetrasaccharide  
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uroniumhexafluorophosphate (HATU), diisopropylethylamine (DIPEA) conditions to give 
the side chain attached compound. Global deprotection under standard basic and then 
hydrogenation conditions provided the final desired fluorous-tagged anthrax tetrasaccharide 
1. 
 
Figure 3-8. Automated synthesis of the cholera-associated tetrasaccharide and post-
automation modifications.  
 
 
Figure 3-9. Side chain synthesis of cholera tetrasaccharide. 
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cycles were executed to build the tetrasaccharide. In approximately 16 hours the ASW 
provided the desired compound 23 in high yields. For the perosamine tetrasaccharide, the 
identical program used for the optimization study with the rhamnose pentasaccharide 
molecule was used. After purification, the tetrasaccharide was subjected to radical reaction 
conditions to reduce the azido groups. The necessary amide-linked side chain was 
synthesized by a known method in 3 steps using (S)-malic acid as starting material [12] 
(Figure 3-9). The requisite acid compound was then attached to the amino groups of the 
molecule and, after global deprotection, the repeating unit cholera tetrasaccharide 2 was 
accomplished (Figure 3-8).  
 
Figure 3-10. Alternative synthetic route for the modified rhamnose donor 33.  
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to have the same deprotection time during the cycles (Figure 3-10). Then, using the program 
originally designed for the cholera oligosaccharide, it was possible to have a single program 
to make both compounds in parallel. The differing reaction times were not problematic; there 
was no evidence by thin layer chromatography (TLC) of significant decomposition of 
products between cycles. Both antigenic tetrasaccharides were successfully synthesized in 
high overall yields: 28% and 33% for the anthrax- and cholera- associated tetrasaccharides 
respectively (Figure 3-11). These overall yields translate to yields of 81% and 80% 
respectively per step for each of the two tetrasaccharides. 
 
 
Figure 3-11. Simultaneous synthesis of the two tetrasaccharides under automated conditions.  
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Conclusion 
 
The successful synthesis of both anthrax- and cholera-associated tetrasaccharides in 
parallel shows the power of the solution-based automation platform for the synthesis of pure 
structurally well-defined carbohydrate compounds. Automation protocols were developed 
that were capable of adding various building blocks for standard glycosylation conditions and 
able to carry out different solution-phase deprotection conditions to completion. The fluorous 
tag offers a convenient and apparently robust purification tool for automated oligosaccharide 
synthesis to eliminate byproducts throughout the synthesis. In addition to providing two 
important antigenic saccharides for possible antibody screening, these results lend credence 
to the prospect of using this platform for the synthesis of carbohydrate libraries. 
 
 
Experimental section 
 
General methods 
 
All commercial reagents and solvents were used as received without further 
purification unless indicated. Reaction solvents were distilled from calcium hydride for 
dichloromethane and from sodium metal and benzophenone for diethyl ether. Amberlyst 15 
ion-exchange resin was washed repeatedly with methanol before use. The reactions were 
monitored and the Rf values determined using analytical thin layer chromatography (tlc) with 
0.25 mm EM Science silica gel plates (60F-254). The developed tlc plates were visualized by 
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immersion in p-anisaldehyde solution followed by heating on a hot plate. Silica gel flash 
chromatography was performed with Selecto Scientific silica gel, 32-63 mm particle size. 
Fluorous phase chromatography was performed using fluorous solid-phase extraction 
cartridges containing silica gel bonded with perfluorooctylethylsilyl chains (Fluorous 
Technologies, Inc.; Pittsburgh, PA). All other fluorous reagents were also obtained from 
Fluorous Technologies, Inc. All moisture sensitive reactions were performed in flame- or 
oven- dried glassware under nitrogen atmosphere. Bath temperatures were used to record the 
reaction temperature in all cases run without microwave irradiation. All reactions were 
stirred magnetically at ambient temperature unless otherwise indicated. 1H NMR and 13C 
NMR spectra were obtained with a Bruker DRX400 at 400 MHz and 162 MHz, Varian400 at 
400 MHz and 100 MHz or Varian300 at 300 MHz and 75 MHz respectively. 1H NMR 
spectra were reported in parts per million (δ) relative to CDCl3 (7.27 ppm) as an internal 
reference. 13C NMR spectra were reported in parts per million (δ) relative to CDCl3 (77.23 
ppm) or CD3OD (49.15 ppm). HPLC traces were obtained from a Varian Inc. HPLC system 
using a Waters Nova-pak 4 µL 3.9 ×150 mm silica column. High-resolution mass 
spectrometry was obtained with Applied Biosystems QSTAR XL Hybrid System from the 
W. M. Keck Metabolomics Research Laboratory or Applied Biosystems DE-Pro MALDI 
mass analyzer from the protein facility at Iowa State University. 
 
 
 
 
General procedure for automated synthesis cycles using ASW 1000  
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Figure 3-12. ASW Automated Synthesizer layout for anthrax associated tetrasaccharide. 
 
1. Sample Preparation 
 
Donor molecule (265.4 mg, 500 µmol) was dissolved with dried toluene (2.5 mL) in 
the 13 mL vial and placed at the stock solution rack (Donor 1) under argon. 0.27 M 
trimethylsilyltrifluoromethanesulfonate (TMSOTf, 1.05 mL) solution in toluene prepared in 
the 8 mL vial and placed as indicated on the stock solution rack under argon. Dried toluene 
(1 L) was placed in the stock solution bottle and placed at the reservoir bottle rack with 
tubing as reservoir solution for rinsing. Methanol (100 mL), 80% methanol/water (100 mL), 
triethylamine (8 mL) were prepared in stock solution bottles and connected to the transfer 
ports. Acceptor molecule (43.7 mg, 50 µmol) was dissolved with dried toluene (0.5 mL) in a 
Wheaton 8 mL E-Z extraction vial (conically- bottomed) capped with pre-punctured septa 
and placed at the reagent rack where indicated (F-tagged OH).  
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0.5 M sodium methoxide solution in methanol (5 mL) was prepared in 8 mL vial 
capped with pre-punctured septa and placed at the reagent rack. 0.2 M acetic acid solution in 
methanol (5 mL) (or TBAF solution in THF, Hydrazine acetate in MeOH/DCM) was 
prepared in 8 mL vial capped with pre-punctured septa and placed at the reagent rack where 
indicated. N, N-dimethylformamide (DMF, 5 mL) directly from Fluka was transferred in 8 
mL vial capped with pre-punctured septa and placed at the reagent rack where indicated. 
Fluorous solid phase extraction (FSPE) cartridge (2 g, 10 cc) was preconditioned with 80% 
methanol(/water) and placed at machined SPE block. An empty Wheaton 8 mL E-Z 
extraction vial was placed under the FSPE cartridge.  
 
2. Cleaning Cycle 
 
Prior to introduction of reagents, the ASW1000 reactor vials were cleaned, dried and 
purged with argon by running the cleaning cycle. During the cleaning cycle each of the 16 
reactor vials (13 mL) were rinsed with 8 mL toluene and 8 mL methanol 3 times each. After 
the solvents were completely removed, the reactor vials were dried under vacuum and purged 
with argon for 45 minutes. Reagent solutions were prepared by azeotroping the building 
blocks individually with toluene and dried under high vacuum. After the cleaning cycles 
were done, the reagents were transferred into the reagent vials respectively, which were then 
placed on the inert condition reagent rack and general atmosphere reagent rack.   
 
3. Method Run 
 
3.1. Glycosylation 
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Reactor vials were cooled to 0 oC during the 5 minutes wait time by the heat transfer 
oil. Then flat-tipped open vial needle transferred the acceptor molecule (F-tagged OH) 
solution (0.6 mL) to the reaction vial 1, followed by the transfer of the acceptor molecule 
solution (0.5 mL) and the TMSOTf solution (56 µL). After each individual transfer, the 
needle was rinsed by 2 mL toluene inside and out before operating the next task. The reaction 
mixture was vortexed at 800 rpm for 30 minutes at 0 oC under inert gas.  After the reaction 
time the needle withdrew 30 µL of the solution from the reaction mixture and placed it into 
the first well of the microtiterplate for thin layer chromatography monitoring. Triethylamine 
(0.5 mL) was added to the solution for quenching and solvent evaporated under reduced 
pressure.   
 
3.2. Deacetylation 
 
To the dried residue, methanol (0.5 mL) was added to the reactor vial followed by 
sodium methoxide solution (0.4 mL). The reaction mixture was vortexed at 800 rpm for 3 
hours at room temperature. After the reaction time the needle withdrew 30 µL from the 
reaction mixture and placed it into the second well of the microtiterplate for thin layer 
chromatography monitoring. Acetic acid (0.75 mL) solution was added to reactor vial for 
quenching followed by addition of toluene (1 mL) and solvent was evaporated under reduced 
pressure.   
 
3.3. Desilylation 
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To the dried residue, THF (0.5 mL) was added to the reactor vial followed by TBAF 
solution (0.4 mL). The reaction mixture was vortexed at 800 rpm for 10 hours at room 
temperature. After the reaction time the needle withdrew 30 µL from the reaction mixture 
and placed it into the second well of the microtiterplate for thin layer chromatography 
monitoring. Toluene (1 mL) was added tor eactor vial and solvent was evaporated under 
reduced pressure.   
 
3.4. Delevulination 
 
To the dried residue, DCM (0.5 mL) was added to the reactor vial followed by 
Hydrazine Acetate/methanol solution (0.4 mL). The reaction mixture was vortexed at 800 
rpm for 3 hours at room temperature. After the reaction time the needle withdrew 30 µL from 
the reaction mixture and placed it into the second well of the microtiterplate for thin layer 
chromatography monitoring. Acetone (0.75 mL) solution was added to reactor vial for 
quenching followed by addition of toluene (1 mL) and solvent was evaporated under reduced 
pressure.   
 
3.5. FSPE 
 
DMF (0.7 mL) was added to dissolve the crude mixture and the vials were vortexed at 
100 rpm for 5 minutes. Reaction mixture (0.8 mL) was carried to the FSPE cartridge at the 
SPE rack dispensed at a speed of 20 mL/s via the 10 mL syringe. Then 80% methanol (4.5 
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mL) was used to rinse the empty reactor vial. 80% methanol solvent was removed from the 
reactor vial each time (1.7 mL, 1.5 mL, 1.5 mL) and delivered to the FSPE cartridge. 
Additional 80 % methanol solution (1 mL) was used to rinse the FSPE cartridge. During the 
80% methanol rinse, the cartridge was positioned at ‘SPE waste’ for the eluted mixture to be 
disposed. Methanol (1.5 mL, repeated 3 times) was used to wash the FSPE cartridge for 
eluting the desired compound. During the task, the FSPE cartridge was positioned as ‘SPE 
collect’ to be placed right above the 8 mL vial for collection of the sample. After the task, the 
position of the SPE rack was changed into ‘SPE direct’ for the needle to withdraw the 
collected sample from the vial and deliver it to the clean reactor vial for the next reaction. 
Toluene (1 mL) was added to the solution and solvent was evaporated under reduced 
pressure. After evaporation cycle, once again toluene (1 mL) was added and removed under 
reduced pressure for complete dryness. 
 
Synthetic Procedures 
 
 
4-O-Benzyl-1,2-O-methylethylidene-β-L-rhamnopyranose (8)  
 
To a solution of 6 (3.34 g, 15.2 mmol) in dry DMF (25 mL) were added sodium hydride 
(0.72 g 13.3 mmol) and benzylbromide (2.67 mL, 22.5 mmol) at 0 oC. The reaction mixture 
was stirred for 2 hours at 0 oC. Then reaction mixture was diluted with ethyl acetate (100 
mL) and the organic layer was washed with 2N HCl solution (2 × 100 mL), brine (2 × 100 
O
BnO
HO
O
O
OMe
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mL) and dried (Mg2SO4), concentrated under reduced pressure. Crude product was purified 
by flash column chromatography on silica gel using 30% EtOAc/hexane as eluent to provide 
the dibenzylated (1.94 g, 4.85 mmol, 32%, white solid) and monobenzylated product (2.16 g, 
6.98 mmol, 46%, colorless oil).  
 
Rf (ethyl acetate/hexane): 0.56 (2/3).  
1H NMR (CD3OD, 400MHz): δ (ppm) 7.46-7.29 (m, 5H, Ar-H), 5.46 (d, J = 2.1 Hz, 1H, H-
1), 4.73 (s, 2H, CH2), 4.84 (dd, J = 4.2 Hz, 2.4 Hz, 1H, H-2), 3.58 (dd, J = 9.3 Hz, 4.2 Hz, 
1H, H-3), 3.69 (t, J = 9.3 Hz, 1H, H-4), 3.30 (m, 1H, H-5), 3.20 (s, 3H, OCH3), 1.59 (s, 3H, 
CH3), 1.26 (d, J = 6.0 Hz, 3H, CH3). 
13C NMR (CD3OD, 100 MHz): δ (ppm) 139.9, 129.5, 129.3, 128.9, 125.1, 99.1, 80.4, 79.1, 
73.4, 72.5, 72.0, 49.8, 25.5, 18.1. 
HRMS-MALDI (m/z): [M+Na]+ Calcd: 333.1314; Found: 333.1470.  
  
 
 
2-O-Acetyl-4-O-benzyl-3-O-tertbutyldimethylsilyl-β-L-rhamnopyranosyl 
Trichloroacetimidate (4)  
 
To a solution of the monobenzylated orthoester (8) (650 mg, 2.09 mmol) in DMF (20 mL) 
were added imidazole  (428 mg, 6.28 mmol) and TBSCl (632 mg, 4.18 mmol). The reaction 
O
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mixture was stirred for 3 hr at 50 oC. After TLC starting material was completely converted, 
reaction mixture was diluted with dichloromethane (50 mL). 2N HCl solution (100 mL) was 
added to the diluted organic mixture and was stirred for 30 min. The organic layer was 
washed with additional 2N HCl solution (2 × 100 mL), brine (2 × 100 mL) and dried 
(Mg2SO4), concentrated under reduced pressure. Crude product was purified by flash column 
chromatography on silica gel using 30% EtOAc/hexane as eluent to provide 2-O-acetyl-4-O-
benzyl-3-O-tertbutyldimethylsilyl-α/β-L-rhamnopyranose (760 g, 1.79 mmol, 86%, colorless 
oil).  
 
To a solution of 2-O-acetyl-4-O-benzyl-3-O-tertbutyldimethylsilyl-α/β-L-rhamnopyranose 
(760 mg, 1.85 mmol) in dry CH2Cl2 (10 mL) were added distilled trichloroacetonitrile (0.927 
mL, 9.25 mmol) and Cs2CO3 (1.50 mg, 4.65 mmol). The reaction mixture was stirred for 1 h 
at room temperature. Then after reaction mixture was filtered over Celite, solvent was 
concentrated under reduced pressure. Crude product was purified by flash column 
chromatography on silica gel using 20% EtOAc/hexane as eluent to provide the product as a 
colorless oil (890 mg, 1.65 mmol, 87%).  
 
Rf (ethyl acetate/hexane): 0.60(1/4).  
1H NMR (CDCl3, 400 MHz): δ (ppm) 8.65 (s, 1H), 7.39-7.29 (m, 5H), 6.14 (s, 1H), 5.24 (t, 
J = 2.4 Hz, 1H), 4.94 (d, J = 10.8 Hz, 1H), 4.64 (d, J = 10.8 Hz, 1H), 4.22 (dd, J = 9.2 Hz, 3.2 
Hz, 1H), 3.93 (m, 1H), 3.48 (t, J = 9.6 Hz, 1H), 2.19 (s, 3H), 1.31 (d, J = 6.0 Hz, 1H), 0.92 (s, 
9H), 0.11 (s, 6H). 
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13C NMR (CDCl3, 100 MHz): δ (ppm) 170.3, 160.3, 138.3, 128.6, 128.2, 128.0, 95.2, 91.2, 
80.8, 75.9, 71.5, 71.1, 71.0, 26.0, 21.2, 18.1, 18.1, -0.5, -0.5.  
HRMS-MALDI (m/z): [M+Na]+ Calcd: 576.1119; Found: 576.2440.  
 
 
Allyl 4-O-benzyl-2,3-O-methoxyethylidene-α-L-rhamnopyranose (28) 
 
To a solution of 27 (4.46 g, 21.3 mmol) in DCM (50 mL) was added CH3C(OMe)3 (6.8 mL, 
53.4 mmol) and CSA (247 mg, 1.07 mmol) at room temperature. The reaction mixture was 
stirred at room temperature for 1 h. After TLC showed completed conversion of the starting 
material the reaction was quenched with a few drops of TEA. Solvent was removed under 
reduced pressue and crude product was purified by flash column chromatography on silica 
gel using 20% EtOAc/hexane as eluent to provide the titled product as colorless oil (4.91g, 
18.9 mmol, 88%).  
 
Rf (ethyl acetate/hexane): 0.57 (2/3).  
1H NMR (CD3OD, 400 MHz): δ (ppm) 6.03 (m, 1H), 5.47 (dd, J = 17.2 Hz, 1.6 Hz, 1H), 
5.25 (dd, J = 10.4 Hz, 1.2 Hz, 1H), 5.00 (s, 1H), 4.33 (d, J = 6.0 Hz, 1H), 4.22 (m, 2H), 4.08 
(dd, J = 11.6 Hz, 4.8 Hz, 1H), 3.65 (m 1H), 3.26 (m, 1H), 1.63 (s, 3H), 1.29 (d, J = 6.0 Hz, 
3H).  
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13C NMR (CD3OD, 100 MHz): δ (ppm) 135.7, 122.7, 117.8, 97.3, 77.9, 75.3, 69.1, 66.6, 
50.1, 23.6, 17.8. 
HRMS-MALDI (m/z): [M+Na]+ Calcd: 283.1158; Found: 283.1760. 
 
 
Allyl 2-O-acetyl-4-O-benzyl-α-L-rhamnopyranoside (30) 
 
To a solution of 28 (458 mg, 1.76 mmol) in DMF (10 mL) was added BnBr (0.313 mL, 2.64 
mmol), and NaH (60%, 140 mg, 3.52 mmol) at room temperature. The reaction mixture was 
stirred at room temperature for 1 hr. After TLC confirmed complete starting material 
consumption the reaction mixture was diluted with dichloromethane (20 mL), washed with 
water (20 mL), NaHCO3 solution (20 mL), and brine (20 mL), and dried over MgSO4. 
Solvent was removed under reduced pressure and the crude product allyl 4-O-benzyl-2,3-O-
methoxyethylidene-α-L-rhamnopyranose (589 mg, 1.68 mmol, 96 %) was used for the next 
step without purification. 
 
To a solution of allyl 4-O-benzyl-2,3-O-methoxyethylidene-α-L-rhamnopyranose (538 mg, 
1.538 mmol) in dry dichloromethane (10 mL), was added TfOH/water (v:v=3:2, 0.95 mL) 
solution at room temperature. The reaction mixture was stirred at room temperature for 1 hr. 
After TLC confirmed complete starting material consumption, the reaction mixture was 
diluted with dichloromethane (20 mL), washed with water (20 mL), NaHCO3 solution (20 
O
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mL), and brine (20 mL), and dried over MgSO4. After the solvent was removed under 
reduced pressure, crude product was purified by flash column chromatography on silica gel 
using 25% EtOAc/hexane as eluent to obtain the title compound (501 mg, 1.49 mmol, 97%) 
as colorless oil.  
 
Rf: (ethyl acetate/hexane) 0.5 (40/60) 
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.35-3.26 (m, 5H), 5.87 (m, 1H), 5.27-5.23 (dd, J = 
17.2 Hz, 1.6 Hz, 1H), 5.17 (dd, J = 17.4 Hz, 1.2 Hz, 1H), 5.09 (dd, J = 3.6 Hz, 1.6 Hz, 1H), 
4.85 (d, J = 11.2 Hz, 1H), 4.74 (d, J = 1.2 Hz, 1H), 4.68 (d, J = 11.2 Hz, 1H), 4.12-4.07 (m, 
2H), 3.93 (dd, J = 12.8 Hz, 6.0 Hz, 1H), 3.75 (m, 1H), 3.36 (t, J = 9.2 Hz, 1H), 2.56 (d, J = 
5.2 Hz, 1H), 2.0 (s, 3H), 1.32 (d, J = 6.4 Hz, 3H).  
13C NMR (CDCl3, 100 MHz): δ (ppm) 171.0, 138.3, 133.6, 128.5, 128.0, 127.9, 117.6, 96.6, 
81.7, 75.3, 72.9, 70.2, 68.1, 67.5, 21.1, 18.0.  
HRMS-MALDI(m/z): [M+Na]+ Calcd: 359.1471; found: 359.2668.  
 
 
Allyl 2-O-acetyl-4-O-benzyl-3-O-levulinyl-α-L-rhamnopyranoside (31) 
 
To a solution of 30 (457.5 g, 1.36 mmol) in anhydrous dichloromethane (5 mL), was added 
DMAP (165 mg, 1.36 mmol), levulinic acid (0.167 mL, 1.63 mmol), DCC (335.8 g, 1.63 
mmol) at 0 oC. The reaction mixture was stirred at 0 oC for 1 hr under nitrogen. After TLC 
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showed complete conversion, reaction mixture was filtered and concentrated under reduced 
pressure. Crude product was purified by flash column chromatography on silica gel using 
30% EtOAc/hexane as eluent to provide the product as colorless oil (507 mg, 1.17 mmol, 
86%).  
 
Rf (ethyl acetate/hexane): 0.40 (3/7).  
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.28-7.23 (m, 5H), 5.82 (m, 1H), 5.29 (dd, J = 10 hA, 
3.6 Hz, 1H), 5.24-5.20 (m 2H), 5.13 (dd, J = 10.4 Hz, 1.6 Hz, 1H), 4.67 (m, 2H), 4.58 (d, J = 
11.2 Hz, 1H), 4.06 (dd, J = 11.8 Hz, 4.0 Hz, 1H), 3.92 (dd, J = 12.8 Hz, 4.8 Hz, 1H), 3.78 (m, 
1H), 3.46 (t, J = 9.6 Hz, 1H), 2.68 (m, 2H), 2.43 (m, 2H), 2.07 (s, 3H), 2.07 (s, 3H), 1.27 (d, J 
= 6.0 Hz, 3H). 
13C NMR (CDCl3, 100 MHz): δ (ppm) 206.2, 171.7, 170.1, 138.1, 138.4, 128.4, 127.8, 96.4, 
78.7, 75.0, 70.3, 68.0, 67.7, 37.8, 29.7, 27.9, 20.9, 17.9. 
HRMS-MALDI(m/z): [M+Na]+ Calcd: 457.4693; Found: 457.3035. 
 
 
 
2-O-Acetyl-4-O-benzyl-3-O-levulinyl-α/β-L-rhamnopyranosyl Trichloroacetimidate (33) 
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To a solution of 31 (527 mg, 1.21 mmol) in dry THF (6 mL), was added 
Ir(COD)(PMePh2)2
.HPF6  (10 mg, 12.1 µmol). After the reaction flask was evacuated, H2 
balloon was added until the reaction mixture turned to a pale yellow. The hydrogen balloon 
was removed and the reaction mixture was stirred under nitrogen at room temperature for an 
additional 3 h. The reaction was diluted with dichloromethane (20 mL), washed with water 
(20 mL), HCl (2N, 20 mL), and brine (20 mL), and dried over MgSO4. The solvent was 
concentrated under reduced pressure to give crude product to be used directly for the next 
step.  
 
To a solution of the crude isomerized compound (520 mg, 1.19 mmol) in acetone/water (5/1, 
6 mL) was added HgCl2 (328.5 mg), and HgO (262 mg) at room temperature. The reaction 
mixture was stirred under nitrogen for 5 hours then was diluted with dichloromethane (20 
mL), wased with aqueous KI solution (20 mL), water (20 mL), HCl (2 N, 20 mL), and brine 
(20 mL), and dried over MgSO4. After the solvent was removed under reduced pressure, 
crude product was purified by flash column chromatography on silica gel using 15% 
EtOAc/hexane as eluent to obtain the free anomeric intermediate 32 (458 mg, 0.16 mmol, 
97%) as colorless oil.  
 
To a solution of 32 (456.9 mg, 1.159 mmol) in dry CH2Cl2 (10 mL) were added distilled 
trichloroacetonitrile (0.581 mL, 5.79 mmol) and Cs2CO3 (944 mg, 2.90 mmol). The reaction 
mixture was stirred for 1 h at room temperature. Then after reaction mixture was filtered over 
Celite, solvent was concentrated under reduced pressure. Crude product was purified by flash 
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column chromatography on silica gel using 20% EtOAc/hexane as eluent to provide the 
product as colorless oil (604.65 mg, 1.19 mmol, 97.4%).  
 
Rf (ethyl acetate/hexane): 0.6 (2/3).  
1H NMR (CDCl3, 400 MHz): δ (ppm) 8.66 (s, 1H), 7.31-3.24 (m, 5H), 6.13 (s, 1H), 5.42 
(dd, J = 3.2 Hz, 2.0 Hz, 1H), 5.33 (dd, J = 9.6 Hz, 3.2 Hz, 1H), 4.76 (d, J = 10.8 Hz, 1H), 
6.63 (d, J = 10.8 Hz, 1H), 4.01 (m, 1H), 3.60 (t, J = 9.6 Hz, 1H), 2.72 (m, 1H), 2.52 (m, 1H), 
2.13 (s, 3H), 2.11 (s, 3H), 1.33 (d, J = 6.0 Hz, 3H).  
13C NMR (CDCl3, 100 MHz): δ (ppm) 206.1, 171.8, 169.8, 137.7, 128.4, 128.0, 127.9, 94.8, 
90.7, 77.9, 75.24, 71.7, 70.6, 68.5, 37.8, 29.8, 27.8, 20.8, 18.0.  
HRMS-ESI (m/z): [M+Na]+ Calcd: 560.0622; Found: 560.0199. 
 
 
 
4-Methoxyphenyl 3,4-O-isopropylidene-β-D-galactopyranoside (10) 
 
To a solution of 4-methoxyphenyl β-D-galactopyranoside (452 mg, 1.57 mmol) in dry DMF 
(5 mL) were added 2,2-dimethoxy propane (0.40 mL, 3.23 mmol) and CSA (74 mg, 0.31 
mmol). The reaction mixture was stirred for 12 h at room temperature. After reaction mixture 
was quenched with triethylamine (1 mL), solvent was evaporated under reduced pressure. 
Crude product was purified by flash column chromatography on silica gel using 30% 
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EtOAc/hexane as eluent to provide the titled product as colorless oil (453 mg, 1.38 mmol, 
88%).  
 
Rf (ethyl acetate/hexane): 0.15 (2/3).  
1H NMR (CDCl3, 400 MHz): δ (ppm) 6.99 (d, J = 9.2 Hz, 2H, Ar-H), 6.84 (d, J = 8.8 Hz, 
2H, Ar-H), 4.72 (d, J = 8.4 Hz, 1H, H-1), 4.20-4.16 (m, 2H), 4.09-3.97 (d, 2H), 3.87-3.80 (d, 
2H), 3.76 (s, 3H, -OCH3), 2.69 (d, J = 2.4 Hz, 1H, OH), 2.20 (dd, J = 9.2 Hz, 3.2 Hz, 1H, 
OH), 1.53 (s, 3H, CH3), 1.38 (s, 3H, CH3). 
13C NMR (CDCl3, 100 MHz): δ (ppm) 155.4, 151.1, 118.8, 114.6, 110.5, 101.5, 79.1, 73.8, 
73.7, 73.2, 62.1, 55.7, 26.4, 25.6. 
HRMS-ESI (m/z): [M+Na]+ Calcd: 349.1263; Found: 349.1263. 
 
 
 
4-Methoxyphenyl 6-iodo-3,4-O-isopropylidene-β-D-galactopyranoside (11) 
 
To a solution of 10 (616 mg, 1.89 mmol) in toluene (10 mL), was added iodine (718.8 mg 
2.83 mmol), imidazole (257 mg, 3.78 mmol) and triphenylphosphine (743 mg, 2.83 mmol). 
The reaction mixture was refluxed for 2 h. After TLC showed complete conversion, reaction 
mixture was cooled to room temperature and diluted with ethyl acetate. The mixture was 
washed with Na2CO3 solution (3 × 30 mL), water (3 × 30 mL) and brine (3 × 30 mL). The 
O
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organic layer was dried (Mg2SO4) and concentrated under reduced pressure. Crude product 
was purified by flash column chromatography on silica gel using 20% EtOAc/hexane as 
eluent to provide the product as colorless oil (669.65 mg, 1.60 mmol, 85%).  
 
Rf (ethyl acetate/hexane): 0.4 (2/3).  
1H NMR (CDCl3, 400 MHz): 7.05 (d, J = 9.2 Hz, 2H, Ar-H), 6.83 (d, J = 8.8 Hz, 2H, Ar-H), 
4.64 (d, J = 8.4 Hz, 1H, H-1), 4.35 (dd, J = 5.6 Hz, 2 Hz, 1H), 4.19 (dd, J = 7.2 Hz, 5.2 Hz, 
1H), 4.02 (dt, J = 6.4 Hz, 2.4 Hz, 1H), 3.83 (dd, J = 7.6 Hz, 2.4 Hz, 1H), 3.78 (s, 3H, -OCH3), 
3.42 (m, 2H, H-6), 2.81 (d, J = 2.8 Hz, 1H, OH), 1.58 (s, 3H, CH3), 1.39 (s, 3H, CH3).  
13C NMR (CDCl3, 100 MHz): δ (ppm) 155.8, 151.9, 118.8, 114.6, 110.5, 102.0, 78.9, 74.3, 
74.0, 73.2, 62.1, 55.8, 28.1, 26.5, 2.0.  
HRMS-ESI (m/z): [M+Na]+ Calcd: 459.0281; Found: 459.0212 
 
 
4-Methoxyphenyl 6-desoxy-3,4-O-isopropylidene-β-D-galactopyranoside (12) 
 
To a solution of 11 (143 mg, 0.33 mmol) in methanol (1 mL) and triethylamine (0.15 mL), 
was added 10% Pd/C (50 mg). After the air was evacuated from the reaction flask, a 
hydrogen balloon was attached. The reaction mixture was stirred at room temperature for 10 
h. After TLC showed complete conversion, reaction mixture was filtered over Celite and 
concentrated under reduced pressure. Crude product was purified by flash column 
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chromatography on silica gel using 20% EtOAc/hexane as eluent to provide the titled product 
as colorless oil (98 mg, 0.32 mmol, 96%).  
 
Rf (ethyl acetate/hexane): 0.43 (2/3).  
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.01-6.98 (d, J = 11.6 Hz, 2H, Ar-H), 6.84-6.81 (d, J 
= 11.6 Hz, 2H, Ar-H), 4.65 (d, J = 8.4 Hz, 1H, H-1), 4.14 (dd, J = 5.6 Hz, 7.2 Hz, 1H, H-3), 
4.06 (dd, J = 2.4, Hz, 5.2 Hz, 1H, H-4), 3.97 (m, 1H, H-5), 3.80 (t, J = 7.6 Hz, 1H, H-2), 3.77 
(s, 3H, -OCH3), 1.57 (s, 3H, CH3), 1.45 (d, J = 6.4 Hz, 3H, CH3), 1.38 (s, 3H, CH3).   
13C NMR (CDCl3, 100 MHz): δ (ppm) 155.8, 151.4, 119.0, 114.6, 110.2, 101.2, 79.0, 76.8, 
73.3, 69.3, 55.8, 28.4, 26.5, 16.5.  
HRMS-ESI (m/z): [M+Na]+ Calcd: 333.1314; Found: 333.1417.  
 
 
 
4-Methoxyphenyl 6-desoxy-3,4-O-isopropylidene-2-levulinoyl-β-D-galactopyranoside (13) 
 
To a solution of 12 (1.64 g, 5.27 mmol) in anhydrous dichloromethane (50 mL), was added 
DMAP (640 mg, 5.27 mmol), levulinic acid (1 mL, 10.54 mmol), DCC (2.1 g, 10.54 mmol) 
at 0 oC. The reaction mixture was stirred at 0 oC for 1 h under nitrogen. After TLC showed 
complete conversion, reaction mixture was filtered and concentrated under reduced pressure. 
Crude product was purified by flash column chromatography on silica gel using 30% 
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EtOAc/hexane as eluent to provide the titled product as colorless oil (2.0 g, 4.90 mmol, 
93%).  
 
Rf (ethyl acetate/hexane): 0.33 (2/3).  
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.02-6.99 (d, J = 11.6 Hz, 2H, Ar-H), 6.85-6.81 (d, J 
= 11.6 Hz, 2H, Ar-H), 5.20 (t, J = 8.0 Hz, 1H, H-2), 4.77 (d, J = 8.4 Hz, 1H, H-1), 4.21 (dd, J 
= 7.2 Hz, 5.2 Hz, 1H, H-3), 4.16 (dd, J = 5.6 Hz, 2.0 Hz, 1H, H-4), 3.97 (m, 1H, H-5), 3.76 
(s, 3H, -OCH3), 2.95-2.59 (m, 4H, CH2), 2.15 (s, 3H, CH3), 1.61 (s, 3H, CH3), 1.45 (d, J=6.4 
Hz, 3H, CH3), 1.38 (s, 3H, CH3). 
13C NMR (CDCl3, 100 MHz): δ (ppm) 171.8, 155.6, 151.6, 118.9, 114.6, 110.5, 100.2, 77.2, 
76.4, 73.2, 69.2, 55.8, 38.1, 30.1, 28.1, 27.9, 26.6, 16.8. 
HRMS-MALDI (m/z): [M+Na]+ Calcd: 431.1682; Found: 431.1441. 
 
 
4-Methoxyphenyl 3-O-benzyl-6-desoxy-2-O-levulinoyl-β-D-galacotopyranoside (14) 
 
To a solution of 13 (200 mg, 0.49 mmol), 80% acetic acid/water (10 mL) was added. The 
reaction mixture was brought to 80 oC and stirred under nitrogen for 1 h. After TLC showed 
complete comversion, the reaction flask was cooled to room temperature and solvent was 
removed under reduced pressure. Crude product was directly used for next reaction without 
further purification. 
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To a solution of 4-methoxyphenyl 6-desoxy-2-O-levulinoyl-β-D-galacotopyranoside (63 mg, 
0.17 mmol) in toluene (3 mL), was added dibutyltin oxide (85 mg, 0.34 mmol) and brought 
to reflux. The reaction was stirred for 1 h until the reaction mixture turned clear, and then 
cooled to room temperature. To the cooled reaction mixture, tetrabutyl ammonium iodide (69 
mg, 0.19 mmol), benzyl bromide (0.02 mL, 0.21 mmol) was added and the flask was brought 
to reflux again for 5 hours. After TLC showed no starting material left, the reaction solvent 
was removed under reduced pressure to obtain crude product. After purification using silica 
gel flash chromatography eluting with 20% EtOAc/Hexane to give titled compound (62 mg, 
0.14 mmol, 80%) as a colorless oil.  
 
Rf (ethyl acetate/hexane): 0.27(β) (2/3).  
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.40-7.32 (m, 5H, Ar-H), 6.98 (d, J = 8.8 Hz, 2H, Ar-
H), 6.79 (d, J = 8.8Hz, 2H, Ar-H), 5.39 (dd, J = 9.6 Hz, 8.4 Hz, 1H, H-2), 4.78 (d, J = 8.0 Hz, 
1H, H-1), 4.74 (d, J = 12.4 Hz, 1H, CH2), 4.61 (d, J = 12.4 Hz, 1H, CH2), 3.84 (d, J = 2.8 Hz, 
1H, H-4), 3.77 (s, 3H, CH3), 3.66 (m, 1H, H-5), 3.58 (dd, J = 9.6 Hz, 3.2 Hz, 1H, H-3), 2.86-
2.51 (m, 2H, CH2), 2.74-2.61 (m, 2H, CH2), 2.18 (s, 3H, CH3), 1.4 (d, J = 6.0 Hz, 3H, CH3). 
13C NMR (CDCl3, 100 MHz): δ (ppm) 171.8, 151.7, 137.6, 128.8, 128.3, 128.1, 118.9, 
114.6, 100.9, 78.9, 71.9, 71.0, 70.0, 68.9, 55.8, 38.1, 30.1, 28.2, 16.6. 
HRMS-ESI (m/z): [M+Na]+ Calcd: 481.1838; Found: 481.2004. 
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4-Methoxyphenyl 4-azido-3-O-benzyl-4,6-dideoxy-2-O-levulinoyl-α/β-D-glucopyranoside 
(15) 
 
To a solution of 14 (736 mg, 1.61 mmol), in CH2Cl2 (10 mL) and pyridine (1.3 mL), was 
added triflic anhydride (0.41 mL, 2.4 mmol) at 0 oC. The reaction was stirred for 1 h, then 
quenched with few drops of water, and extracted with ethyl ether (3 × 30 mL). The organic 
mixture was washed with saturated Na2CO3 solution (3 × 30 mL), dried (Mg2SO4), 
concentrated under reduced pressure and used directly for the next step. 
 
To a solution of triflate (138 mg, 0.24 mmol) in DMF (4 mL), was added NaN3 (155.37 mg, 
2.39 mmol). The mixture was placed in a CEM Voyager microwave and set at 70 oC for 1 h, 
then quench with 1 mL of water. Mixture was extracted with ethyl ether (3 × 20 mL), and 
organic mixture was washed with saturated Na2CO3 solution (3 × 20 mL), dried (Mg2SO4), 
concentrated under reduced pressure and then purified using silica gel flash chromatography 
eluting with 15% EtOAc/Hexane to give titled compound (94 mg, 0.20 mmol, 82%) as a 
colorless oil.  
 
Rf (ethyl acetate/hexane): 0.57(β) (2/3).  
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.38-7.32 (m, 5H, Ar-H), 7.02 (d, J = 8.8 Hz, 2H, Ar-
H), 6.83 (d, J = 8.8Hz, 2H, Ar-H), 5.25 (t, J = 8.4 Hz, 1H, H-2), 4.88-4.68 (dd, d, J = 11.2 
Hz, 8.4 Hz, 3H, H-1, CH2), 3.77 (s, 3H, CH3), 3.63 (t, J = 9.2 Hz, 1H, H-4), 3.41-3.24 (m, t, J 
= 9.6 Hz, 2H, H-3, H-5), 2.74-2.61 (m, 2H, CH2), 2.57-2.47 (m, 2H, CH2), 2.18 (s, 3H, CH3), 
1.4 (d, J = 6.0 Hz, 3H, CH3). 
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13C NMR (CDCl3, 100 MHz): δ (ppm) 206.23, 170.87, 157.33, 150.91, 137.66, 128.70, 
128.56, 128.22, 118.43, 114, 89, 100.50, 81.22, 75.02, 73.69, 71.17, 67.84, 55.97, 38.78, 
30.01, 27.99, 19.13.  
HRMS-ESI (m/z): [M+Na]+ Calcd: 506.1903; Found: 506. 2989. 
 
 
4-Azido-3-O-benzyl-4,6-dideoxy-2-O-levulinoyl-α-D-glucopyranosyl Trichloroacetimidate 
(5) 
 
To a solution of 15 (166 mg, 0.39 mmol) in acetonitrile (10 mL)/water (2.5 mL) mixture. 
Cerium ammonium nitrate (2.13 g, 3.89 mmol) was added to the solution and stirred for 2 h 
at room temperature. After TLC confirmed consumption of starting material, the mixture was 
diluted with ethyl acetate and was washed with water (3 × 30 mL), dried (Mg2SO4), 
concentrated under reduced pressure. The crude product was purified by column 
chromatography (1:2 hexane/ethyl acetate) to afford 147 mg of 4-azido-3-O-benzyl-6-
desoxy-2-O-levulinoyl-α-D-glucopyranoside as pale yellow oil.  
 
To a solution of 4-azido-3-O-benzyl-6-desoxy-2-O-levulinoyl-α-D-glucopyranoside (147 mg, 
0.390 mmol) in dry CH2Cl2 (4 mL) were added distilled trichloroacetonitrile (0.20 mL, 1.95 
mmol) and Cs2CO3 (317 mg, 0.97 mmol). The reaction mixture was stirred for 1 h at room 
temperature. Then after reaction mixture was filtered over Celite, solvent was concentrated 
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under reduced pressure. Crude product was purified by flash column chromatography on 
silica gel using 20% EtOAc/hexane as eluent to provide the product as a colorless oil (184 
mg, 0.35 mmol, 91%). 
  
Rf (ethyl acetate/hexane): 0.67 (2/3).  
1H NMR (CDCl3, 400 MHz): δ (ppm) 8.60 (s, 1H, NH), 7.40-7.27 (m, 5H, Ar-H), 6.40 (d, J 
= 3.3 Hz, 1H, H-1), 5.15 (dd, J = 9.9 Hz, 3.6 Hz, 1H, H-2), 4.89-4.78 (m, 2H, CH2), 3.92 (t, J 
= 9.6 Hz, 1H, H-3), 3.81 (m, 1H, H-5), 3.33 (t, J = 9.6 Hz, 1H, H-4), 2.68 (t, J = 6.8 Hz, 2H, 
CH2), 2.51 (t, J = 6.8 Hz, 2H, CH2), 2.12 (s, 3H, CH3), 1.39 (d, J = 6.0 Hz, 3H, CH3). 
13C NMR (CDCl3, 100MHz): δ (ppm) 205.5, 171.7, 160.8, 137.1, 128.7, 128.4, 128.2, 93.7, 
75.0, 72.6, 69.9, 67.3, 37.7, 29.8, 27.6, 18.2. 
HRMS-ESI (m/z): [M+Na]+ Calcd: 543.0581; Found: 543.0608. 
 
 
 
4-Methoxyphenyl 4-azido-3-O-benzyl-4,6-dideoxy-β-D-glucopyranoside  
 
To a solution of 15 (73 mg, 0.15 mmol) in CH2Cl2 (3.7 mL)/methanol (0.37 mL) mixture 
were added hydrazine acetate (16 mg, 0.3 mmol). The reaction mixture was stirred for 3 h at 
room temperature. Then after reaction TLC showed the completion of the reaction solvent 
was evaporated and crude product was purified by flash column chromatography on silica gel 
using 20% EtOAc/hexane as eluent to provide the product as pale yellow oil (55 mg, 0.14 
mmol, 96%).  
O
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Rf (ethyl acetate/hexane): 0.6 (2/3).  
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.49-7.00 (m, 5H, Ar-H), 6.94 (d, J = 8.8 Hz, 2H, Ar-
H), 6.78 (d, J = 8.8 Hz, 2H, Ar-H), 4.91 (d, J = 10.8 Hz, 1H, CH2), 4.88 (d, J=10.8 Hz, 1H, 
CH2), 4.72 (d, J = 8.0 Hz, 1H, H-1), 3.82-3.69 (m, 4H, H-2, OCH3), 3.52 (t, J = 9.2 Hz, 1H, 
H-3), 3.36 (m, 1H, H-5), 3.23 (t, J = 9.6 Hz, 1H, H-5), 2.57 (d, J = 2.8 Hz, 1H, OH), 1.40 (d, 
J = 6.0 Hz, 3H, CH3).  
 
 
 
4-Methoxyphenyl 2-O-acetyl-4-azido-3-O-benzyl-4,6-dideoxy-α/β-D-mannopyranoside (16) 
 
To a solution of 4-methoxyphenyl 3-O-benzyl-6-desoxy-α/β-D-galactopyranoside (117 mg, 
0.30 mmol), in CH2Cl2 (4 mL) and pyridine (0.23 mL), was added triflic anhydride (0.10 mL, 
0.60 mmol) at 0 oC. The reaction was stirred for 1 h, then quenched with few drops of water, 
and extracted with ethyl ether (3 × 10 mL). The organic mixture was washed with saturated 
Na2CO3 solution (3 × 10 mL), dried (Mg2SO4), concentrated under reduced pressure and used 
directly for the next step. 
 
To a solution of triflate (145 mg, 0.28 mmol) in toluene (3 mL), was added tetrabutyl 
ammonium acetate (843 mg, 2.8 mmol). The mixture was placed in a CEM Voyager 
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microwave and set at 70 oC for 1 h, then quenched with water (1 mL). Mixture was extracted 
with ethyl ether (3 × 10 mL), and organic mixture was washed with saturated Na2CO3 
solution (3 × 10 mL), dried (Mg2SO4), concentrated under reduced pressure and then purified 
using silica gel flash chromatography eluting with 15% EtOAc/Hexane to give titled 
compound (110 mg, 0.26 mmol, 92%) as colorless oil.  
 
Rf (ethyl acetate/hexane): 0.5(α)  (1/1).  
1H NMR (CDCl3, 400MHz): δ (ppm) 7.42-7.32 (m, 5H, Ar-H), 6.96 (d, J = 9.2 Hz, 2H, 
CH2), 6.82 (d, J = 8.8 Hz, 2H, CH2), 5.78 (d, J = 2.4 Hz, 1H, H-2), 4.94 (d, J = 0.8 Hz, 1H, 
H-1), 4.81 (d, J = 10.8 Hz, 1H, CH2), 4.55 (d, J = 11.2 Hz, 1H, CH2), 3.77 (s, 3H, CH3), 3.57 
(dd, J = 9.6 Hz, 3.2 Hz, 1H, H-3), 3.48 (t, J = 9.6 Hz, 1H, H-4), 2.23 (s, 3H, CH3), 1.4 (d, J = 
6.0 Hz, 3H, CH3).  
13C NMR (CDCl3, 100MHz): δ (ppm) 170.6, 155.5, 150.9, 136.8, 128.6, 128.5, 128.2, 
118.2, 114.5, 97.1, 78.4, 71.5, 71.3, 67.1, 63.6, 55.7, 21.1, 18.6.  
HRMS-MALDI (m/z): [M+Na]+ Calcd: 450.1641; Found: 450.1639. 
 
 
 
 
2-O-Acetyl-4-azido-3-O-benzyl-4,6-dideoxy-β-D-mannpyranosyl Tricloroacetimidate (17) 
 
To a solution of 16 (141 mg, 0.33 mmol) in acetonitrile (1 mL)/water (1 mL) mixture, cerium 
ammonium nitrate (904 mg, 1.7 mmol) was added to the solution and stirred for 2 h at room 
O
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temperature. After TLC confirmed complete consumption of starting material, the mixture 
was diluted with ethyl acetate and was washed with water (3 × 30 mL), dried (Mg2SO4), 
concentrated under reduced pressure. The crude product was purified by column 
chromatography (1:2 hexane/ethylacetate) to afford 2-O-acetyl-4-azido-3-O-benzyl-4,6-
dideoxy-α/β-D-mannopyranoside (82 mg, 0.25 mmol) as pale yellow oil.  
 
To a solution 2-O-acetyl-4-azido-3-O-benzyl-4,6-dideoxy-α/β-D-mannopyranoside (82 mg, 
0.25 mmol) in dry CH2Cl2 (5 mL) were added distilled trichloroacetonitrile (0.125 mL, 1.25 
mmol) and Cs2CO3 (203 mg, 0.63 mmol). The reaction mixture was stirred for 1 h at room 
temperature. Then after reaction mixture was filtered over Celite, solvent was concentrated 
under reduced pressure. Crude product was purified by flash column chromatography on 
silica gel using 20% EtOAc/hexane as eluent to provide the product as colorless oil (95 mg, 
0.20 mmol, 80.5%).  
 
Rf (ethyl acetate/hexane): 0.5 (1/4).  
1H NMR (CDCl3, 400 MHz): δ (ppm) 8.52 (s, 1H, NH), 7.40-7.31 (m, 5 H, Ar-H), 6.19 (d, 
1H, J = 1.6 Hz, H-1) 5.48 (t, J = 2.4 Hz, 1H, H-2), 4.78-4.53 (dd, J = 11.2 Hz, 8.4 Hz, 2H, 
CH2), 3.88 (dd, J = 10.0 Hz, 3.2 Hz, 1H, H-3), 3.73 (m, 1H, H-5), 3.55 (t, J = 10.0 Hz, 1H, 
H-4), 2.19 (s, 3H, CH3), 1.40 (d, J = 6.1 Hz, 3H, CH3).  
13C NMR (CDCl3, 100 MHz): δ (ppm) 169.1, 159.8, 136.7, 128.6, 1288.5, 128.4, 128.2, 
94.9, 75.2, 71.8, 69.9, 65.9, 63.4, 20.9, 18.6. 
HRMS-MALDI (m/z): [M+Na]+ Calcd: 487.0319; Found: 487.0596. 
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cis-4-(1H, 1H, 2H, 2H, 3H, 3H-Perfluoroundecyloxy)-2-butenyl 2-O-Acetyl-4-azido-3-O-
benzyl-4,6-dideoxy-α-D-mannopyranoside 
 
To a solution of fluorous alcohol (67 mg, 0.12 mmol) in anhydrous CH2Cl2 (0.5 mL) at 0 
oC 
was added the donor (37 mg, 0.08 mmol) in anhydrous CH2Cl2 (0.5 mL) followed by 
trimethylsilyl trifluoromethanesulfonate (1.45 µL, 8.0 µmol). The reaction mixture was 
stirred for 0.5 h and then quenched with a few drops of triethylamine. The reaction mixture 
was concentrated under reduced pressure and dissolved with DMF (0.4 mL) to load onto a 2 
g FSPE cartridge. The loaded cartridge was first washed with 3 mL (1 column volume) 80% 
methanol/20% water mixture 5 times. After TLC confirmed that no compounds were eluting 
from the cartridge, the solvent was changes into 100% methanol (10 mL) to elute out the 
desired compound. The eluent was concentrated under reduced pressure to provide the titled 
compound (61 mg, 0.07 mmol, 91%) as colorless oil.  
 
Rf (ethyl acetate/hexane): 0.53 (1/4).  
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.40-7.25 (m, 5H, Ar-H), 5.79-5.73 (m, 1H, CH), 
5.71-5.65 (m, 1H, CH), 5.34 (s, 1H, H-2), 4.78 (s, 1H, H-1), 4.73 (d, J = 12.8 Hz, 1H, CH2), 
4.54 (d, J = 10.8 Hz, 1H, CH2), 4.20 (dd, J = 12.8 Hz, 5.6 Hz, 1H, CH2), 4.11 (dd, J = 12.8 
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Hz, 7.2 Hz, 1H, CH2), 4.05 (d, J = 6.0 Hz, 2H, CH2), 3.81 (dd, J = 10.0 Hz, 3.2 Hz, 1H, H-3), 
3.59-3.54 (m, 1H, H-5), 3.51 (t, J = 6.0 Hz, 2H, CH2), 3.45 (t, J = 9.6 Hz, 1H, H-4), 2.37-2.15 
(m, 2H, CH2), 2.14 (s, 3H, CH3), 1.94-1.84 (m, 2H, CH2), 1.36 (d, J = 6.0 Hz, 3H, H-6).  
13C NMR (CDCl3, 100 MHz): δ (ppm) 170.5, 137.5, 130.5, 128.6, 128.5, 128.2, 128.1, 97.1, 
76.4, 71.9, 69.1, 67.6, 67.3, 66.6, 64.2, 63.1, 28.2, 21.2, 21.0, 18.7. 
HRMS-MALDI (m/z): [M+Na]+ Calcd: 874.1761; Found: 874.0923. 
 
 
 
 
cis-4-(1H, 1H, 2H, 2H, 3H, 3H-Perfluoroundecyloxy)-2-butenyl 4-Azido-3-O-benzyl-4,6-
dideoxy-α-D-mannopyranoside (18) 
 
To a solution of cis-4-(1H, 1H, 2H, 2H, 3H, 3H-perfluoroundecyloxy)-2-butenyl 2-O-acetyl-
4-azido-3-O-benzyl-4,6-dideoxy-α-D-mannopyranoside (27 mg, 0.03 mmol) in methanol (1 
mL) at rt was added 0.5 M NaOMe solution (0.01 mL). The reaction mixture was stirred for 
0.5 h and when TLC showed complete conversion of starting material, acidic resin was added 
for neutralization. The reaction mixture was concentrated under reduced pressure and 
dissolved with DMF (0.4 mL) to load onto a 2 g FSPE cartridge. The loaded cartridge was 
first washed with 3 mL (1 column volume) 80% methanol/20% water mixture 5 times. After 
TLC confirmed that no compounds were eluting from the cartridge, the solvent was changes 
into 100% methanol (10 mL) to elute out the desired compound. The eluent was concentrated 
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under reduced pressure to provide the titled compound (25 mg, 0.03 mmol, 97.7%) as 
colorless oil.  
 
Rf (ethyl acetate/hexane): 0.23 (1/4).  
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.70-7.31 (m, 5H, Ar-H), 5.79-5.74 (m, 1H, CH), 
5.73-5.65 (m, 1H, CH), 4.86 (d, J = 1.2 Hz, 1H, H-1), 4.76 (d, J = 11.6 Hz, 1H, CH2), 4.66 
(d, J = 11.2 Hz, 1H, CH2), 4.16 (dd, J = 12.8 Hz, 5.6 Hz, 1H, CH2), 4.10 (dd, J = 12.8 Hz, 7.2 
Hz, 1H, CH2), 4.05 (d, J = 6.0 Hz, 2H, CH2), 3.99 (t, J = 1.6 Hz, 1H, H-2), 3.75 (dd, J = 9.6 
Hz, 3.2 Hz, 1H, H-3), 3.55 (m, 1H, H-6), 3.49 (t, J = 6.0 Hz, 2H, CH2), 3.43 (t, J = 10.0 Hz, 
1H, H-4), 2.44 (d, J = 1.6 Hz, 1H, OH), 2.27-2.13 (m, 2H, CH2), 1.96-1.86 (m, 2H, CH2), 
1.33 (d, J = 6.4 Hz, 3H, CH3). 
13C NMR (CDCl3, 100 MHz): δ (ppm) 137.2, 130.3, 128.7, 128.3, 128.1, 128.1, 98.1, 78.4, 
77.3, 72.1, 68.9, 67.3, 66.8, 66.5, 64.9, 62.7, 28.0, 20.8, 18.5. 
HRMS-ESI (m/z): [M+Na]+ Calcd: 832.1665; Found: 832.1965. 
 
 
 
cis-4-(1H, 1H, 2H, 2H, 3H, 3H-Perfluoroundecyloxy)-2-butenyl 4-azido-3-O-benzyl-4,6-
dideoxy-β-D-glucopyranosyl-(1→3)-2-O-acetyl-4-O-benzyl-α-L-rhamnopyranosyl-(1→3)-2-
O-acetyl-4-O-benzyl-α-L-rhamnopyranosyl-(1→2)-3,4-O-benzyl-α-L-rhamnopyranoside (19) 
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- 3 cycles completed for the synthesis of anthrax tetrasaccharide 
Step Task Reagent/ Operation Operation 
Time 
1 
 
 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
 
31 
32 
33 
34 
35 
36 
  37 
38 
39 
40 
41 
42 
Glycosylation 
 
 
TLC sample 
Quenching 
Evaporation 
Desilylation 
TLC sample 
Evaporation 
FSPE 
Sample loading 
Wash 
Wash 
Transfer 
Evaporation 
Transfer 
Evaporation 
 
Glycosylation 
 
TLC sample 
Quenching 
Evaporation 
Delevulinoylation  
TLC sample 
Evaporation 
FSPE 
Sample loading 
Wash 
Wash 
1.5 equivalent first donor  (75 µmol) in 0.5 mL toluene,  
1 equivalent F-tagged acceptor (50 µmol) in 1 mL toluene; 0.1 
equivalent TMSOTf, rt 
20 µL of crude reaction mixture withdrawn 
0.5 mL TEA 
40 oC 
 0.4 mL 1.0 M TBAF/THF solution in 1 mL THF, rt 
20 µL of crude reaction mixture withdrawn 
40 oC 
0.4 mL DMF used to dissolve crude mixture 
0.7 mL crude sample transferred to cartridge 
5.5 ml 80% methanol wash 
2.0 mL methanol wash (repeated 3 times) 
5.3 mL collected sample transferred to clean vial 
50 oC 
2 mL toluene added 
50 oC 
Repeat 1-15 for trisaccharide 
2 equivalent second donor  (100 µmol) in 1 mL toluene,  
0.1 equivalent TMSOTf, 0 oC 
20 µL of crude reaction mixture withdrawn 
0.5 mL TEA 
40 oC 
Hydrazine acetate solution in CH2Cl2/MeOH 
20 µL of crude reaction mixture withdrawn 
50 oC 
0.4 mL DMF used to dissolve crude mixture 
0.7 mL crude sample transferred to cartridge 
5.5 mL 80% methanol wash 
2.0 mL methanol wash (repeated 3 times) 
45 min 
 
 
 
 
45 min 
10 hrs 
 
45 min 
 
 
 
 
 
45 min 
 
45 min  
 
45 min  
 
 
 
45 min 
1 hr 
 
45 min 
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HPLC traces of crude anthrax tetrasaccharide run 
 
 
15% Ethyl acetate/Hexane run for 10 minutes. 
 
 
The 100% methanol elution from the last FSPE wash was removed from the ASW and 
concentrated under reduced pressure. Crude product was purified by preparative TLC using 
30% EtOAc/hexane as eluent to provide the desired compound (16.9 mg, 0.010 mmol, 20% 
overall) as colorless oil.  
 
Rf (ethyl acetate/hexane): 0.27 (1/4).  
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.39-7. 27 (m, 25H, Ar-H), 5.73 (m, 2H, CH), 5.31 
(s, 1H), 5.25 (s, 1H), 5.06 (s, 1H), 5.01 (s, 1H), 4.92-4.78 (m, 5H), 4.72-4.56 (m, 6H), 4.32 (t, 
J = 6.0 Hz, 1H), 4.26 (d, J = 7.6 Hz, 1H), 4.19-4.10 (m 3H), 4.02-3.98 (m, 2H), 3.92 (s, 1H), 
3.83 (m, 3H), 3.63 (m, 2H), 3.55-3.40 (m, 6H), 3.28 (t, J = 9.2 Hz, 1H), 3.07-2.96 (m, 3H), 
2.27-2.12 (m, 8H), 1.89 (m, 2H), 1.32-1.27 (m, 9H), 1.16 (d, J = 6.0 Hz, 3H).  
 120 
13C NMR (CDCl3, 100 MHz): δ (ppm) 170.3, 170.2, 139.8, 138.3, 139.2, 138.1, 137.2, 
136.5, 133.0, 130.0, 129.2, 129.1, 128.8, 128.7, 128.6, 128.5, 128.5, 128.4, 128.3, 128.2, 
128.2, 128.0, 127.9, 127.9, 127.8, 127.6, 127.5, 127.4, 105.1, 99.3, 99.2, 98.2, 82.2, 81.0, 
79.8, 79.8, 77.6, 77.3, 76.5, 75.4, 74.8, 72.0, 71.0, 71.0, 68.9, 68.6, 68.1, 67.9, 67.8, 67.4, 
66.8, 66.6, 62.8, 28.0, 21.1, 20.8, 18.6, 18.4, 18.1, 17.3. 
HRMS-MALDI (m/z): [M+Na]+ Calcd: 1714.5482; Found: 1714.5214. 
 
 
 
cis-4-(1H, 1H, 2H, 2H, 3H, 3H-Perfluoroundecyloxy)-2-butenyl 4-Azido-3-O-benzyl-4,6-
dideoxy-2-O-methyl-β-D-glucopyranosyl-(1→3)-2-O-acetyl-4-O-benzyl-α-L-
rhamnopyranosyl-(1→3)-2-O-acetyl-4-O-benzyl-α-L-rhamnopyranosyl-(1→2)-3,4-O-benzyl-
α-L-rhamnopyranoside 
 
To a solution of the fluorous-tagged tetrasaccharide 19 (54 mg, 0.032 mmol) in anhydrous 
methyl iodide (1 mL) was added freshly prepared silver oxide (146 mg, 0.63 mmol). The 
reaction mixture was then brought to reflux and stirred under argon for 3 days. After TLC 
confirmed complete conversion of starting material, the reaction mixture was filtered over 
Celite and concentrated under reduced pressure. Crude product was purified by flash column 
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chromatography on silica gel using 20% EtOAc/hexane as eluent to provide the titled product 
as colorless oil (44 mg, 0.25 mmol, 81%).  
 
Rf (ethyl acetate/hexane): 0.67 (3/7).  
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.51-7.26 (m, 25H, Ar-H), 5.74-5.67 (m, 2H, CH), 
5.56 (dd, J = 2.8 Hz, 2.1 Hz, 1H, CH), 5.51 (dd, J = 2.8 Hz, 2.1 Hz, 1H, CH), 5.23 (d, J = 1.4 
Hz, 1H, CH), 4.96-4.93 (m, 3H), 4.82 (d, J = 10.5 Hz, 1H, CH2), 4.74-4.64 (m, 6H), 4.50-
4.49 (m, 2H), 4.20 (dd, J = 13.3 Hz, 5.6 Hz, 1H, CH2), 4.01-4.03 (m, 3H), 3.98 (t, J = 2.8 Hz, 
1H, CH), 3.90-3.87 (m, 2H), 3.81-3.77 (m, 3H), 3.72-3.46 (m, 10H), 3.33 (m, 1H), 3.12-3.03 
(m, 3H), 2.23-2.15 (m, 2H, CH2), 2.10 (s, 3H, CH3), 2.01 (s, 3H, CH3), 1.90-1.86 (m, 2H, 
CH2), 1.34-1.25 (m, 12H, CH3).  
13C NMR (CDCl3, 100 MHz): δ (ppm) 170.2, 170.2, 138.6, 138.6, 138.4, 138.1, 137.6, 
130.0, 129.4, 129.0, 128.7, 128.7, 128.5, 128.2, 128.2, 128.1, 128.1, 127.9, 127.7, 103.1, 
99.8, 99.7, 98.7, 85.0, 82.9, 80.1, 80.0, 78.7, 78.0, 75.7, 75.4, 72.5, 72.5, 71.2, 70.2, 69.1, 
68.7, 68.4, 68.3, 68.2, 67.9, 67.8, 66.8, 63.1, 60.8, 28.3, 28.2, 21.4, 21.3, 21.1, 18.7, 18.7, 
18.3, 18.0. 
HRMS-MALDI (m/z): [M+Na]+ Calcd: 1728.5638; Found: 1728.5759. 
 
 
 
Ethyl 3-hydroxy-3-methylbutanoate (21) 
 
O
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To a solution of ethyl bromoacetate 20 (500 mg, 2.99 mmol) in dry THF was added distilled 
acetone (2.19 mL, 29.9 mmol), unactivated ㅋinc dust (391 mg, 6.0 mmol) and I2 in room 
temperature. The reaction flask was placed in the CEM microwave and was stirred at 50 oC 
for 15 min. Reaction mixture was filtered over Celite and diluted with THF (20 mL). The 
organic layer was washed with water (3 × 10 mL), saturated Na2CO3 solution (3 × 10 mL), 
dried (Mg2SO4), concentrated under reduced pressure and then purified using silica gel flash 
chromatography eluting with 15% EtOAc/Hexane to give titled compound (340 mg, 2.33 
mmol, 78%) as colorless oil.  
 
Rf (ethyl acetate/hexane): 0.7  (4/6).  
1H NMR (CDCl3, 400MHz): δ (ppm) 4.24 (q), 2.44 (s, 2H), 1.32 (m, 9H). 
 
 
 
3-Hydroxy-3-methylbutanoic acid (22) 
 
To a solution of 21 (300 mg, 2.05 mmol) in THF/water (2 mL, v:v/1:1) was added LiOH.H2O 
(2.58 g) at room temperature. Reaction mixture was stirred under microwave conditions at 50 
oC for 1 h. Mixture was diluted with THF (20 mL) and the organic layer was washed with 
water (3 × 10 mL), 2N HCl (3 × 10 mL), saturated Na2CO3 solution (3 × 10 mL), dried 
(Mg2SO4), concentrated under reduced pressure and then purified using silica gel flash 
chromatography eluting with 80% EtOAc/Hexane to give titled compound (166 mg, 1.41 
mmol, 69%) as a colorless oil.  
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1H NMR (CDCl3, 400MHz): δ (ppm) 7.48 (br, 1H), 2.52 (s, 2H), 1.28 (s, 6H). 
13C NMR (CDCl3, 100 MHz): δ (ppm) 177.1, 69.8, 46.2, 29.1, 29.1. 
 
 
 
 
4-(1H, 1H, 2H, 2H, 3H, 3H-Perfluoroundecyloxy)-butyl 4,6-dideoxy-4-(3-hydroxy-3-
methylbutanamido)-2-O-methyl-β-D-glucopyranosyl-(1→3)- α-L-rhamnopyranosyl-(1→3)- 
α-L-rhamnopyranosyl-(1→2)- α-L-rhamnopyranoside (1) 
 
To a solution of the fluorous-tagged tetrsaccharide (40.7 mg, 0.023 mmol) in anhydrous 
toluene (1 mL) was added tributyl tinhydride (0.184 mL, 0.69 mmol) and 2,2’-
azobisisobutyronitrile, 98% (0.33 mg, 0.002 mmol). The reaction mixture was degassed with 
argon bubbling in for 30 minutes. The mixture was then brought to reflux and stirred under 
argon for 2 hours. The mixture was cooled to room temperature and filtered through a short 
plug of silica gel. The crude product was then concentrated and purified by a FSPE cartridge 
to give the product as colorless oil (34.8 mg, 0.020 mmol, 90%).  
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To a solution of the animo tetrasaccharide (34.8 mg 0.02 mmol), in DCM (2 mL), 3-hydroxy-
3-methylbutanoic acid (5 mg, 0.03 mmol), HATU (11.4 mg, 0.03 mmol) and DIPEA (5 µL, 
0.03 mmol) was added. Reaction mixture was stirred at room temperature for 2 h. After the 
reaction time, crude product was then concentrated and purified by a FSPE cartridge to give 
the product as colorless oil (31.7 mg, 0.0178 mmol, 89%).  
 
To a solution of the side chain attached tetrasaccharide (31.7 mg, 0.0178 mmol), in MeOH (2 
mL), 10% Pd/C (5 mg) was added. The reaction flask was evacuated and a hydrogen balloon 
was attached. Reaction mixture was stirred at room temperature overnight. After the reaction 
time, crude product was then concentrated and filtered over Celite and then again purified by 
a FSPE cartridge to give the product as colorless oil (16.8 mg, 0.0135 mmol, 76%).  
 
1H NMR (CD3OD, 400MHz): δ (ppm) 5.03 (m, 1H), 4.96 (m, 1H), 4.91 (d, J = 1.8 Hz, 1H), 
4.77 (d, J = 1.6 Hz, 1H), 4.62 (d, J = 7.8 Hz, 1H), 4.18 (dd, J = 3.3 Hz, J = 1.7 Hz, 1H), 4.05 
(dd, J = 3.2 Hz, J = 1.9 Hz, 1H), 3.90 (dd, J = 9.4 Hz, J = 3.3 Hz, 1H), 3.83 (m, 1H), 3.80 (m, 
2H), 3.70-3.78 (m, 3H), 3.67 (m, 2H), 3.66 (s, 3H), 3.55-3.60, (m, 3H), 3.51 (t, J = 9.6 Hz, 
1H), 3.40-3.44 (m, 3H), 3.38 (m, 1H), 3.02 (dd, J = 9.1 Hz, J = 7.9 Hz, 1H), 2.36 (m, 2H), 
2.15 (m, 2H), 1.68 (m, 2H), 1.29 (m, 9H), 1.25 (d, J = 6.2 Hz, 3H), 1.24 (d, J = 6.2 Hz, 3H), 
1.21 (d, J = 6.2 Hz, 3H). 
13C NMR (CD3OD, 100 MHz): δ (ppm) 174.7, 105.5, 104.0, 103.6, 100.4, 85.7, 82.0, 80.1, 
79.2, 75.1, 74.4, 73.4, 73.2, 72.3, 72.2, 71.9, 71.8, 70.8, 70.6, 70.2, 70.0, 68.0, 61.2, 58.2, 
49.8, 31.5, 30.0, 29.7, 29.6, 18.5, 18.2, 18.1, 18.0. 
HRMS-MALDI (m/z): [M+Na]+ Calcd: 1270.3855; Found: 1270.8002. 
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cis-4-(1H, 1H, 2H, 2H, 3H, 3H-Perfluoroundecyloxy)-2-butenyl 2-O-acetyl-4-azido-3-O-
benzyl-4,6-dideoxy-α-D-mannopyranosyl-(1→2)-2-O-acetyl-4-azido-3-O-benzyl-4,6-
dideoxy-α-D-mannopyranosyl-(1→2)-2-O-acetyl-4-azido-3-O-benzyl-4,6-dideoxy-α-D-
mannopyranosyl-(1→2)-2-O-acetyl-4-azido-3-O-benzyl-4,6-dideoxy-α-D-mannopyranoside 
(23) 
 
- 2.5 cycles completed for the synthesis of cholera tetrasaccharide 
 
Step Task Reagent/ Operation Operation 
Time 
1 
 
 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
Glycosylation 
 
 
TLC sample 
Quenching 
Evaporation 
Deacetylation 
TLC sample 
Quenching 
Evaporation 
FSPE  
Sample loading 
         Wash 
1.5 equivalent donor  (75 µmol) in 0.5 mL toluene, 
1 equivalent F-tagged acceptor (50 µmol) in 1 mL toluene; 0.1 
equivalent TMSOTf, rt 
20 µL of crude reaction mixture withdrawn 
0.5 mL TEA 
40 oC 
3 equivalent of NaOMe solution, rt 
30 µL of crude reaction mixture withdrawn 
0.3 mL 0.5 M Acetic acid solution in MeOH 
50 oC 
0.4 mL DMF used to dissolve crude mixture 
0.7 mL crude sample transferred to cartridge 
5.5 mL 80% methanol wash 
45 min 
 
 
 
 
45 min 
3 h 
 
 
45 min 
 
 
 
O
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12 
13 
14 
15 
16 
 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
Wash 
Transfer 
Evaporation 
Transfer 
Evaporation 
 
Glycosylation 
 
TLC sample 
Quenching 
Evaporation 
Deacetylation 
TLC sample 
Quenching 
Evaporation 
FSPE 
Sample loading 
Wash 
Wash 
2.0 mL methanol wash (repeated 3 times) 
5.3 mL collected sample transferred to clean vial 
50 oC 
2 mL toluene added 
50 oC 
Repeat 1-16 
1.5 equivalent donor  (75 µmol) in 0.5 mL toluene, 
 0.1 equivalent TMSOTf, rt 
20 µL of crude reaction mixture withdrawn 
0.5 mL TEA 
40 oC 
3 equivalent of NaOMe solution, rt 
30 µL of crude reaction mixture withdrawn 
0.3 mL 0.5 M Acetic acid solution in MeOH 
50 oC 
0.4 mL DMF used to dissolve crude mixture 
0.7 mL crude sample transferred to cartridge 
5.5 mL 80% methanol wash 
2.0 mL methanol wash (repeated 3 times) 
 
 
45 min 
 
45 min 
 
45 min 
 
 
 
45 min 
3 hr 
 
 
45 min 
 
HPLC traces of crude cholera tetrasaccharide run 
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15% Ethyl acetate/Hexane run for 10 minutes. (Desired tetrasaccharide eluted in 4.07 
minutes) 
 
 
The 100% methanol elution from the last FSPE wash was removed from the ASW and 
concentrated under reduced pressure.  Crude product was purified by preparative TLC using 
30% EtOAc/hexane as eluent to provide the titled compound (35.12 mg, 0.021 mmol, 28.9% 
overall) as colorless oil.  
 
 
 
cis-4-(1H, 1H, 2H, 2H, 3H, 3H-Perfluoroundecyloxy)-2-butenyl 2-O-acetyl-4-azido-3-O-
benzyl-4,6-dideoxy-α-D-mannopyranosyl-(1→2)-4-azido-3-O-benzyl-4,6-dideoxy-α-D-
mannopyranosyl-(1→2)-4-azido-3-O-benzyl-4,6-dideoxy-α-D-mannopyranosyl-(1→2)-4-
azido-3-O-benzyl-4,6-dideoxy-α-D-mannopyranoside (23) 
 
Rf (ethyl acetate/hexane): 0.5 (1/4).  
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.38-7.31 (m, 20H, Ar-H), 5.78-5.61 (m, 2H, 2×CH), 
5.42 (dd, J = 2.8 Hz, 2.0 Hz, 1H, CH), 4.95 (s, 1H, CH), 4.87 (s, 1H, CH), 4.86 (s, 1H, CH), 
4.75-4.53 (m, 9H, CH, 4×CH2), 4.20-3.19 (m, 21H, 15×CH, 3×CH2), 2.27-2.20 (m, 2H, 
CH2), 2.12 (s, 3H, CH3), 1.93-1.86 (m, 2H, CH2), 1.29-1.16 (m, 12H, 4×CH3). 
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13C NMR (CDCl3, 100 MHz): δ (ppm) 170.0, 137.6, 137.5, 137.3, 130.3, 128.8, 128.8, 
128.7, 128.7, 128.7, 128.6, 128.5, 128.3, 128.3, 129.2, 128.2, 100.7, 100.3, 99.3, 98.0, 77.4, 
75.7, 74.2, 73.6, 73.6, 72.4, 72.3, 72.2, 71.8, 69.1, 68.0, 67.9, 67.5, 67.3, 66.6, 64.5, 64.4, 
64.2, 64.0, 63.0, 29.9, 28.2, 21.2, 18.8, 18.3, 18.2, 18.1 
HRMS-MALDI (m/z): [M+Na]+ Calcd: 1657.5101; Found: 1657.5433. 
 
 
 
 
4-(1H, 1H, 2H, 2H, 3H, 3H-Perfluoroundecyloxy)-butyl 4-(3-deoxy-L-glycero-tetronamido)-
4,6-dideoxy-α-D-mannopyranosyl-(1→2)-4-(3-deoxy-L-glycero-tetronamido)-4,6-dideoxy-α-
D-mannopyranosyl-(1→2)-4-(3-deoxy-L-glycero-tetronamido)-4,6-dideoxy-α-D-
mannopyranosyl-(1→2)-4-(3-deoxy-L-glycero-tetronamido)-4,6-dideoxy-α-D-
mannopyranoside (2) 
 
To a solution of the fluorous-tagged tetrsaccharide 23 (87.7 mg, 0.054 mmol) in anhydrous 
toluene (5 mL) was added tributyl tinhydride (0.866 mL, 3.22 mmol) and 2,2’-
azobisisobutyronitrile, 98% (0.88 mg, 0.005 mmol). The reaction mixture was degassed with 
argon bubbling in for 30 minutes. The mixture was then brought to reflux and stirred under 
argon for 2 hours. The mixture was cooled to room temperature and filtered through a short 
plug of silica gel. The crude product was then concentrated and purified by a FSPE cartridge 
to give the product cis-4-(1H, 1H, 2H, 2H, 3H, 3H-perfluoroundecyloxy)-2-butenyl 2-O-
O
HO
OH
O O
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acetyl-4-amino-3-O-benzyl-4,6-dideoxy-α-D-mannopyranosyl-(1→2)-2-O-acetyl-4-amino-3-
O-benzyl-4,6-dideoxy-α-D-mannopyranosyl-(1→2)-2-O-acetyl-4-amino-3-O-benzyl-4,6-
dideoxy-α-D-mannopyranosyl-(1→2)-2-O-acetyl-4-amino-3-O-benzyl-4,6-dideoxy-α-D-
mannopyranoside as colorless oil (81 mg, 0.053 mmol, 98%).  
 
To a solution of the tetramino compound (40 mg, 0.026 mmol) in DCM (3 mL) was added 
2,4-O-benzylidene-3-deoxy-L-glycero-tetronic acid (20 mg, 0.159 mmol), EDC (30 mg, 
0.159 mmol) HOBT (21 mg, 0.159 mmol) Reaction mixture was stirred at room temperature 
for 2 h. After the reaction time, crude product was then concentrated and purified by a FSPE 
cartridge to give cis-4-(1H, 1H, 2H, 2H, 3H, 3H-perfluoroundecyloxy)-2-butenyl 2-O-acetyl-
3-O-benzyl-4-(2,4-O-benzylidene-3-deoxy-L-glycero-tetronamido)-4,6-dideoxy-α-D-
mannopyranosyl-(1→2)-3-O-benzyl-4-(2,4-O-benzylidene-3-deoxy-L-glycero-tetronamido)-
4,6-dideoxy-α-D-mannopyranosyl-(1→2)-3-O-benzyl-4-(2,4-O-benzylidene-3-deoxy-L-
glycero-tetronamido)-4,6-dideoxy-α-D-mannopyranosyl-(1→2)-3-O-benzyl-4-(2,4-O-
benzylidene-3-deoxy-L-glycero-tetronamido)-4,6-dideoxy-α-D-mannopyranoside as colorless 
oil (45.8 mg, 0.020 mmol, 77%).  
 
To a solution of the side chain attached tetrasaccharide (45.8 mg, 0.020 mmol), in MeOH (2 
mL), 10% Pd/C (5 mg) was added. The reaction flask was evacuated and a hydrogen balloon 
was attached. Reaction mixture was stirred at room temperature overnight. After the reaction 
time, crude product was then concentrated and filtered over Celite and then again purified by 
a FSPE cartridge to give the product as colorless oil (21.2 mg, 0.0138 mmol, 69%).  
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1H NMR (CD3OD, 400MHz): δ (ppm) 5.38-5.29 (m, 3H), 5.01 (s 1H), 4.99 (s 1H), 4.87 (t, J 
= 9.6 Hz, 1H), 4.76-4.55 (m, 8H), 4.22–3.76 (m, 8H), 3.66 (m, 2H), 3.54-3.42 (m, 8H), 2.74–
2.44 (m, 8H), 2.22–2.05 (m, 10H), 1.97–1.79 (m, 2 H), 1.38–1.25 (m, 12H).  
13C NMR (CD3OD, 100 MHz): δ (ppm) 174.7, 175.5, 175.4, 175.4, 105.5, 104.0, 103.6, 
100.4, 85.7, 82.0, 80.1, 79.2, 75.1, 74.4, 73.4, 73.2, 72.3, 72.2, 71.9, 71.8, 70.8, 70.6, 70.2, 
70.0, 69.5, 69.3, 68.0, 61.2, 58.2, 49.8, 31.5, 30.0, 29.7, 29.6, 26.7, 25.6, 18.5, 18.2, 18.1, 
18.0.  
HRMS-MALDI (m/z): [M+Na]+ Calcd: 1561.4992; Found: 1562.8831. 
 
 
2,4-Benzylidene-(S)-1,2,4-butanetriol (25) 
 
To a solution of BH3
.SMe, (2M solution, 3.915 mL, 7.83mmol) and B(OMe)3 (98%, 0.84 
mL, 7.83 mmol) was added (S)-malic acid 24 (350 mg, 2.61mmol) in anhydrous THF (1.7 
mL) solution dropwise in a 0 oC ice bath. After 10 min, ice bath was removed and reaction 
flask was stirred under argon at room temperature overnight. Reaction mixture was quenched 
with MeOH (6 mL) and solvent was removed under reduced pressure. The crude product was 
then concentrated and purified by silica gel flash column chromatography to give the product 
as colorless oil (187 mg, 1.76 mmol, 68%) and was used directly for the next step. 
 
To a solution of the triol (187 mg, 1.76 mmol), PhCH(OMe)2 (2.65 mL, 17.6 mmol) and 
PTSA (76 mg, 0.35 mmol) was added. Reaction mixture was stirred at room temperature 
O
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under argon for 6 h. TEA (1 mL) was added to quench the reaction and solvent was removed 
under reduced pressure. The crude product was purified by silica gel flash column 
chromatography to give the product as colorless oil (235 mg, 1.21 mmol, 69%). 
 
Rf (methanol/chloroform, 20/80): 0.87 (1/4).  
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.52-7.51 (m, 2H), 7.40-7.36 (m, 3H), 5.55 (s, 1H), 
4.33-4.29 (ddd, J = 11.2 Hz, 4.8 Hz, 0.8 Hz, 1H), 4.02-3.96 (m, 2H), 3.67 (m, 1H), 2.26 (m, 
1H), 1.92 (dq, J = 12.0 Hz, 5.2 Hz, 1H), 1.46 (qd, J = 13.6 Hz, 1.6 Hz, 1H).   
13C NMR (CDCl3, 100 MHz): δ (ppm) 138.4, 129.0, 128.4, 126.2, 101.3, 77.6, 66.7, 65.7, 
26.9.  
HRMS-MALDI (m/z): [M+Na]+ Calcd: 217.0841; Found: 217.2892.  
 
 
2,4-O-Benzylidene-3-deoxy-L-glycero-tetronic acid (26) 
 
Pyridinium dichromate (2.39 g, 6.36 mmol) was added at room temperature to a solution of 
25 (308.9 mg, 1.59 mmol) in DMF (3 mL), and the mixture was stirred overnight. When 
TLC showed absence of starting material, the reaction was quenched with water (5 mL) and 
was stirred for an additional few minutes. The reaction mixture was dilluted with ethyl 
acetate (50 mL) and was washed with water (3 × 50 mL). The organic layer was dried 
O
OH
O
ph
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(Mg2SO4) and then concentrated under reduced pressure. Spectral data matched the previous 
publication. [10] 
 
 
 
Additional Information: Experimental details, including copies of 1H NMR spectra, for the 
synthesis and production of the carbohydrate microarrays and the complete ref 2h, and 
competition experiment plots are found in the Appendix at the end of this chapter. 
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CHAPTER 4 
Mono- vs. Di-fluorous-tagged Glucosamines for Iterative 
Oligosaccharide Synthesis 
A paper published in Journal of Fluorine Chemistry1 
Gisun Park, Kwang-Seuk Ko, Aleksandra Zakharova and Nicola L. Pohl* 
 
Abstract 
 
Fluorous-tagged protecting groups are attractive tools for elongating carbohydrate 
chains in oligosaccharide synthesis. To eliminate the accumulation of failed sequences during 
automated oligosaccharide synthesis conditions, an additional C8F17 ester derived protecting 
group was attached to the glycosyl donor to better retain the desired doubly-tagged 
glycosylation product on fluorous solid phase extraction (FSPE) cartridges. Initial studies 
show that the double-fluorous-tagging strategy offers a robust enough separation using a 
commercial FSPE cartridge using simple gravity filtration to separate the desired product 
from the singly-fluorous-tagged starting materials and their decomposition products. In 
addition, removal of the fluorous acetate and its byproducts after sodium methoxide 
treatment and neutralization required only dissolution of the desired sugar in toluene and 
subsequent removal of the toluene layer from the denser fluorous byproducts.  
 
 
 
                                                
1 Reproduced with permission of J. Fluorine. Chem. (2008) 129, 978-982. Copyright 2008 
Elsevier. 
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Introduction 
 
The isolation of pure, structurally well-defined oligosaccharides from nature is 
generally a tedious and inefficient process, because these biomolecules are often present in 
low concentrations as microheterogeneous mixtures. A better understanding of the growing 
numbers of biological processes that carbohydrates mediate [1] demands efficient ways to 
access these structures.  Studies of proteins and nucleic acids have thrived since automated 
solid-phase chemistry has been discovered [2]. The same principle was applied to automated 
oligosaccharide synthesis as well to produce various oligosaccharide compounds [3]. 
However the production of these compounds required a large excess of donor molecules to 
achieve reasonable coupling yields on a solid support and reaction monitoring is more 
difficult than in solution. To circumvent some of the inherent limitations of automated solid-
phase synthesis, we have pursued a solution-phase approach. A lipid introduced to a 
monosaccharide building block [4] while maintaining solubility in organic solvents offers a 
handle to easily purify the desired compound; however, this tag complicates reaction 
monitoring by proton NMR. Due to its facile purification from non-fluorous compounds and 
silence in proton NMR spectra, fluorous tags have become an attractive tool for many 
synthetic processes [5]. Highly fluorinated versions of silyl, ether, and ester protecting 
groups [6] have been applied to oligosaccharides synthesis using liquid phase extractions. 
Unfortunately, solubility of compounds with heavy fluorous tags in organic solvents is hard 
to predict. A light fluorous (C8F17) tag, on the other hand, has been shown to cap failed 
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sequences in solid-phase oligosaccharide synthesis [7] and more recently has been shown [8] 
to be stable to all the reaction conditions required for the requisite glycosylation and 
deprotection conditions with no problems with solubility or purification of intermediates 
using fluorous solid phase extraction [9] (FSPE). The fast and robust separation of the 
fluorinated compounds also makes the method amenable to automation.  
 
Figure 4-1. Comparison of a single- versus double-fluorous-tag strategy for 
iterative oligosaccharide synthesis. 
 
A potential problem with a single-fluorous-tag strategy occurs when a reaction does 
not go to completion. Addition of a fluorous tag to both rather than just one of the coupling 
partners offers a chance to eliminate by-product build up during the synthesis without 
addition of a capping [7] step (Figure 4-1). The structure/retention trends in fluorous 
chromatography have been studied previously [10] where the larger the tag size, the stronger 
its retention on fluorinated silica gel. However, these comparison studies were performed on 
a FluoroFlashTM HPLC column. Success needs to be demonstrated using a simple gravity 
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elution strategy for ready incorporation into an automation scheme. In addition, the benefit of 
removing singly-tagged starting materials and their decomposition products from the doubly-
tagged desired products after a glycosylation cycle might be lost if the two single-fluorous-
tagged products generated during the deprotection cycle are not easily separated by means 
other than FSPE. Herein we report the introduction of a light fluorous acetate protecting 
group for oligosaccharide synthesis and the viability of separating mono- from di-tagged 
saccharides using only simple FSPE cartridges to remove any excess/unreacted reagents in 
the context of building 1-4-linked glucosamine oligomers. We also report a simple method to 
remove the fluorous acetate byproduct from the desired fluorous-tagged sugar in the 
deprotection cycle.  
 
Results and discussion 
 
In order to investigate the ease of purification of di-tagged saccharide products, the 
synthesis of a fluorous tagged donor and fluorous-tagged acceptor was necessary. In our 
previous studies using fluorinated tags for oligosaccharide synthesis [11], fluorous allyl 
groups are attached at the anomeric position of the reducing end of the oligosaccharide for 
chain extension at the nonreducing end. This fluorous allyl group would again serve as a 
good acceptor. The synthesis of an activated glucosamine donor was then undertaken in 
which a fluorous acetate was installed at the chain extension position. Among the different 
functionalities of fluorinated-protecting groups that could be applied, an ester derived 
fluorous protecting group was selected for its simple and readily automated deprotection 
conditions. The known partially-protected glucosamine building block 1 (Figure 4-2) [12] 
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with an easily removable tert-butyl dimethyl silyl group on the anomeric position served as a 
good starting point. The 4-position hydroxyl 1 was treated with 2H, 2H, 3H, 3H-perfluoro 
undecanoic acid to provide compound 2. This fluorous-tagged intermediate was then further 
elaborated to the trichloroacetimidate [13] donor 4 ready for glycosylation.  
 
 
 
Figure 4-2. Synthesis of di-fluorous-tagged compound 5. 
 
With the fluorous-tagged monosaccharide donor 4 in hand, we next tested the use of the di-
tagging strategy by addition of the donor to a fluorous allyl [11d] group (Figure 4-2). After 
the 0.5 h reaction time, the quenched crude mixture was concentrated and then loaded onto a 
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2 g fluorous solid phase extraction cartridge (Figure 4-3). The cartridge was first eluted with 
80% methanol/20% water for 5 column volumes. All the non-fluorinated compounds were 
thereby eluted. The elution solvent was then changed to 90% methanol/10% water for 5 
column volumes to investigate any elution of fluorinated compounds. Fortunately, the excess 
donor that was now decomposed to hydroxyl 3 started to elute out of the cartridge along with 
a trace amount of the unreacted fluorous allyl tag (Figure 4-3). The desired di-fluorous 
tagged compound was readily retained in the FSPE cartridge while all the unreacted/excess 
reagents were removed. Finally, the desired di-tagged compound 5 was eluted from the 
cartridge using 100% methanol as eluent. HPLC traces (Figure 4-3) of the eluents confirmed 
the complete separation of the desired di-fluorous-tagged compound from the crude 
glycosylation mixture.  
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Figure 4-3. a) Selective elution of the multiple fluorous-tagged compounds using 
a FSPE cartridge and various elution conditions. b) HPLC traces of the compounds 
eluted off the FSPE cartridge with 90% or 100% methanol elution. (HPLC 
conditions: 15% ethyl acetate/85% hexane, 1mL/min flow rate, injection peak 
appeared at 1.5 min on a standard silica gel column). 
 
Figure 4-4. Deprotection of fluorous acetate protecting group. 
 
The di-tagged monosaccharide 5 was then deprotected at the 4-position to allow 
further chain elongation (Figure 4-4). Removal of the 2H, 2H, 3H, 3H-perfluoro undecanoyl 
group was performed under standard sodium methoxide conditions to provide compound 6. 
Now, of course, the desired product and the by-product both contain just one C8F17 tag and 
therefore FSPE is no longer a simple strategy for separation. However, alcohol 6, containing 
a large organic portion in addition to the fluorous tag, readily dissolved in toluene whereas 
the fluorous acetate byproducts formed a separate denser layer for easy separation. Hence, 
the physical property differences could be exploited for facile separation. Because growing 
saccharide chains with the fluorous allyl tag have good solubility in toluene as a rule, this 
method of fluorous acetate removal from the desired compound after the deprotection 
reaction should be a general strategy. In addition to fluorous acetate, other fluorous 
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protecting groups have the potential to be used after testing of their solubility and volatility 
properties.  
 
Conclusion 
 
In conclusion, we have introduced a fluorous acetate group as a second protecting 
group to use in conjunction with our previously reported fluorous allyl group for light-
fluorous-based carbohydrate synthesis. Use of a fluorous tag on not just the glycosyl 
acceptor, but also the glycosyl donor proved useful in the separation of the desired 
glycosylation product from the unreacted or decomposed starting materials with only simple 
gravity filtration over a commercially available FSPE cartridge. The doubly-tagged 
carbohydrate compound was retained in the cartridge sufficiently well to allow facile 
separation with a discrete increase of methanol concentrations in the aqueous eluent. The 
problem of thereby generating two singly-fluorous tagged components in the deprotection 
cycle was avoided by exploiting the difference in solubility between the tagged sugar and the 
fluorous acetate protecting group byproducts. Work is now in progress to test the feasibility 
of this double-fluorous-tagging approach in the iterative synthesis of oligosaccharides using 
FSPE separations on a solution-based automation platform. 
 
Experimental section 
 
General methods 
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Commercial reagents and solvents were used as received without further purification 
unless otherwise stated. The reactions were monitored and the Rf values determined using 
analytical thin layer chromatography (tlc) with 0.25 mm EM Science silica gel plates (60F - 
254). The developed tlc plates were visualized by immersion in p-anisaldehyde solution 
followed by heating on a hot plate. Silica gel flash chromatography was performed with 
Selecto Scientific silica gel, 32-63 mm particle size. Fluorous phase chromatography was 
performed using fluorous solid-phase extraction cartridges containing silica gel bonded with 
perfluorooctylethylsilyl chains (Fluorous Technologies, Inc.; Pittsburgh, PA). All other 
fluorous reagents were also obtained from Fluorous Technologies, Inc. All moisture sensitive 
reactions were performed in flame- or oven- dried glassware under nitrogen atmosphere. 
Bath temperatures were used to record the reaction temperature. All reactions were stirred 
magnetically at ambient temperature unless otherwise indicated. 1H NMR and 13C NMR 
spectra were obtained with a Bruker DRX400 at 400 MHz and 162 MHz. 1H NMR spectra 
were reported in parts per million (δ) relative to CDCl3 (7.27 ppm) as an internal reference.
 
13C NMR spectra were reported in parts per million (δ) relative to CDCl3 (77.23 ppm). HPLC 
traces were obtained using a Varian Inc. HPLC with a Waters Nova-pak 4 µL 3.9 ×150 mm 
silica column. High relosution mass spectrometry was obtained with Applied Biosystems 
QSTAR XL Hybrid System.  
 
Synthetic Procedures 
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tert-Butyldimethylsilyl 3,6-di-O-benzyl-2-deoxy-2-trichloroacetimido-4-2H, 2H, 3H, 3H, -
perfluoroundecanoatyl-β-D-glucopyranoside (2) 
 
To a solution of tert-butyldimethylsilyl 3,6-di-O-benzyl-2-deoxy-2-trichloroacetimido-β-D-
glucopyranoside [9] 1 (100 mg, 0.16 mmol) in dichloromethane (10 mL) cooled to 0 °C, was 
added DCC (66.5 mg, 0.32 mmol), DMAP (19.5 mg, 0.16 mmol) and 2H, 2H, 3H, 3H, -
perfluoroundecanoic acid (157 mg, 0.32 mmol). The reaction mixture was allowed to warm 
to room temperature over 2 h. The reaction was diluted with dichloromethane (20 mL), 
washed with water (20 mL), HCl (2N, 20 mL), and brine (20 mL), and dried over MgSO4. 
After the solvent was removed under reduced pressure, crude product was purified by flash 
column chromatography on silica gel using 15% EtOAc/hexane as eluent to obtain the title 
compound (160 mg, 0.14 mmol, 92%) as colorless oil.  
 
1H NMR (400 MHz, CDCl3): δ 0.23 (6H, d, 2CH3), 0.9 (9H, s, t-Bu-), 2.11-2.29 (4H, m, 
CH2CH2), 3.45 (1H, m, H-3), 3.56 (2H, m, H-6), 3.74 (1H, m, H-5), 4.35 (1H, dd, J = 9.2 Hz, 
10.4 Hz, H-2), 4.46-4.74 (4H, m, 2CH2), 5.12 (1H, t, J = 9.2 Hz, H-4), 5.23 (1H, d, J = 7.8 
Hz, H-1), 7.06 (1H, d, J = 7.6 Hz, NH), 7.22-7.40 (10H, m, -CH2C6H5). 
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13C NMR (162, MHz, CDCl3): δ -5.2, -4.2, 17.9, 25.7, 61.1, 69.8, 72.5, 72.8, 73.6, 74.2, 
76.8, 77.1, 77.3, 92.4, 94.0, 127.7, 127.7, 127.8, 128.0, 128.4, 128.5, 137.6, 137.7, 161.8, 
170.0.  
MS (ESI) m/z = calcd. for C39H41Cl3F17NNaO7Si : 1014.1344; found : 1014.1367 [M+Na]
+. 
 
 
 
3,6-Di-O-benzyl-2-deoxy-2-trichloroacetimido-4-(2H, 2H, 3H, 3H-perfluoroundecanoyl)-α-
D-glucopyranosyl trichloroacetimidate (4) 
 
To a solution of tert-butyldimethylsilyl 3,6-di-O-benzyl-2-deoxy-2-trichloroacetimido-β-D-
glucopyranoside 2 (100 mg, 0.09 mmol) in anhydrous THF, 1.0 M TBAF solution in THF 
(0.18 mL, 0.18 mmol) was added dropwise in a 0 oC ice bath. The reaction mixture was 
allowed to warm to room temperature over 1 h. After the solvent was removed under reduced 
pressure, crude reaction mixture was dissolved with DMF (0.4 mL) and loaded onto a 2 g 
FSPE cartridge. The cartridge was washed with 80% methanol (10 mL) followed by 100% 
methanol (10 mL) to elute the fluorinated desired product. The solvent was removed under 
reduced pressure to obtain the product (80 mg, 0.08 mmol, 89%) as colorless oil. The 
compound was used directly for the next step without further purification. 
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To a solution of the alcohol (80 mg, 0.08 mmol) in anhydrous DCM (5 mL) was added 
Cs2CO3 (66.6 mg, 0.2 mmol) and distilled trichloroacetonitrile (0.04 mL, 0.4 mmol). The 
reaction mixture was stirred at room temperature for 0.5 h and then filtered over a pad of 
Celite. The filtered solution was concentrated under reduced pressure and the crude product 
was purified by flash column chromatography on silica gel using 10% EtOAc/hexane as 
eluent to obtain compound 4 (83 mg, 0.083 mmol, 93%) as a colorless oil.  
 
1H NMR (400 MHz, CDCl3): δ 2.22-2.54 (4H, m, CH2CH2), 3.50-3.67 (2H, m, H-3, H-5), 
4.01-4.09 (2H, m, H-6), 4.37 (1H, t, J = 10.0 Hz, H-2), 4.43-4.70 (4H, m), 5.40 (1H, t, J = 9.9 
Hz, H-4), 6.47(1H, d, J = 3.6 Hz, H-1), 6.67 (1H, d, J = 8.8 Hz, NH), 7.25-7.39 (10H, m, 
C6H5), 8.80 (1H, s, NH).  
13C NMR (162, MHz, CDCl3): δ 61.2, 68.3, 69.8, 69.9, 70.0, 72.1, 73.2, 73.6, 76.0, 90.7, 
92.1, 94.3, 127.7, 128.2, 128.3, 128.4, 128.4, 128.7, 137.0, 137.8, 158.9, 161.8, 170.0.  
MS (ESI) m/z = calcd. for C35H27Cl6F17N2NaO7 : 1142.9576; found : 1142.9590 [M+Na]
+. 
 
 
cis-4-(1H, 1H, 2H, 2H, 3H, 3H-Perfluoroundecyloxy)-2-butenyl-3,6-di-O-benzyl-2-deoxy-2-
trichloroacetimido-4-(2H, 2H, 3H, 3H, -perfluoroundecanoyl)-β-D-glucopyranoside (5) 
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To a solution of the imidate (83 mg, 0.07 mmol) in anhydrous toluene (2 mL) at 0 oC was 
added fluorous allyl alcohol [11d] (25.5 mg, 0.05 mmol) in anhydrous toluene (2 mL) 
followed by trimethylsilyl trifluoromethanesulfonate (0.9 µL, 5.0 µmol). The reaction 
mixture was stirred for 0.5 h and then quenched with 3 drops of triethylamine. The reaction 
mixture was concentrated under reduced pressure and dissolved with DMF (0.4 mL) to load 
onto a 2 g FSPE cartridge. The loaded cartridge was first washed with 3 mL (1 column 
volume) 80% methanol/ 20% water mixture 5 times and then was washed with 3 ml 90% 
methanol/10% water mixture 5 times. After TLC confirmed that no other compounds were 
eluting from the cartridge, the solvent was changed into 100% methanol (10 ml) to elute out 
the desired compound. The eluent was concentrated under reduced pressure to provide 5 as a 
colorless oil (65 mg, 0.044 mmol, 87%).   
 
1H NMR (400 MHz, CDCl3): δ 1.87-1.88 (2H, m, -OCH2CH2CH2C8F17), 2.01-2.43 (6H, m, 
C(O)CH2CH2C8F17,-OCH2CH2CH2C8F17), 3.46 (3H, m, CH2O-, H-3), 3.56 (2H, d, J =  4.8 
Hz, H-6), 3.66 (1H, m, H-5), 4.04 (2H, t, J = 5.2 Hz, CH2CH=), 4.26-4.38 (3H, m, H-2, 
CH2CH=), 4.46-4.73 (4H , m, 2 CH2), 5.07 (1H, d, J = 8.0 Hz, H-1), 5.12 (1H, t, J = 9.6 Hz, 
H-4), 5.64 – 5.76 (2H, m, -CH=CH-), 7.01 (1H, d, J = 6.8 Hz, NH), 7.27-7.35 (m, 10H).  
13C NMR (162, MHz, CDCl3): δ 25.4, 26.3, 64.9, 66.6, 69.0, 69.7, 72.5, 72.7, 73.1, 73.2, 
73.8, 74.8, 77.4, 77.5, 97.6, 98.5, 127.7, 128.2, 128.3, 128.4, 128.4, 128.7, 130.8, 
130.9,137.0, 137.7, 162.0, 170.2. 
MS (ESI) m/z = calcd. for C48H38Cl3F34NNaO8 : 1530.1018; found : 1530.1198 [M+Na]
+. 
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cis-4-(1H, 1H, 2H, 2H, 3H, 3H-Perfluoroundecyloxy)-2-butenyl-3,6-di-O-benzyl-2-deoxy-2-
trichloroacetimido-β-D-glucopyranoside (6) 
 
To a solution of the glycosylated compound 5 (50 mg, 0.03 mmol) in methanol (1 mL) was 
added 0.5 M NaOMe solution (0.06 mL, 0.03 mmol). The reaction mixture was stirred for 
0.5 h and then was neutralized with Amberlyst acidic resin. The reaction mixture was filtered 
and the solvent was removed under reduced pressure. The crude product was shaken with 
toluene (1 mL). The clear solution was removed with a pipette from a denser yellow oil and 
the solvent was removed under reduced pressure to yield 6 as a colorless oil (31 mg, 0.027 
mol, 91%).  
 
1H NMR (400 MHz, CDCl3): δ 1.72-1.80 (2H, m, -OCH2CH2CH2C8F17), 2.04-2.17 (2H, m, 
-OCH2CH2CH2C8F17), 3.01 (1H, d, J = 2.2 Hz, -OH), 3.46 (2H, m, CH2O-), 3.60-3.65 (1H, 
m, H-5), 3.75-3.91 (5H, m, H-4, H-6, CH2CH=), 4.05-4.21 (4H, m, H-2, H-3, CH2CH=), 
4.50-4.77 (4H, m, 2CH2), 5.12 (1H, d, J = 8.0 Hz, H-1), 5.64 – 5.76 (2H, m, -CH=CH-), 7.00 
(1H, d, J = 6.9 Hz, NH), 7.27-7.35 (10H, m).  
MS (ESI) m/z = calcd. for C37H35Cl3F17NNaO7 : 1056.1105; found : 1056.1177 [M+Na]
+. 
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CHAPTER 5 
Automated Solution Phase Synthesis: A Di-Fluorous-Tagging 
Strategy  
Manuscript in preparation 
Gisun Park and Nicola L. B. Pohl* 
 
Abstract 
 
 Automated solution-phase oligosaccharide synthesis relying on fluorous solid-phase 
extraction (FSPE) for purification of intermediates is a powerful tool to construct highly 
functionalized oligosaccharides. A potential problem in some cases of incomplete 
glycosylation reactions with only tagging the reducing end of the growing chain can be failed 
sequences that would be carried along with the desired product during the automated 
sequence. In order to solve this issue, a di-fluorous tagged building block was synthesized 
and tested under conventional manual conditions to explore its physical properties. Initial 
results using FSPE had shown that the di-tagged saccharides had a stronger ability to interact 
with the fluorinated silica gel, therefore offering a robust separation from the mono-tagged 
saccharide molecules. However, it was unclear whether the differences in retention time 
would be great enough for robotically-controlled separations. Fortunately, careful 
observations of retention times of compounds on the FSPE cartridge allowed the 
programming of a robust protocol that can be introduced when needed for particularly 
challenging glycosylation cycles In this process of this work, automated protocols were also 
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developed to introduce a new per-fluorinated silyl group as a temporary masking group and 
the pentenyl activating group as a alternative glycosyl donor.  
 
Introduction 
 
Automated solution-phase oligosaccharide synthesis relying on fluorous solid-phase 
extraction (FSPE) for purification of intermediates is a powerful tool to construct highly 
functionalized oligosaccharides. [1]. Major benefits of this methodology are that the entire 
synthetic process can be easily monitored, most of the conventional solution-phase chemistry 
is readily applicable, and significantly less building block waste is generated. In addition, the 
use of the fluorous allyl tag at the reducing end of the first building block (Figure 5-1) allows 
a FSPE step during the iterative synthetic cycle that eliminates the by-products and excess 
donors that do not have the fluorous group.     
 
 
Figure 5-1. Schematic of the fluorous allyl tag used for the iterative automated synthesis of 
oligosaccharides. 
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A potential problem with only tagging the reducing end of the growing chain can be 
failed sequences in instances of incomplete glycosylation reactions; these failed sequences 
would be carried along with the desired product during the automated protocol. Although 
often these failed sequences are easily removed at the end of an entire synthesizer run, in 
some cases the final separation is quite challenging. A potential solution to this problem 
would be the addition of a single fluorous tag to not only the glycosyl acceptor, but also to 
the glycosyl donor. The resulting coupling product would then have two fluorous tags 
whereas the starting materials and excess reagents would have lower or no fluorous content. 
However, although the differences between fluorous-tagged and untagged compounds proved 
great enough for reliable automated separation using a standard protocol, it was unclear 
whether the differences in retention time between the doubly-tagged and singly-tagged 
fluorous compounds would be great enough for robotically-controlled separations. To test 
this strategy, an additional C8F17 ester or a perfluoro silyl-derived protecting group was 
attached to the O-2 position of the donor molecule as a second fluorous handle. In the course 
of this work, another donor activation strategy, in addition to the trichloroacetimidate donor, 
was also tested to expand the possible kinds of activated donors used in an automated 
protocol.  
 
Results and discussion 
 
To investigate the possibility of forming di-fluorous-tagged compounds under 
automated conditions, an activated rhamnosyl donor was prepared. Rhamnose was chosen to 
allow comparisons with the initial studies of the single tagged oligosaccharides using the 
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automation protocols with this sugar. To this end, the synthesis of an activated rhamnosyl 
donor was started from the known orthoester derivative 1 [2]. Compound 2 was provided 
after selective opening of the orthoester with allyl alcohol under acidic conditions followed 
by deprotection of the resulting acetate to reveal a free hydroxyl group. This 2-position 
hydroxyl was then treated with 2H, 2H, 3H, 3H-perfluoro undecanoic acid to provide singly-
fluorous-tagged compound 3. After deprotection of the anomeric allyl group under well-
established catalytic iridium conditions [3], the fluorous acetylated intermediate was then 
further elaborated to the desired trichloroacetimidate donor 5.  
 
The separation of a di-fluorous-tagged compound from a singly-tagged 
monosaccharide was previously studied using a glucosamine building block. Results show 
that the separation between the two was possible with a commercially available FSPE 
cartridge by simply changing the solvent used to elute out the two compounds. Also, 
deprotection of the fluorous acetate group demonstrated that the solubility difference of the 
sugar chain and the detached fluorous tag was big enough in toluene to have good separation 
based on such physical properties.   
 
With this information in hand, the synthesis of a 1,2-linked pentarhamnose was 
attempted under automated conditions. The initial acceptor 5 was prepared in 7 steps using 
known conditions [4]. The synthetic protocol and sample preparation mostly followed the 
previously reported procedure [1]. The major change came in the FSPE task, which was 
modified by using an additional 90% methanol wash before the usual 100% methanol wash. 
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Figure 5-2. Synthesis of the fluorous acetate protected donor 5.  
 
 
Unfortunately, the previous protocol failed to produce the desired pentamer; the 
initial protocol would require modifications. Unlike the conventional bench-top conditions, 
the FSPE cartridge can easily dry out and become unusable when performing the solid-phase 
extraction step. The robotic needle is programmed to transfer a certain amount of solvent to 
elute out compounds from the FSPE cartridge, but occasionally the cartridge becomes dried 
out resulting a poor separation between the mono-tagged and di-tagged compounds. 
Surprisingly, it was observed that the separation was especially difficult between the imidate 
form of the donor and the di-tagged compound, as opposed to the decomposed donor and 
other by-products that are singly-tagged. Clearly, separations using fluorous silica gel are not 
always completely predicated on fluorous content alone. In order to get around this 
unexpected problem, we decided to add a water addition step to the glycosylation pot before 
quenching to ensure complete decomposition of any excess donor. With this modification to 
the glycosylation step, the modified strategy now successfully delivered only the di-tagged 
compound to the new pot for the deprotection reaction. 
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Figure 5-3. Automated iterative synthesis of a linear rhamnose pentamer.  
 
After conditions were discovered to circumvent purification difficulties after the 
glycosylation step, a second problem was encountered in purifying the product resulting from 
the deprotection step. This challenge was more expected, however, as now a mono-fluorous-
tagged product would need to be separated from the removed fluorous acetate protecting 
group. Prior experience with the manual synthesis of linked-glucosamines with a di-tagging 
plan [5] fortunately hinted at a potential resolution. Because toluene is a strongly 
fluorophobic solvent, the crude reaction mixture could be separated after the deprotection 
step by simply adding toluene. The desired saccharide compound was dissolved in toluene 
whereas the fluorous-containing material formed an oil on the wall of the reactor vial. 
Unfortunately, the acetic acid solution used to quench the sodium methoxide-containing 
reaction generates a good amount of salt that leads to the failure of the separation. Simply 
changing the acid to a solid resin instead of a solution form solved the problem of generating 
salts in the reaction pot. In the revised protocol, the robot was programmed to transfer the 
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reaction mixture to a reactor vial that was pre-packed with an acidic solid resin and then 
again transferred to a clean vial for solvent removal and separation via toluene addition. 
 
 
 
Figure 5-4. Overall schematic of the automated synthesis of a ditagged-rhamnose 
pentasaccharide. 
 
In order to examine the success of this modified method in the synthesis of the 
original pentarhamnose target, the fluorous tailed acceptor 8 was again injected into the 
machine. After 22 hours, the di-tagged rhamnose pentamer was successfully retrieved from 
the robotics platform. For comparison, an HPLC trace of the crude product taken directly 
after the run is shown below along with the HPLC trace of the crude mono-tagged rhamnose 
pentamer, which was previously synthesized by the initial protocol [1].   
 
 
3.5 automation cycles
Glycosylation (30 min)
Deacetylation (2 h)
Fluorous Solid Phase 
Extraction (FSPE)
5
8
2 equiv.
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Step Task Reagents/Operation Time 
1 
2 
3 
4 
5 
6 
 
 
7 
8 
9 
10 
11 
12 
13 
Glycosylation 
TLC 
Water 
Quench 
Evaporation 
FSPE 
 
 
Evaporation 
Deprotection 
TLC 
Quench 
Evaporation 
Separation 
Evaporation 
Donor 5, TMSOTf, toluene, 0 oC 
 
water 
triethylamine 
40 oC 
80% methanol (6 mL) 
90% methanol (6 mL) 
100% methanol (6 mL) 
40 oC 
NaOMe, rt 
 
Acidic Amberlyst resin 
40 oC 
toluene 
40 oC 
45 
 
 
 
45 
 
 
 
45 
180 
 
 
45 
 
45 
Table 5-1. Modified tasks for the automated synthesis platform. 
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Figure 5-5. HPLC traces for the two compounds obtained from the automated synthesis 
platform (1 mL/min flow rate, 20% ethyl acetate/hexane, 10 minute run a standard silica 
column.)  
 
With these initial results in hand, the next goal was to synthesize a silyl-derivatized 
fluorous protecting group for application to a similar robotically-controlled synthesis run. 
Because ester derived protecting groups are used frequently throughout the construction of 
oligosaccharide molecules, an orthogonal protecting group with different functionality and 
that lacked the ability to aid in neighboring group participation in the glycosylation steps 
would be useful. A second fluorous protecting group would also test the generality of the 
solutions devised for a successful di-tagging approach to automated oligosaccharide 
synthesis. Numerous types of silyl ether protecting groups have been used in oligosaccharide 
synthesis mainly due to their stability throughout the various synthetic procedures [6]. 
Among the many known silyl derivatives, tert-butyldimethylsilyl and tert-butyldiphenylsilyl 
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groups are the most frequently used groups. However fluorous versions of the tert-
butyldimethyl and tert-butyldiphenyl groups were not readily available. From a 
commercially available diisopropyl-(1H,1H,2H,2H,-perfluorodecyl)silane, the triflated 
intermediate was synthesized [7] and used directly to protect the free hydroxyl group of 13 to 
obtain the silyl derived fluorous-tail protecting group. 
 
In parallel with testing the generality of the di-tagging protocol with another 
protecting group, we also probed the use of a different glycosyl donor activation strategy. To 
date, only the trichloroacetimidate group [8] has been used in the automated synthesis of 
various oligosaccharides. Activation of a free anomeric hydroxyl group to the 
trichloroacetimidate group is a convenient process that is high yielding. In addition, the 
trichloroacetimidate donors are reliably reactive species for high conversion to the 
glycosylated products. These attributes make the group one of the most commonly used 
methods for donor building block activation [9]. However depending on the reactivity of the 
resulting glycosyl donor, the activated building block can sometimes be unstable such that 
long term storage is challenging. The rearrangement of the acetimidate to the amide moiety is 
also a concern and was observed in a number of cases. As a potential solution for cases in 
which the trichloroacetimidate proves too unstable for use, a more stable pentenyl donor [10] 
was synthesized and investigated under automated conditions. Pentenyl glycosides, first 
reported by Fraser-Reid, have been extensively studied and have proven to be a promising 
activation/protecting group at the anomeric position for constructing complex 
oligosaccharides [10]. 
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A study of the utility if these n-pentenyl glycosides (NPGs) as a component for 
automated oligosaccharide synthesis is attractive for a number of reasons. The synthesis of 
individual monosaccharide building blocks that bear the correct arrangements of orthogonal 
protecting groups is often a tedious process. The synthetic process to obtain a final donor 
monosaccharide can take as few as 3 steps or as many as 16 synthetic steps. The majority of 
these building block synthetic schemes involve the protection/deprotection and activation of 
the anomeric position. Use of the NPG group as the anomeric protecting group for the 
building block synthesis has the advantage of not usually requiring repetitive 
protection/deprotection/activation steps on the C-1 position throughout the synthesis. The 
NPG group can be introduced at the C-1 position at the beginning of the synthesis and carried 
through the synthesis as the other protecting groups are incorporated at the designated 
position of the sugar molecule. In the end, a protection and deprotection step is saved to 
thereby shorten the overall building block scheme. The pentenyl groups are then generally 
activated by halogenation of the pentenyl double bond, which results in cyclization and the 
release of the agylcone in the form of a halogenated furanose moiety as well as of the active 
glycosylation species [11]. The activation of these NPGs is achieved by using various 
promoters such as iodonium dicollidine perchlorate (IDC), or the corresponding triflate 
(IDCT), iodine [12]. Alternatively, the use of NBS, NIS in combination with either TfOH or 
TESOTf has been reported as well [10].   
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Figure 5-6. n-Pentenyl glycoside activation process. [6] 
 
 
Finally and most importantly, the NPGs provide excellent stability under a variety of 
protecting group manipulations. In addition, unlike the trichloroacetimidate species, long 
term storage of these donors should be possible both in solution on the robotics platform 
when running long programs and also neat under low temperature conditions for future use 
without fear of rearrangement by-products.  
 
To test the feasibility of incorporation of pentenyl glycosides into automated 
oligosaccharide synthesis runs, a new rhamnose hexasaccharide 10 was selected as a target. 
This target molecule has been found in streptococcal group A bacteria as a polyrhamnose 
(polyRha) core [13] in alternating 1,2 and 1,3 linkages with N-acetylglucosamine (GlcNAc) 
residues β-1,2-linked to available 3-positions of the rhamnose core [14]. The synthesis of the 
target hexasaccharide was designed to have a disaccharide repeating unit 11 that contains the 
alternating 1,2 and 1,3-linkages (Figure 5-7). The initial disaccharide contains the fluorous 
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tag at the anomeric position for ease of purification during automated cycles, and the second 
fluorous tag is attached to the O-3 position of the second rhamnose to test the new silyl 
derived fluorous protecting group for purification. Also, instead of a trichloroacetimidate 
donor, the n-pentyl group was introduced into the synthetic scheme. 
 
 
Figure 5-7. Retrosynthesis of the rhamnose hexasaccharide repeating building block. 
 
The synthesis of the disaccharide building block was started by a previously discussed 
allyl-rhamnose intermediate with a free O-3 position (12). The commercially available 
diisopropyl-(1H,1H,2H,2H,-perfluorodecyl)silane was converted into its triflated 
intermediate [7] and was used directly in the same pot to protect the O-3 position of the 
rhamnose monosaccharide. The diisopropyl perfluoro silyl group will serve as the second 
fluorous tag to test its robustness as a second purification handle under automation. This 
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silyl-protected building block was carried through a series of reactions to remove the allyl 
group and further activate the group into the trichloroacetimidate donor. The pentenyl 
rhamnose acceptor 15 was prepared from a known rhamnose orthoester intermediate [2] and 
was deprotected at the O-2 position to attach the second rhamnose building block and 
complete the disaccharide repeating unit. With the disaccharide repeating unit containing 
both the perfluoro silyl protecting group and the n-pentenyl anomeric group, the next step 
was to subject this repeating unit to glycosylation reaction conditions in the automated 
platform and build up the target hexasaccharide. 
 
 
 
Figure 5-8. Synthetic scheme for the disaccharide repeating unit building block for the 
automated synthesizer. 
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The initial idea for the modified glycosylation conditions was to use NIS as the 
promotor along with TESOTf in dichloromethane conditions. However, these conditions 
turned out to be problematic under the automation platform because the solubility of NIS in 
dichloromethane was poor. Preparing a homogenous solution of NIS is important for the 
needle to robotically transfer an accurate quantity of NIS into the reactor vial and thereby 
fully convert the donor into its active species. To make this condition amenable for 
automation, a dual solvent reaction condition was attempted by making a NIS/acetonitrile 
stock solution vial to transfer the exact equimolar amount of NIS solution to the programmed 
reactor vial where the donor disaccharide/dichloromethane solution is located. After 20 
minutes of vortexing, the TLC aliquot collected showed a high conversion of donor molecule 
to the anomeric fluorous tail product. The crude sample was then transferred to the FSPE 
station for purification. Fortunately, use of the same solvent conditions described earlier 
allowed the di-fluorous tagged molecule to be easily separated from the mono-fluorous 
tagged compounds. The purified di-tagged intermediate was then carried back to a clean 
reactor vial for deprotection of the fluorous silyl protecting group. In this case, too, the 
desired mono-fluorous product could be removed from the fluorous-containing silyl material 
using differential solubility in toluene. The reaction conditions and times are described in the 
table below. 
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Step Task Reagents/Operation Time 
1 
2 
3 
4 
5 
6 
 
 
7 
8 
9 
10 
11 
12 
13 
Glycosylation 
TLC 
Water 
Quench 
Evaporation 
FSPE 
 
 
Evaporation 
Deprotection 
TLC 
Quench 
Evaporation 
Separation 
Evaporation 
NIS/MeCN, TESOTf, Donor, DCM,  
25 oC 
 
sodium thiosulfate solution 
40 oC 
80% methanol (6 mL) 
90% methanol (6 mL) 
100% methanol (6 mL) 
40 oC 
TBAF/THF, rt 
 
 
40 oC 
toluene 
40 oC 
30 
 
 
 
45 
 
 
 
45 
600 
 
 
45 
 
45 
 
Table 5-2. Description of the rhamnose hexasaccharide synthesis protocol. 
 
 
After 56 hours, the di-tagged rhamnose hexamer was successfully synthesized under 
automated means in a pure form in 11% overall yield, which corresponds to approximately 
70% per step yields. The separation conditions proved robust enough for application to this 
new activation and protecting group strategy.  
 
Conclusion 
 
In summary, this report presents a new protecting group strategy for complex 
oligosaccharide syntheses under automated conditions. We have demonstrated the convenient 
synthesis of the fluorous acetate protecting group and how it could be used to easily purify 
the elongated oligosaccharide chains away from failed sequences with a simple gravity 
filtration. Also, conditions to deprotect the fluorous acetate group and remove these fluorous 
by-products from the desired singly-tagged saccharide chain were demonstrated. In addition, 
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the fluorous silyl protecting group was introduced into automated oligosaccharide synthesis 
and tested to serve as an orthogonal protecting group that delivers some of the same 
advantages of the fluorous acetate group. Finally, the development of conditions for the 
inclusion of n-pentenyl glycosyl donor into automated oligosaccharide protocols offers more 
choices in glycosyl donor and a more stable and convenient option compared to some 
trichloroacetimidate donors. With protocols now in hand that expand the range of protecting 
group, purification, and donor activation options in automated oligosaccharide synthesis, an 
even greater range of complex oligosaccharides should succumb to synthesis and the 
possibilities for carbohydrate library synthesis are significantly expanded. 
 
Experimental section 
 
General methods 
 
Commercial reagents and solvents were used as received without further purification 
unless otherwise stated. The reactions were monitored and the Rf values determined using 
analytical thin layer chromatography (tlc) with 0.25 mm EM Science silica gel plates (60F - 
254). The developed tlc plates were visualized by immersion in p-anisaldehyde solution 
followed by heating on a hot plate. Silica gel flash chromatography was performed with 
Selecto Scientific silica gel, 32-63 mm particle size. Fluorous phase chromatography was 
performed using fluorous solid-phase extraction cartridges containing silica gel bonded with 
perfluorooctylethylsilyl chains (Fluorous Technologies, Inc.; Pittsburgh, PA). All other 
fluorous reagents were also obtained from Fluorous Technologies, Inc. All moisture sensitive 
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reactions were performed in flame- or oven- dried glassware under nitrogen atmosphere. 
Bath temperatures were used to record the reaction temperature. All reactions were stirred 
magnetically at ambient temperature unless otherwise indicated. 1H NMR and 13C NMR 
spectra were obtained with a Bruker DRX400 at 400 MHz and 162 MHz. 1H NMR spectra 
were reported in parts per million (δ) relative to CDCl3 (7.27ppm) as an internal reference.
 
13C NMR spectra were reported in parts per million (δ) relative to CDCl3 (77.23 ppm). HPLC 
traces were obtained using a Varian Inc. HPLC with a Waters Nova-pak 4 µL 3.9 ×150 mm 
silica column. High-resolution mass spectrometry was obtained with Applied Biosystems 
QSTAR XL Hybrid System.  
 
General procedures of Automated Synthetic Cycles using ASW 1000 
<ASW 1000 platform> 
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1. Sample Preparation 
 
Donor molecule (361.1 mg, 375 µmol) was dissolved with dried toluene (2.5 mL) in the 8 
mL vial and placed at the stock solution rack (Donor 1) under nitrogen. 0.27 M 
trimethylsilyltrifluoromethanesulfonate (TMSOTf, 1.05 mL) solution in toluene prepared in 
the 13 mL vial and placed as indicated on the stock solution rack under nitrogen. Dried 
toluene (800 mL) was prepared in the 1 L reservoir bottle and placed with the syringe tubing 
connected for reaction conditions and reservoir solution for rinsing. Methanol (100 mL) was 
prepared in the 100 mL vial and placed under nitrogen at the inert condition rack. 80% 
methanol/water (100 mL), triethylamine (10 mL) were prepared in stock solution bottles and 
connected to the transfer ports. Acceptor molecule (43.7 mg, 50 µmol) was dissolved with 
dried toluene (0.5 mL) in a Wheaton 8 mL E-Z extraction vial (conical bottomed) capped 
with pre-punctured septa and placed at the reagent rack where indicated (F-tagged OH).  
 
0.5 M sodium methoxide solution in methanol (5 mL) was prepared in 8 mL vial capped with 
pre-punctured septa and placed at the reagent rack where indicated. N,N-dimethylformamide 
(DMF, 5 mL) directly from Fluka was transferred to an 8-mL vial capped with pre-punctured 
septa and placed at the reagent rack where indicated. Fluorous solid phase extraction (FSPE) 
cartridges (2 g, 10 cc) were preconditioned with 80% methanol and placed on the machined 
SPE block. An empty Wheaton 8 mL E-Z extraction vial (conical bottomed) was placed 
under the FSPE cartridge.  
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2. Cleaning Cycle 
 
Prior to introduction of reagents, the ASW1000 reactor vials were cleaned, dried and purged 
with argon by running the cleaning cycle. During the cleaning cycle each of the 16 reactor 
vials (13 mL) were rinsed with 8 mL toluene and 8 mL methanol 3 times each. After the 
solvents were completely removed, the reactor vials were dried under vacuum and purged 
with argon for 45 minutes. Reagent solvents were prepared by azeotroping the building 
blocks individually with toluene and dried under high vacuum. After the reactor vials were 
dry, the reagents were transferred into the vials to be placed on the inert condition reagent 
rack and general atmosphere reagent rack.   
 
3. Method Run 
 
3.1. Glycosylation (Trichloroacetimidate donor method) 
 
Reactor vials were cooled to 0 oC during the 5 minutes wait time by the heat transfer oil. The 
needle transferred the acceptor molecule (F-tagged monomer) solution (0.6 mL) to the 
reaction vial 1, followed by the transfer of the acceptor molecule solution (0.5 mL) and the 
TMSOTf solution (56 µL). After each individual transfer, the needle was rinsed by 2 mL 
toluene inside and out before operating the next task. The reaction mixture was vortexed at 
800 rpm for 45 minutes at 0 oC under inert gas.  After the reaction time, the needle withdrew 
20 µL from the reaction mixture and placed it onto the first well of the microtiterplate for 
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thin layer chromatography monitoring. Water (0.5 mL), triethylamine (0.5 mL) was added to 
the solution for quenching and solvent evaporated under reduced pressure.   
 
3.2. Glycosylation (Pentenyl donor method) 
 
In a clean reactor vial the needle transferred the donor molecule (disaccharide repeating unit) 
solution (0.6 mL) to the reaction vial 1, followed by the transfer of the NIS/MeCN solution 
and the TESOTf solution (56 µL). After vortexing the reactor vials at 300 rpm for 3 min, 
accpetor monosaccharide (0.5 mL) was added to the same vial. Between each individual 
transfer, the needle was rinsed by 2 mL toluene inside and out before operating the next task. 
The reaction mixture was vortexed at 800 rpm for 30 minutes at 25 oC under inert gas.  After 
the reaction time, the needle withdrew 20 µL from the reaction mixture and placed it onto the 
first well of the microtiterplate for thin layer chromatography monitoring. Triethylamine (0.5 
mL) was added to the solution for quenching and solvent evaporated under reduced pressure.   
 
3.3. FSPE 
 
DMF (0.4 mL) was added to dissolve the crude mixture and the vials were vortexed at 100 
rpm for 5 minutes. Reaction mixture (0.7 mL) was carried to the FSPE cartridge at the SPE 
rack dispensed at a speed of 20 mL/s via the 1 mL syringe. Then 80% methanol (4.5 mL) was 
used to rinse the empty reactor vial. 80% methanol solvent was removed from the reactor vial 
each time (1.7 mL, 1.5 mL, 1.5 mL) and delivered to the FSPE cartridge. Additional 80% 
methanol solution (1.5 mL) was used to rinse the FSPE cartridge. During the 80% methanol 
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rinse, the cartridge was positioned at ‘SPE waste’ for the eluted mixture to be disposed. 90% 
methanol solution (2 mL) was used to rinse the FSPE cartridge 3 times. After all the 
undesired compounds were eluted out, methanol (2 mL, repeated 3 times) was used to wash 
the FSPE cartridge for eluting the desired compound. During the task, the FSPE cartridge 
was positioned as ‘SPE collect’ to be placed right above the 8 mL vial for collection of the 
sample. After the task, the position of the SPE rack was changed into ‘SPE direct’ for the 
needle to withdraw the collected sample from the vial and deliver it to the clean reactor vial 
for the next reaction. Toluene (1 mL) was added to the solution and solvent was evaporated 
under reduced pressure. After evaporation cycle, once again toluene (1 mL) was added and 
removed under reduced pressure for complete dryness. 
 
3.4. Deacetylation 
 
To the dried residue, methanol (0.5 mL) was added to the reactor vial followed by sodium 
methoxide solution (0.4 mL). The reaction mixture was vortexed at 800 rpm for 3 hours at 
room temperature. After the reaction time, the needle transferred the reaction mixture to a 
clean reactor vial that contains acidic Amberlyst resin to quench the reaction. The reaction 
mixture was vortexed at 800 rpm for 15 minutes and then again transferred to a clean vial. 
Solvent was evaporated under reduced pressure to give crude product. Then 1 mL of toluene 
was added, and vortexed for an additional 15 minutes. The resulting solution was transferred 
to a clean vial and the solvent was evaporated under reduced pressure. 
 
3.5. Desilylation 
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To the dried residue, THF (0.5 mL) was added to the reactor vial followed by TBAF solution  
(0.4 mL). The reaction mixture was vortexed at 800 rpm for 10 hours at room temperature. 
After the reaction time, solvent was evaporated under reduced pressure to give crude product. 
Then 1 mL of toluene was added, and vortexed for an additional 15 minutes. The resulting 
solution was transferred to a clean vial and the solvent was evaporated under reduced 
pressure. 
 
Synthetic Procedure 
 
 
 
 
Allyl 3,4-di-O-benzyl-α-L-rhamnopyranoside (2)  
 
To a solution of rhamnose orthester [15] (591 mg, 1.48 mmol), allyl alcohol (0.6 ml, 8.86 
mmol) in dry CH2Cl2 (10 mL), was added TfOH (3 µL) at -40 
oC bath. After stirring at -40 
oC under nitrogen for 30 minutes, the reaction mixture was stirred for another 30 minutes to 
be brought up to room temperature. The mixture was diluted with CH2Cl2 (20 mL) and 
washed with saturated aqueous NaHCO3 solution, water and dried over MgSO4. The solvent 
was removed under reduced pressure and the residue was dissolved in a solution of NaOMe 
in MeOH (10 mL). The mixture was stirred at room temperature for 1 h, then was quenched 
with acidic Amberlyst resin. After the resin was filtered, the solvent was concentrated under 
O
BnO
BnO
OH
O
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vacuum. The crude product was purified by silica gel chromatography to give the titled 
compound [16] as a colorless syrup (449 mg, 1.17 mmol, 79%).  
 
Rf (ethyl acetate/hexane): 0.67 (40/60) 
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.49-7.32 (m, 10H, OBn), 5.99-5.89 (m, 1H, CH=), 
5.36 (dd, J = 17.1 Hz, 1.5 Hz, 1H, CH2=), 5.26 (dd, J = 10.5 Hz, 1.5 Hz, 1H, CH2=), 5.00 (d, 
J = 10.8 Hz, 1H, CH2), 4.92 (s, 1H, H-1), 4.75 (s, 2H, CH2), 4.72 (d, J = 11.1 Hz, 1H, CH2), 
4.24 (dd, J = 13.2 Hz, 6.4 Hz 1H, CH2), 4.12 (dd, J = 3.2 Hz, 1.6 Hz, 1H, H-2), 4.00 (dd, J = 
12.9 Hz, 5.1 Hz, 1H, CH2), 3.95 (dd, J = 9.2 Hz, 3.2 Hz, 1H, H-3), 3.83 (m, 1H, H-5), 3.73 (t, 
J = 9.6 Hz, 1H, H-4), 2.85 (s, 1H, OH), 1.40 (d, J = 6 Hz, 3H, H-6). 
 13C NMR (CDCl3, 162 MHz): δ (ppm) 139.0, 138.2, 134.0, 128.8, 128.7, 128.3, 128.2, 
128.1, 128.0 118.0, 98.5, 80.4, 80.3, 75.8, 72.5, 68.8, 68.1, 67.7, 18.4.  
MS (ESI) m/z = calcd: 407.1834; found: 407.1941 [M+Na]+. 
 
 
 
 
Allyl 3,4-di-O-benzyl-2-(2H, 2H, 3H, 3H-perfluoroundecanoatyl)-α-L-rhamnopyranoside (3) 
  
To a solution of 2 (306 mg, 0.79 mmol) in dry dichloromethane (10 mL) cooled to 0 °C, was 
added DCC (327 mg, 1.7 mmol), DMAP (97 mg, 0.79 mmol) and 2H, 2H, 3H, 3H, -
perfluoroundecanoic acid (624 mg, 1.6 mmol). The reaction mixture was allowed to warm to 
O
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O
O
C8F17
O
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room temperature over 2 h. The reaction was diluted with dichloromethane (20 mL), washed 
with water (20 mL), HCl (2 N, 20 mL), and brine (20 mL), and dried over MgSO4. After the 
solvent was removed under reduced pressure, crude product was purified by flash column 
chromatography on silica gel using 15% EtOAc/hexane as eluent to obtain the title 
compound (622 mg, 0.72 mmol, 91%) as a colorless oil.  
 
Rf (ethyl acetate/hexane): 0.73 (40/60) 
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.49-7.32 (m, 10H, OBn), 5.97-5.86 (m, 1H, CH=), 
5.49 (dd, J = 3.2 Hz, 1.6 Hz, 1H, H-2), 5.35 (dd, J = 10.5 Hz, 1.5 Hz, 1H, CH2=), 5.24 (d, J = 
10.8 Hz, 1H, CH2), 4.98 (d, J = 11.1 Hz, 1H, CH2), 4.84 (d, J = 1.6 Hz, 1H, H-1), 4.74 (d, J = 
11.1 Hz, 1H, CH2), 4.66 (d, J = 11.1 Hz, 1H, CH2), 4.62 (d, J = 11.1 Hz, 1H, CH2), 4.21 (dd, 
J = 12.8 Hz, 5.2 Hz, 1H, H-3), 4.03 (m, 2H, CH2), 3.85 (m, 1H, H-5), 3.47 (t, J = 9.2 Hz, 1H, 
H-4), 2.78 (m, 2H, CH2), 2.56-2.40 (m, 2H, CH2), 1.39 (d, J=6.0 Hz, 3H, H-6). 
13C NMR (CDCl3, 100 MHz): δ (ppm) 171.0, 138.4, 138.1, 133.9, 128.5, 128.44, 128.2, 
127.9, 117.9, 96.5, 80.0, 78.1, 75.6, 72.0, 70.0, 68.1, 67.9, 26.8, 25.8, 18.9.  
HRMS-MALDI m/z = calcd: 859.1927; found: 859.1351 [M+Na]+. 
 
 
 
 
3,4-Di-O-benzyl-2-(2H, 2H, 3H, 3H-perfluoroundecanoatyl)-α/β-L-rhamnopyranoside (4) 
  
O
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O
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To a solution of 3 (380 mg, 0.44 mmol) in dry THF (5 mL), was added 
Ir(COD)(PMePh2)2
.HPF6  (3.7 mg, 4.4 µmol). After the reaction flask was evacuated, a H2 
balloon was added until the reaction mixture turned to a pale yellow. The hydrogen balloon 
was removed and the reaction mixture was stirred under nitrogen at room temperature for an 
additional 3 hours. The reaction was diluted with dichloromethane (20 mL), washed with 
water (20 mL), HCl (2 N, 20 mL), and brine (20 mL), and dried over MgSO4. The solvent 
was concentrated under reduced pressure to give crude product to be used directly for the 
next step.  
 
To a solution of the crude isomerized compound (337 mg, 0.39 mmol) in acetone/water (5/1, 
6 mL) was added HgCl2 (106 mg, 0.39 mmol), and HgO (85 mg, 0.39 mmol) at room 
temperature. The reaction mixture was stirred under nitrogen for 5 hours then was diluted 
with dichloromethane (20 mL), washed with water (20 mL), HCl (2 N, 20 mL), and brine (20 
mL), and dried over MgSO4. After the solvent was removed under reduced pressure, crude 
product was purified by flash column chromatography on silica gel using 15% EtOAc/hexane 
as eluent to obtain the title compound (252 mg, 0.31 mmol, 79%) as colorless oil.  
 
Rf (β): (ethyl acetate/haxane) 0.60 (60/40) 
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.49-7.32 (m, 10H, OBn), 5.45-5.43 (dd, J = 3.2 Hz, 
2 Hz, 1H, H-2), 5.15 (d, J = 1.6 Hz, 1H, H-1), 4.94 (d, J = 11.1 Hz, 1H, CH2), 4.70 (d, J = 
11.1 Hz, 1H, CH2), 4.65 (d, J = 11.1 Hz, 1H, CH2), 4.58 (d, J = 11.1 Hz, 1H, CH2), 4.03-3.97 
(m, 2H), 3.42 (t, J = 9.6 Hz, 1H, H-4), 2.75 (t J = 8.0 Hz, 2H, CH2), 2.45 (m, 2H, CH2), 1.33 
(d, J = 6 Hz, 3H, CH3). 
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13C NMR (CDCl3, 162MHz): δ (ppm) 171.1, 138.4 138.1, 128.6, 128.4, 128.6, 128.4, 128.1, 
128.0, 92.6, 81.7, 77.8, 75.6, 72.1, 70.4, 68.1, 26.8, 25.8, 18.2. 
HRMS-MALDI m/z = calcd: 841.1434; found: 841.1511 [M+Na]+. 
 
 
 
3,4-Di-O-benzyl-2-(2H, 2H, 3H, 3H-perfluoroundecanoatyl)-α/β-L-rhamnopyranosyl 
trichloroacetimidate (5) 
  
To a solution of the alcohol 4 (80 mg, 0.08 mmol) in anhydrous DCM (5 mL) was added 
Cs2CO3 (66.6 mg, 0.20 mmol) and distilled trichloroacetonitrile (0.04 mL, 0.4 mmol). The 
reaction mixture was stirred at room temperature for 0.5 h and then filtered over a pad of 
Celite. The filtered solution was concentrated under reduced pressure and the crude product 
was purified by flash column chromatography on silica gel using 10% EtOAc/hexane as 
eluent to obtain titled compound (83 mg, 0.08 mmol, 93%) as a colorless oil.  
 
Rf: (ethyl acetate/haxane) 0.93 (60/40) 
1H NMR (CDCl3, 400 MHz): δ (ppm) 8.60 (s, 1H, NH), 7.36-7.15 (m, 10H, OBn), 6.19 (dd, 
J = 1.6 Hz, 1H, H-1), 5.51 (dd, J = 3.2 Hz, 2.0 Hz, 1H, H-2), 4.92 (d, J = 10.4 Hz, 1H, CH2), 
4.71 (d, J = 10.4 Hz, 1H, CH2), 4.64 (d, J = 10.4 Hz, 1H, CH2), 4.59 (d, J = 10.4 Hz, 1H, 
CH2), 4.02 (dd, J = 9.6 Hz, 3.2 Hz, 1H, H-3), 3.97-3.92 (m, 1H, H-5), 3.52 (t, J = 9.6 Hz, 1H, 
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H-4), 2.82-2.72 (m, 2H, CH2), 2.54-2.41 (m, 2H, CH2), 2.37 (s, 3H, CH3), 1.36 (d, J = 6.0 Hz, 
3H, H-6). 
13C NMR (CDCl3, 162MHz): δ (ppm) 170.8, 160.7, 138.1, 137.9, 128.8, 128.7, 128.5, 
128.4, 128.2, 128.1, 95.1, 79.8, 77.3, 75.9, 72.4, 71.0, 68.5, 26.8, 25.8, 18.2. 
HRMS-MALDI m/z = calcd: 984.0530; found: 984. 0599 [M+Na]+. 
 
 
 
 
 
- 3.5 cycles completed for the synthesis of the di-tagged pentasaccharide 
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Table 5-3. List of synthetic procedures programmed 
Step Task Reagent/ Operation Operation 
Time 
1 
 
 
2 
3 
4 
5 
 
 
6 
7 
8 
9 
10 
11 
12 
13 
14 
 
 
 
43 
 
 
44 
45 
46 
47 
 
 
48 
Glycosylation 
 
 
TLC sample 
Quenching 
Evaporation 
FSPE 
 
 
Transfer 
Evaporation 
Deacetylation 
TLC sample 
Quenching 
Transfer 
Evaporation 
Separation 
Evaporation 
 
 
 
Glycosylation 
 
 
TLC sample 
Quenching 
Evaporation 
FSPE 
 
 
Transfer 
1.5 equivalent first donor  (75 µmol) in 0.5 mL toluene,  
1 equivalent F-tagged acceptor (50 µmol) in 1 mL toluene; 0.1 
equivalent TMSOTf, 0 oC 
20 µL of crude reaction mixture withdrawn 
0.5 mL water, then 0.5 mL TEA 
40 oC 
 0.4 mL DMF used to dissolve crude mixture 
80% methanol (6 mL), 90% methanol (6 mL), 100% methanol 
(6 mL) 
6 mL collected sample transferred to clean vial 
40 oC 
NaOMe, rt 
20 µL of crude reaction mixture withdrawn 
Transfer mixture to prepacked acidic resin reactor vial 
Transfer solution to clean reactor vial 
40 oC 
3 mL toluene used to dissolve out desired compound 
40 oC 
 
Repeat 1-14 (x 2) 
 
1.5 equivalent first donor  (75 µmol) in 0.5 mL toluene,  
1 equivalent F-tagged acceptor (50 µmol) in 1 mL toluene; 0.1 
equivalent TMSOTf, 0 oC 
20 µL of crude reaction mixture withdrawn 
0.5 mL water, then 0.5 mL TEA 
40 oC 
 0.4 mL DMF used to dissolve crude mixture 
80% methanol (6 mL), 90% methanol (6 mL), 100% methanol 
(6 mL) 
6 mL collected sample transferred to clean vial 
 
45 min 
 
 
 
 
45 min 
 
 
 
 
45 min 
3 hrs 
 
 
 
45 min 
 
45 min 
 
 
 
45 min 
 
 
 
 
45 min 
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cis-4-(1H, 1H, 2H, 2H, 3H, 3H-Perfluoroundecyloxy)-2-butenyl 3,4-Di-O-benzyl-2-(2H, 2H, 
3H, 3H-perfluoroundecanoatyl)-α-L-rhamnopyranosyl-(1→2)-3,4-di-O-benzyl-α-L-
rhamnopyranosyl-(1→2)-3,4-di-O-benzyl-α-L-rhamnopyranosyl-(1→2)-3,4-di-O-benzyl-α-
L-rhamnopyranosyl-(1→2)-3,4-di-O-benzyl-α-L-rhamnopyranoside (9) 
 
Rf: (ethyl acetate/haxane) 0.77 (60/40) 
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.36-7.15 (m, 50H), 5.80-5.60 (m, 2H), 5.68 (d, J = 
3.2 Hz, 1.6 Hz, 1H), 5.28-4.54 (m, 25H), 4.13 (m, 18H), 3.49-3.31 (m, 7H), 2.30-2.14 (m, 
7H), 1.95-1.80 (m, 4H), 1.45 (m, 15H). 
13C NMR (CDCl3, 162 MHz): δ (ppm) 171.3, 138.7, 138.6, 138.6, 138.6, 138.5, 138.5, 
138.5, 138.4, 138.4, 138.3, 129.9, 129.9, 128.6, 128.6, 128.6, 128.6, 128.5, 128.5, 128.4, 
128.3, 128.2, 128.2, 128.2, 128.1, 127.9, 127.9, 127.9, 127.7, 100.8, 100.5, 99.3, 98.2, 80.6, 
80.5, 80.4, 80.4, 80.3, 80.3, 80.3, 79.6, 79.1, 78.0, 78.0, 77.9, 77.4, 75.7, 75.6, 74.9, 74.8, 
74.77, 72.4, 72.3, 72.2, 72.1, 72.0, 69.1, 69.0, 68.7, 68.5, 68.2, 66.7, 62.7, 28.9, 21.6, 21.2, 
18.9, 18.3.  
HRMS-MALDI m/z = calcd: 2675.8045; found: 2675.8102 [M+Na]+. 
 
 
n-Pentenyl 2-O-acetyl-3,4-di-O-benzyl-α-L-rhamnopyranoside. 
O
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To a solution of rhamnose orthester [15] (705 mg, 1.76 mmol), n-pentenyl alcohol (1.07 mL, 
10.6 mmol) in dry CH2Cl2 (5 mL), was added TfOH (5 µL) at -40 
oC bath. After stirring at -
40 oC under nitrogen for 30 minutes, the reaction mixture was stirred for another 30 minutes 
to be brought up to room temperature. The mixture was diluted with CH2Cl2 (20 mL) and 
washed with saturated aqueous NaHCO3 solution, water and dried over MgSO4. The solvent 
was removed under reduced pressure and the residue was dissolved in a solution of NaOMe 
in MeOH (10 mL). The mixture was stirred at room temperature for 1 h, then was quenched 
with acidic Amberlyst resin. After the resin was filtered, the solvent was concentrated under 
vacuum. Crude product was purified by silica gel chromatography to give titled compound as 
a colorless syrup (632 mg, 1.39mmol, 79%).  
 
Rf: (ethyl acetate/hexane) 0.90 (40/60) 
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.34-7.27 (m, 10H, OBn), 5.84-5.77 (m, 1H, CH=), 
5.37 (s, 1H), 5.06-4.91 (m, 3H), 4.73 (m, 2H), 4.63 (d, J = 10.8 Hz, 1H), 4.56 (d, J = 11.2 Hz, 
1H), 3.96 (dd, J = 9.2 Hz, 3.2 Hz, 1H), 3.78 (m, 1H), 3.67 (m, 1H), 3.44-3.35 (m, 2H), 2.16 
(s, 3H), 2.10 (m, 2H), 1.67 (m, 2H), 1.35 (d, J = 6.0 Hz, 3H).  
13C NMR (CDCl3, 100 MHz): δ (ppm) 171.0, 138.4, 138.1, 133.9, 128.5, 128.44, 128.2, 
127.9, 117.9, 96.5, 80.0, 78.1, 75.6, 72.0, 70.0, 68.1, 67.9, 26.8, 25.8, 18.9.  
HRMS-MALDI [M+Na]+ m/z = calcd: 477.2253; found: 477.8130.  
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n-Pentenyl 3,4-di-O-benzyl-α-L-rhamnopyranoside (15) 
  
To a solution of n-pentenyl 2-O-acetyl-3,4-di-O-benzyl-α-L-rhamnopyranoside (500 mg, 
1.10 mmol) in methanol (5 mL), was added a small piece of sodium (~ 10 mg) at room 
temperature. After stirring at rt under nitrogen for 30 minutes, the reaction mixture was 
quenched with acidic Amberlyst resin and filtered. The solvent was removed under reduced 
pressure and the crude product was purified by silica gel chromatography to give the titled 
compound as a colorless syrup (449 mg, 1.09 mmol, 99%).  
 
Rf: (ethyl acetate/hexane) 0.83 (40/60) 
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.40-7.31 (m, 10H, OBn), 5.84-5.81 (m, 1H, CH=), 
5.07 (dd, J = 17.2 Hz, 1.6 Hz, 1H), 5.09 (dd, J = 12.4 Hz, 2.4 Hz, 1H), 4.92 (d, J = 10.8 Hz, 
1H), 4.81 (d, J = 1.2 Hz, 1H), 4.72 (s, 2H), 4.68 (d, J = 10.8 Hz, 1H), 4.04 (dd, J = 2.8 Hz, 
1.6 Hz, 1H), 3.88 (dd, J = 9.2 Hz, 3.2 Hz, 1H), 3.77-3.66 (m, 2H), 3.50 (t, J = 9.2 Hz, 1H), 
3.44 (m, 1H), 2.53 (d, J = 2.0 Hz, 1H), 2.15 (m, 1H), 1.71 (m, 1H), 1.34 (d, J = 6.4 Hz, 3H).  
13C NMR (CDCl3, 100 MHz): δ (ppm) 138.6, 138.2, 138.1, 128.7, 128.7, 128.6, 128.2, 
128.1, 128.0, 127.9, 115.1, 99.1, 80.3, 80.2, 75.6, 72.2, 68.8, 67.4, 67.1, 30.5, 28.8, 18.0. 
HRMS-MALDI [M+Na]+ m/z = calcd: 435.2147; found: 435.9012.  
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Allyl 2-O-acetyl-4-O-benzyl-α-L-rhamnopyranoside (12) 
  
To a solution of allyl 4-O-benzyl-2,3-O-methoxyethylidene-α-L-rhamnopyranose (538 mg, 
1.54 mmol) in dry dichloromethane (10 mL), was added TfOH/water (v:v=3:2, 0.95 mL) 
solution at room temretature. The reaction mixture was stirred at room temperature for 1 
hour. After TLC confirmed complete starting material comsumption the reaction mixture was 
diluted with dichloromethane (20 mL), washed with water (20 mL), NaHCO3 solution (20 
mL), and brine (20 mL), and dried over MgSO4. After the solvent was removed under 
reduced pressure, crude product was purified by flash column chromatography on silica gel 
using 25% EtOAc/hexane as eluent to obtain the title compound (501 mg, 1.49 mmol, 97%) 
as colorless oil.  
 
Rf: (ethyl acetate/hexane) 0.5 (40/60) 
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.35-3.26 (m, 5H), 5.87 (m, 1H), 5.27-5.23 (dd, J = 
17.2 Hz, 1.6 Hz, 1H), 5.17 (dd, J = 17.4 Hz, 1.2 Hz, 1H), 5.09 (dd, J = 3.6 Hz, 1.6 Hz, 1H), 
4.85 (d, J = 11.2 Hz, 1H), 4.74 (d, J = 1.2 Hz, 1H), 4.68 (d, J = 11.2 Hz, 1H), 4.12-4.07 (m, 
2H), 3.93 (dd, J = 12.8 Hz, 6.0 Hz, 1H), 3.75 (m, 1H), 3.36 (t, J = 9.2 Hz, 1H), 2.56 (d, J = 
5.2 Hz, 1H), 2.0 (s, 3H), 1.32 (d, J = 6.4 Hz, 3H).  
13C NMR (CDCl3, 100 MHz): δ (ppm) 171.0, 138.3, 133.6, 128.5, 128.0, 127.9, 117.6, 96.6, 
81.7, 75.3, 72.9, 70.2, 68.1, 67.5, 21.1, 18.0.  
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HRMS-MALDI [M+Na]+ m/z = calcd: 359.1471; found: 349.1108.  
 
 
Allyl 2-O-acetyl-4-O-benzyl-3-O-{(1H, 1H, 2H, 2H-perfluorodecyl)-diisopropylsilyl}-α-L-
rhamnopyranoside (13) 
 
To a solution of diisopropyl-(1H, 1H, 2H, 2H, perfluorodecyl)silane (130 mg, 0.23 mmol) in 
anhydrous dichloromethane (1.5 mL) was added triflic acid (18.7 µL, 0.23 mmol) at room 
temperature. After the reaction mixture was stirred for 30 min, a solution of 12 (25 mg, 0.07 
mmol) and 2,6-lutidine (45 µL) in dry dichloromethane (1 mL) was added at room 
temperature and the solution was stirred for an additional 15 min. Afer TLC confirmed 
complete starting material consumption, the solution was diluted with dichloromethane (20 
mL), washed with water (20 mL), saturated NaHCO3 solution (20 mL), and brine (20 mL), 
and dried over MgSO4. After the solvent was removed under reduced pressure, crude product 
was purified by flash column chromatography on silica gel using 20% EtOAc/hexane as 
eluent to obtain the title compound (59 mg, 0.07 mmol, 86%) as colorless oil.  
 
Rf: (ethyl acetate/hexane) 0.93 (40/60) 
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.32-7.26 (m, 5H), 5.84 (m, 1H), 5.27 (dd, J = 17.2 
Hz, 1.2 Hz, 1H), 5.27 (dd, J = 17.4 Hz, 1.4 Hz, 1H), 5.10 (s, 1H), 4.87 (d, J = 11.2 Hz, 1H), 
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4.69 (s, 1H), 4.61 (d, J = 11.6 Hz, 1H), 4.22 (dd, J = 9.2 Hz, 3.2 Hz, 1H), 4.11 (dd, J = 13.2 
Hz, 4.8 Hz, 1H), 3.93 (dd, J = 13.2 Hz, 5.6 Hz, 1H), 3.69 (m, 1H), 3.44 (t, J = 9.2 Hz, 1H), 
2.11 (m, 7H), 1.29 (d, J = 6.0 Hz, 3H), 1.05 (m, 12H), 0.84 (m, 2H). 
13C NMR (CDCl3, 162 MHz): δ (ppm) 170.0, 138.2, 133.5, 128.2, 127.5, 127.4, 116.8, 96.7, 
81.6, 71.4, 68.2, 67.9, 20.6, 18.5, 18.2, 17.8, 17.3, 17.3, 17.3, 17.0, 16.9, 12.9, 12.8.  
HRMS-MALDI [M+Na]+m/z = calcd: 833.1203; found: 833.5600.    
 
 
2-O-Acetyl-4-O-benzyl-3-O-{(1H, 1H, 2H, 2H-perfluorodecyl)-diisopropylsilyl}-α/β-L-
rhamnopyranosyl trichloroacetimidate (14) 
 
To a solution of the alcohol (653 mg, 0.76 mmol) in anhydrous DCM (5 mL) was added 
Cs2CO3 (621 mg, 1.9 mmol) and distilled trichloroacetonitrile (0.38 mL, 3.8 mmol). The 
reaction mixture was stirred at room temperature for 0.5 h and then filtered over a pad of 
Celite. The filtered solution was concentrated under reduced pressure and the crude product 
was purified by flash column chromatography on silica gel using 10% EtOAc/hexane as 
eluent to obtain titled compound (663 mg, 0.07 mmol, 87%) as a colorless oil.  
 
Rf: (ethyl acetate/hexane) 0.53 (20/80) 
O
BnO
O
OAc
O CCl3
Si
C8F17 i Pr
i Pr
NH
 186 
1H NMR (CDCl3, 400 MHz): δ (ppm) 8.68 (s, 1H), 7.53-7.19 (m, 5H), 6.14 (s, 1H), 5.26 (s, 
1H), 4.88 (d, J = 11.2 Hz, 1H), 4.65 (d, J = 11.2 Hz, 1H), 4.35 (dd, J = 9.2 Hz, 2.8 Hz, 1H), 
3.91 (m, 1H), 3.51 (t, J = 9.6 Hz, 1H), 2.16-2.02 (m, 7H), 1.26 (d, J = 6.0 Hz, 3H), 1.05 (s, 12 
H), 0.93 (m, 2H). 
13C NMR (CDCl3, 100 MHz): δ (ppm) 170.3, 160.2, 138.0, 128.6, 128.0, 127.8, 127.7, 94.9, 
80.9, 75.8, 71.8, 71.3, 71.2, 21.0, 18.2, 17.8, 17.7, 17.6, 13.0, 12.9, 0.7.  
HRMS-MALDI [M+Na]+ m/z = calcd: 935.9986; found: 935.1280.  
 
Pent-4-enyl 2-O-acetyl-4-O-benzyl-3-O-{(1H, 1H, 2H, 2H-perfluorodecyl) diisopropylsilyl}-
α-L-rhamnopyranosyl-(1→2)-3,4-di-O-benzyl-α-L-rhamnopyranoside (11) 
  
To a solution of the rhamnose donor 14 (48 mg, 0.048 mmol) in dry dichloromethane (0.5 
mL), was added the rhamnose pentenyl acceptor 15 (20 mg, 0.048 mmol) in dichloromethane 
(0.5 mL). TMSOTf (1 µL) was added to the solution and the reaction mixture was stirred at 
room temperature for 20 min. TLC of mixture shows complete conversion of the starting 
material. Reaction mixture was quenched with a few drops of triethylamine and solvent was 
concentrated under reduced pressure. The crude product was dissolved in DMF (0.5 mL) 
loaded onto a 2 g FSPE cartridge. The SPE cartridge was washed with 80% methanol/water 
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(10 mL) and 100% methanol (10 mL). The methanol solution was concentrated under 
reduced pressure to give the titled compound   (49 mg, 0.042 mmol, 88%) as colorless oil. 
 
Rf: (ethyl acetate/hexane) 0.53 (20/80). 
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.34-7.24 (m, 15H, OBn), 5.82 (m, 1H), 5.25 (s, 1H), 
4.96 (m, 3H), 4.85 (dd, J = 10.4 Hz, 6.0 Hz, 1H), 4.67-4.53 (m, 5H), 4.29 (dd, J = 9.2 Hz, 2.8 
Hz, 1H), 3.9 (s, 1H), 3.84-3.78 (m, 2H), 3.66-3.58 (m, 2H), 3.37 (m, 3H), 2.10-2.05 (m, 9H), 
1.65 (m, 2H), 1.25 (s, 3H), 1.23 (s, 3H), 1.04 (m, 12H), 0.85 (m, 2H).  
13C NMR (CDCl3, 162 MHz): δ (ppm) 170.3, 138.7, 138.6, 138.3, 138.2, 128.6, 128.5, 
128.4, 127.9, 127.8, 127.7, 127.7, 127.6, 115.1, 99.6, 98.9, 81.6, 80.7, 79.7, 75.7, 75.4, 73.2, 
72.0, 71.5, 68.9, 68.0, 67.0, 30.5, 28.8, 21.2, 18.2, 18.1, 17.9, 17.8, 17.7, 17.4, 17.3, 13.0, 
13.0, 13.0, 0.2. 
HRMS-MALDI  m/z = calcd: 1187.3034; found: 1187.9891. [M+Na]+. 
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cis-4-(1H, 1H, 2H, 2H, 3H, 3H-Perfluoroundecyloxy)-2-butenyl 2-O-acetyl-4-O-benzyl-α-L-
rhamnopyranosyl-(1→2)-3,4-di-O-benzyl-α-L-rhamnopyranosyl-(1→3)-2-O-acetyl-4-O-
benzyl-α-L-rhamnopyranosyl-(1→2)-3,4-di-O-benzyl-α-L-rhamnopyranosyl-(1→3)-2-O-
acetyl-4-O-benzyl-α-L-rhamnopyranosyl-(1→2)-3,4-di-O-benzyl-α-L-rhamnopyranoside (10) 
 
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.34-7.24 (m, 45H), 5.82 (m, 2H), 5.58 (s, 1H), 5.47 
(s, 1H), 5.29 (s, 1H), 5.20 (s, 1H), 4.96-4.55 (m, 18H), 4.48 (m, 2H), 4.35 (m, 2H), 4.23 (m, 
2H), 4.10-3.89 (m, 6H), 3.77-3.36 (m, 20H), 3.25 (m, 6H), 2.18-1.96 (m, 11H), 1.85 (m, 2H), 
1.28-1.23 (m, 18H). 
HRMS-MALDI  m/z = calcd: 2675.8054; found: 2675.2209. [M+Na]+. 
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CHAPTER 6 
 
Conclusions and Future Directions 
   
This dissertation reports the first development of an automated platform for solution-
phase oligosaccharide synthesis. Synthetic protocols in templated tasks were designed in 
order to build up continuous sequences for iterative synthetic cycles. A major advantage for 
this new strategy is that the majority of the bench-top solution-phase reaction conditions are 
directly transferrable to the automated platform. Therefore, when performing glycosylation 
reactions, less than 3 equivalents of donor molecules are required, which saves more than 7 
fold of material waste compared to standard solid-phase oligosaccharide synthesis protocols. 
In addition, monitoring of the reaction progress is much easier compared to the previously 
described solid-phase automated synthesis. An aliquot for thin layer chromatography (TLC) 
or high performance liquid chromatography (HPLC) was programmed to be withdrawn from 
the reaction mixture to determine whether additional purification steps might be required. 
Another major advantage to a solid versus solution-phase-based approach is that the 
instrument could be stopped and started at any stage of the programmed acquisition. Most 
importantly, the fluorous-tag, which is incorporated in the initial acceptor monosaccharide, 
offers a robust means of purification by simply taking advantage of the fluorous-fluorous 
interactions between the tagged molecule and fluorinated silica gel. Although the fluorous-
tail strategy has been used before for convenient purification, this report is the first to 
demonstrate that this noncovalent interaction is robust enough to fully automated iterative 
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synthesis protocols with fluorous solid-phase extraction (FSPE) processes. The automated 
solution-phase oligosaccharide synthesis method was tested with various oligosaccharide 
compounds in order to probe its versatility and robustness. Not only linear, but branched 
oligosaccharides were successfully composed and chemically challenging 1,2-cis glycosidic 
linkages were achieved under carefully controlled conditions. Rhamnose pentasaccharide 
was chosen to be used as a model study for optimizing the automated conditions. Based on 
the successful acquisition of the linear rhamnose synthesis, both anthrax- and cholera 
associated antigenic tetrasaccharides were achieved simultaneously by running a slightly 
modified method. During the optimization process, future limitations were foreseen and 
strategies such as the di-tagged methodology and n-pentenyl glycoside formation were tested 
to serve as additional possibilities when needed. Results with the reported oligosaccharides 
offer suitable alternative methods when difficulties in intermediate purification or instability 
of the usual trichloroacetimidate donors is encountered. 
 
The development of the first automated solution-phase oligosaccharide synthesis 
platforms now opens greater possibilities for obtaining pure, structurally well-defined 
oligosaccharide compounds. For future work, this strategy should be effective in constructing 
various combinations of sugar molecules to study structure-function relationships to 
contribute to the development of carbohydrate-based combinatorial libraries and ultimately 
carbohydrate-based vaccines and diagnostics. In addition, a labor-saving method to assemble 
oligosaccharides should aid in providing authentic samples to foster oligosaccharide structure 
determination methodologies such as mass-spectrometry-based sequencing and to carry out 
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carbohydrate structure and conformation work, especially with carbohydrate-binding 
proteins.     
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APPENDIX A.  CHAPTER 2    1H AND 13C NMR SPECTRA 
 
1, 2, 3, 4-Tetra-O-acetyl-α-L-rhamnopyranosde 
CDCl3, 400 MHz 
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1, 2, 3, 4-Tetra-O-acetyl-α-L-rhamnopyranosde 
CDCl3, 100 MHz 
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1-Bromo-2, 3, 4-tri-O-acetyl-α-L-rhamnopyranoside 
CDCl3, 400 MHz 
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1-Bromo-2, 3, 4-tri-O-acetyl-α-L-rhamnopyranoside 
CDCl3, 100 MHz 
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3, 4-O-Di-acetyl-1,2-O-methoxyethylidene-β-L-rhamnopyranose 
CD3OD, 400 MHz 
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3, 4-O-Di-acetyl-1,2-O-methoxyethylidene-β-L-rhamnopyranose 
CD3OD, 100 MHz 
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1,2-O-Methoxyethylidene-β-L-rhamnopyranose 
CD3OD, 400 MHz 
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1,2-O-Methoxyethylidene-β-L-rhamnopyranose 
CD3OD, 100 MHz 
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3,4-Di-O-benzyl-1,2-O-methoxyethylidene-β-L-rhamnopyranose 
CD3OD, 400 MHz 
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3,4-Di-O-benzyl-1,2-O-methoxyethylidene-β-L-rhamnopyranose 
CD3OD, 100 MHz 
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2-O-Acetyl-3,4-di-O-benzyl-α/β-L-rhamnopyranose 
CD3OD, 400 MHz 
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2-O-Acetyl-3,4-di-O-benzyl-α/β-L-rhamnopyranose 
CD3OD, 100 MHz 
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2-O-Acetyl-3,4-di-O-benzyl-α/β-L-rhamnopyranoside trichloroacetimidate (2) 
CDCl3, 400 MHz 
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2-O-Acetyl-3,4-di-O-benzyl-α/β-L-rhamnopyranoside trichloroacetimidate (2) 
CDCl3, 100 MHz 
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cis-4-(1H, 1H, 2H, 2H,3H, 3H-Perfluoroundecyloxy)-2-butenyl-2-O-acetyl-3,4-O-dibenzyl-
α-L-rhamnopyranoside 
CDCl3, 400 MHz 
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cis-4-(1H, 1H, 2H, 2H,3H, 3H-Perfluoroundecyloxy)-2-butenyl-2-O-acetyl-3,4-O-dibenzyl-
α-L-rhamnopyranoside 
CDCl3, 100 MHz 
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cis-4-(1H, 1H, 2H, 2H, 3H, 3H-Perfluoroundecyloxy)-2-butenyl-2-O-hydroxyl-3,4-O-
dibenzyl- α-L-rhamnopyranoside (1) 
CDCl3, 400 MHz 
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cis-4-(1H, 1H, 2H, 2H, 3H, 3H-Perfluoroundecyloxy)-2-butenyl-2-O-hydroxyl-3,4-O-
dibenzyl- α-L-rhamnopyranoside (1) 
CDCl3, 100 MHz 
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cis-4-(1H, 1H, 2H, 2H, 3H, 3H-Perfluoroundecyloxy)-2-butenyl 2-O-acetyl-3,4-di-O-benzyl-
α-L-rhamnopyranosyl-(1→2)-3,4-di-O-benzyl-α-L-rhamnopyranosyl-(1→2)-3,4-di-O-
benzyl-α-L-rhamnopyranosyl-(1→2)-3,4-di-O-benzyl-α-L-rhamnopyranosyl-(1→2)-3,4-di-
O-benzyl-α-L-rhamnopyranoside (3) 
CDCl3, 400 MHz 
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cis-4-(1H, 1H, 2H, 2H, 3H, 3H-Perfluoroundecyloxy)-2-butenyl 2-O-acetyl-3,4-di-O-benzyl-
α-L-rhamnopyranosyl-(1→2)-3,4-di-O-benzyl-α-L-rhamnopyranosyl-(1→2)-3,4-di-O-
benzyl-α-L-rhamnopyranosyl-(1→2)-3,4-di-O-benzyl-α-L-rhamnopyranosyl-(1→2)-3,4-di-
O-benzyl-α-L-rhamnopyranoside (3) 
CDCl3, 100 MHz 
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 215 
 
HPLC traces of rhamnose pentasaccharide run 
 
 
 
 
Analytical HPLC chromatogram of Rhamnose pentamer synthesis (1 mL/min 
flowrate, 20% Ethyl acetate/Hexane, 10 minute run). 
 
 
 
 
 
 
 
 216 
 
Allyl 2-O-acetyl-3,4-di-O-benzyl-α-L-rhamnopyranosyl-(1→2)-3,4-di-O-benzyl-α-L-
rhamnopyranosyl-(1→2)-3,4-di-O-benzyl-α-L-rhamnopyranosyl-(1→2)-3,4-di-O-benzyl-α-
L-rhamnopyranosyl-(1→2)- 3,4-di-O-benzyl-α-L-rhamnopyranoside (4) 
CDCl3, 400 MHz 
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Allyl 2-O-acetyl-3,4-di-O-benzyl-α-L-rhamnopyranosyl-(1→2)-3,4-di-O-benzyl-α-L-
rhamnopyranosyl-(1→2)-3,4-di-O-benzyl-α-L-rhamnopyranosyl-(1→2)-3,4-di-O-benzyl-α-
L-rhamnopyranosyl-(1→2)- 3,4-di-O-benzyl-α-L-rhamnopyranoside (4) 
CDCl3, 100 MHz 
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4-O-Benzyl-1,2-O-methylethylidene-β-L-rhamnopyranose 
CD3OD, 400MHz 
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4-O-Benzyl-1,2-O-methylethylidene-β-L-rhamnopyranose 
CD3OD, 100MHz 
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2-O-Acetyl-4-O-benzyl-3-O-tertbutyldimethylsilyl-β-L-rhamnopyranosyl 
Trichloroacetimidate (4)  
CDCl3, 400 MHz 
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2-O-Acetyl-4-O-benzyl-3-O-tertbutyldimethylsilyl-β-L-rhamnopyranosyl 
Trichloroacetimidate (4)  
CDCl3, 100 MHz 
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Allyl 4-O-benzyl-2,3-O-methoxyethylidene-α-L-rhamnopyranose (28) 
CD3OD, 400 MHz 
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Allyl 4-O-benzyl-2,3-O-methoxyethylidene-α-L-rhamnopyranose (28) 
CD3OD, 100 MHz 
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Allyl 2-O-acetyl-4-O-benzyl-α-L-rhamnopyranoside (30) 
CDCl3, 400 MHz 
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Allyl 2-O-acetyl-4-O-benzyl-α-L-rhamnopyranoside (30) 
CDCl3, 100 MHz 
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Allyl 2-O-acetyl-4-O-benzyl-3-O-levulinyl-α-L-rhamnopyranoside (31) 
CDCl3, 400 MHz 
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Allyl 2-O-acetyl-4-O-benzyl-3-O-levulinyl-α-L-rhamnopyranoside (31) 
CDCl3, 100 MHz 
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2-O-Acetyl-4-O-benzyl-3-O-levulinyl-α/β-L-rhamnopyranosyl Trichloroacetimidate (33) 
CDCl3, 400 MHz 
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2-O-Acetyl-4-O-benzyl-3-O-levulinyl-α/β-L-rhamnopyranosyl Trichloroacetimidate (33) 
CDCl3, 100 MHz 
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4-Methoxyphenyl 3,4-O-isopropylidene-β-D-galactopyranoside (10) 
CDCl3, 400 MHz 
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4-Methoxyphenyl 3,4-O-isopropylidene-β-D-galactopyranoside (10) 
CDCl3, 100 MHz 
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4-Methoxyphenyl 6-iodo-3,4-O-isopropylidene-β-D-galactopyranoside (11) 
CDCl3, 400 MHz 
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4-Methoxyphenyl 6-iodo-3,4-O-isopropylidene-β-D-galactopyranoside (11) 
CDCl3, 100 MHz 
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4-Methoxyphenyl 6-desoxy-3,4-O-isopropylidene-β-D-galactopyranoside (12)  
CDCl3, 400 MHz 
 
 
 
 
 
 
 
 
O
O
O
HO
OMP
 235 
 
4-Methoxyphenyl 6-desoxy-3,4-O-isopropylidene-β-D-galactopyranoside (12)  
CDCl3, 100 MHz 
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4-Methoxyphenyl 6-desoxy-3,4-O-isopropylidene-2-levulinoyl-β-D-galactopyranoside (13) 
CDCl3, 400 MHz 
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4-Methoxyphenyl 6-desoxy-3,4-O-isopropylidene-2-levulinoyl-β-D-galactopyranoside (13) 
CDCl3, 100 MHz 
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4-Methoxyphenyl 4-azido-3-O-benzyl-4,6-dideoxy-2-O-levulinoyl-α/β-D-glucopyranoside 
(15) 
CDCl3, 400 MHz 
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4-Methoxyphenyl 4-azido-3-O-benzyl-4,6-dideoxy-2-O-levulinoyl-α/β-D-glucopyranoside 
(15) 
CDCl3, 100 MHz 
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4-Azido-3-O-benzyl-4,6-dideoxy-2-O-levulinoyl-α-D-glucopyranosyl Trichloroacetimidate 
(5) 
CDCl3, 400 MHz 
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4-Azido-3-O-benzyl-4,6-dideoxy-2-O-levulinoyl-α-D-glucopyranosyl Trichloroacetimidate 
(5) 
CDCl3, 100 MHz 
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4-Methoxyphenyl 2-O-acetyl-4-azido-3-O-benzyl-4,6-dideoxy-α/β-D-mannopyranoside (16) 
CDCl3, 400MHz 
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4-Methoxyphenyl 2-O-acetyl-4-azido-3-O-benzyl-4,6-dideoxy-α/β-D-mannopyranoside (16) 
CDCl3, 100MHz 
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2-O-Acetyl-4-azido-3-O-benzyl-4,6-dideoxy-β-D-mannpyranosyl Tricloroacetimidate (17) 
CDCl3, 400 MHz 
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2-O-Acetyl-4-azido-3-O-benzyl-4,6-dideoxy-β-D-mannpyranosyl Tricloroacetimidate (17) 
CDCl3, 100 MHz 
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cis-4-(1H, 1H, 2H, 2H, 3H, 3H-Perfluoroundecyloxy)-2-butenyl 2-O-Acetyl-4-azido-3-O-
benzyl-4,6-dideoxy-α-D-mannopyranoside 
CDCl3, 400 MHz 
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cis-4-(1H, 1H, 2H, 2H, 3H, 3H-Perfluoroundecyloxy)-2-butenyl 2-O-Acetyl-4-azido-3-O-
benzyl-4,6-dideoxy-α-D-mannopyranoside 
CDCl3, 100 MHz 
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cis-4-(1H, 1H, 2H, 2H, 3H, 3H-Perfluoroundecyloxy)-2-butenyl 4-Azido-3-O-benzyl-4,6-
dideoxy-α-D-mannopyranoside (18) 
CDCl3, 400 MHz 
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cis-4-(1H, 1H, 2H, 2H, 3H, 3H-Perfluoroundecyloxy)-2-butenyl 4-Azido-3-O-benzyl-4,6-
dideoxy-α-D-mannopyranoside (18) 
CDCl3, 100 MHz 
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cis-4-(1H, 1H, 2H, 2H, 3H, 3H-Perfluoroundecyloxy)-2-butenyl 4-azido-3-O-benzyl-4,6-
dideoxy-β-D-glucopyranosyl-(1→3)-2-O-acetyl-4-O-benzyl-α-L-rhamnopyranosyl-(1→3)-2-
O-acetyl-4-O-benzyl-α-L-rhamnopyranosyl-(1→2)-3,4-O-benzyl-α-L-rhamnopyranoside (19) 
CDCl3, 400 MHz 
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cis-4-(1H, 1H, 2H, 2H, 3H, 3H-Perfluoroundecyloxy)-2-butenyl 4-azido-3-O-benzyl-4,6-
dideoxy-β-D-glucopyranosyl-(1→3)-2-O-acetyl-4-O-benzyl-α-L-rhamnopyranosyl-(1→3)-2-
O-acetyl-4-O-benzyl-α-L-rhamnopyranosyl-(1→2)-3,4-O-benzyl-α-L-rhamnopyranoside (19) 
CDCl3, 100 MHz 
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cis-4-(1H, 1H, 2H, 2H, 3H, 3H-Perfluoroundecyloxy)-2-butenyl 4-Azido-3-O-benzyl-4,6-
dideoxy-2-O-methyl-β-D-glucopyranosyl-(1→3)-2-O-acetyl-4-O-benzyl-α-L-
rhamnopyranosyl-(1→3)-2-O-acetyl-4-O-benzyl-α-L-rhamnopyranosyl-(1→2)-3,4-O-benzyl-
α-L-rhamnopyranoside 
CDCl3, 400 MHz 
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cis-4-(1H, 1H, 2H, 2H, 3H, 3H-Perfluoroundecyloxy)-2-butenyl 4-Azido-3-O-benzyl-4,6-
dideoxy-2-O-methyl-β-D-glucopyranosyl-(1→3)-2-O-acetyl-4-O-benzyl-α-L-
rhamnopyranosyl-(1→3)-2-O-acetyl-4-O-benzyl-α-L-rhamnopyranosyl-(1→2)-3,4-O-benzyl-
α-L-rhamnopyranoside 
CDCl3, 100 MHz 
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4-(1H, 1H, 2H, 2H, 3H, 3H-Perfluoroundecyloxy)-butyl 4,6-dideoxy-4-(3-hydroxy-3-
methylbutanamido)-2-O-methyl-β-D-glucopyranosyl-(1→3)- α-L-rhamnopyranosyl-(1→3)- 
α-L-rhamnopyranosyl-(1→2)- α-L-rhamnopyranoside (1) 
CD3OD, 400 MHz 
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4-(1H, 1H, 2H, 2H, 3H, 3H-Perfluoroundecyloxy)-butyl 4,6-dideoxy-4-(3-hydroxy-3-
methylbutanamido)-2-O-methyl-β-D-glucopyranosyl-(1→3)- α-L-rhamnopyranosyl-(1→3)- 
α-L-rhamnopyranosyl-(1→2)- α-L-rhamnopyranoside (1) 
CD3OD, 100 MHz 
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Ethyl 3-hydroxy-3-methylbutanoate (21) 
CDCl3, 400 MHz 
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3-Hydroxy-3-methylbutanoic acid (22) 
CDCl3, 400 MHz 
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3-Hydroxy-3-methylbutanoic acid (22) 
CDCl3, 100 MHz 
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cis-4-(1H, 1H, 2H, 2H, 3H, 3H-Perfluoroundecyloxy)-2-butenyl 2-O-acetyl-4-azido-3-O-
benzyl-4,6-dideoxy-α-D-mannopyranosyl-(1→2)-2-O-acetyl-4-azido-3-O-benzyl-4,6-
dideoxy-α-D-mannopyranosyl-(1→2)-2-O-acetyl-4-azido-3-O-benzyl-4,6-dideoxy-α-D-
mannopyranosyl-(1→2)-2-O-acetyl-4-azido-3-O-benzyl-4,6-dideoxy-α-D-mannopyranoside 
(23) 
CDCl3, 400 MHz 
 
 
 
O
BnO
O
N3
O O
C8F17
O
BnO
O
N3
O
BnO
O
N3
O
BnO
OAc
N3
 261 
 
cis-4-(1H, 1H, 2H, 2H, 3H, 3H-Perfluoroundecyloxy)-2-butenyl 2-O-acetyl-4-azido-3-O-
benzyl-4,6-dideoxy-α-D-mannopyranosyl-(1→2)-2-O-acetyl-4-azido-3-O-benzyl-4,6-
dideoxy-α-D-mannopyranosyl-(1→2)-2-O-acetyl-4-azido-3-O-benzyl-4,6-dideoxy-α-D-
mannopyranosyl-(1→2)-2-O-acetyl-4-azido-3-O-benzyl-4,6-dideoxy-α-D-mannopyranoside 
(23) 
CDCl3, 100 MHz 
 
O
BnO
O
N3
O O
C8F17
O
BnO
O
N3
O
BnO
O
N3
O
BnO
OAc
N3
 262 
 
 
 
 
 
 
 
 
 
 263 
 
4-(1H, 1H, 2H, 2H, 3H, 3H-Perfluoroundecyloxy)-butyl 4-(3-deoxy-L-glycero-tetronamido)-
4,6-dideoxy-α-D-mannopyranosyl-(1→2)-4-(3-deoxy-L-glycero-tetronamido)-4,6-dideoxy-α-
D-mannopyranosyl-(1→2)-4-(3-deoxy-L-glycero-tetronamido)-4,6-dideoxy-α-D-
mannopyranosyl-(1→2)-4-(3-deoxy-L-glycero-tetronamido)-4,6-dideoxy-α-D-
mannopyranoside (2) 
CD3OD, 400MHz 
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2,4-Benzylidene-(S)-1,2,4-butanetriol (25) 
CDCl3, 400 MHz 
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2,4-Benzylidene-(S)-1,2,4-butanetriol (25) 
CDCl3, 100 MHz 
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tert-Butyldimethylsilyl 3,6-di-O-benzyl-2-deoxy-2-trichloroacetimido-4-2H, 2H, 3H, 3H, -
perfluoroundecanoatyl-β-D-glucopyranoside (2) 
400 MHz, CDCl3 
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tert-Butyldimethylsilyl 3,6-di-O-benzyl-2-deoxy-2-trichloroacetimido-4-2H, 2H, 3H, 3H, -
perfluoroundecanoatyl-β-D-glucopyranoside (2) 
100 MHz, CDCl3 
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3,6-Di-O-benzyl-2-deoxy-2-trichloroacetimido-4-(2H, 2H, 3H, 3H-perfluoroundecanoyl)-α-
D-glucopyranosyl trichloroacetimidate (4) 
400 MHz, CDCl3 
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3,6-Di-O-benzyl-2-deoxy-2-trichloroacetimido-4-(2H, 2H, 3H, 3H-perfluoroundecanoyl)-α-
D-glucopyranosyl trichloroacetimidate (4) 
100 MHz, CDCl3 
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Allyl 3,4-di-O-benzyl-α-L-rhamnopyranoside (2)  
CDCl3, 400 MHz 
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Allyl 3,4-di-O-benzyl-α-L-rhamnopyranoside (2)  
CDCl3, 100 MHz 
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Allyl 3,4-di-O-benzyl-2-(2H, 2H, 3H, 3H-perfluoroundecanoatyl)-α-L-rhamnopyranoside (3) 
CDCl3, 400 MHz 
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Allyl 3,4-di-O-benzyl-2-(2H, 2H, 3H, 3H-perfluoroundecanoatyl)-α-L-rhamnopyranoside (3) 
CDCl3, 100 MHz 
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3,4-Di-O-benzyl-2-(2H, 2H, 3H, 3H-perfluoroundecanoatyl)-α/β-L-rhamnopyranoside (4) 
CDCl3, 400 MHz 
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3,4-Di-O-benzyl-2-(2H, 2H, 3H, 3H-perfluoroundecanoatyl)-α/β-L-rhamnopyranoside (4) 
CDCl3, 100 MHz 
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3,4-Di-O-benzyl-2-(2H, 2H, 3H, 3H-perfluoroundecanoatyl)-α/β-L-rhamnopyranosyl 
trichloroacetimidate (5) 
CDCl3, 400 MHz 
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3,4-Di-O-benzyl-2-(2H, 2H, 3H, 3H-perfluoroundecanoatyl)-α/β-L-rhamnopyranosyl 
trichloroacetimidate (5) 
CDCl3, 100 MHz 
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cis-4-(1H, 1H, 2H, 2H, 3H, 3H-Perfluoroundecyloxy)-2-butenyl 3,4-Di-O-benzyl-2-(2H, 2H, 
3H, 3H-perfluoroundecanoatyl)-α-L-rhamnopyranosyl-(1→2)-3,4-di-O-benzyl-α-L-
rhamnopyranosyl-(1→2)-3,4-di-O-benzyl-α-L-rhamnopyranosyl-(1→2)-3,4-di-O-benzyl-α-
L-rhamnopyranosyl-(1→2)-3,4-di-O-benzyl-α-L-rhamnopyranoside (9) 
CDCl3, 400 MHz 
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cis-4-(1H, 1H, 2H, 2H, 3H, 3H-Perfluoroundecyloxy)-2-butenyl 3,4-Di-O-benzyl-2-(2H, 2H, 
3H, 3H-perfluoroundecanoatyl)-α-L-rhamnopyranosyl-(1→2)-3,4-di-O-benzyl-α-L-
rhamnopyranosyl-(1→2)-3,4-di-O-benzyl-α-L-rhamnopyranosyl-(1→2)-3,4-di-O-benzyl-α-
L-rhamnopyranosyl-(1→2)-3,4-di-O-benzyl-α-L-rhamnopyranoside (9) 
CDCl3, 100 MHz 
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n-Pentenyl 2-O-acetyl-3,4-di-O-benzyl-α-L-rhamnopyranoside. 
CDCl3, 400 MHz 
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n-Pentenyl 3,4-di-O-benzyl-α-L-rhamnopyranoside (15) 
CDCl3, 400 MHz 
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n-Pentenyl 3,4-di-O-benzyl-α-L-rhamnopyranoside (15) 
CDCl3, 100 MHz 
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Allyl 2-O-acetyl-4-O-benzyl-α-L-rhamnopyranoside (12) 
CDCl3, 400 MHz 
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Allyl 2-O-acetyl-4-O-benzyl-α-L-rhamnopyranoside (12) 
CDCl3, 100 MHz 
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Allyl 2-O-acetyl-4-O-benzyl-3-O-{(1H, 1H, 2H, 2H-perfluorodecyl)-diisopropylsilyl}-α-L-
rhamnopyranoside (13) 
CDCl3, 400 MHz 
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Allyl 2-O-acetyl-4-O-benzyl-3-O-{(1H, 1H, 2H, 2H-perfluorodecyl)-diisopropylsilyl}-α-L-
rhamnopyranoside (13) 
CDCl3, 100 MHz 
 
 
 
 
 
 
O
BnO
O
OAc
O
Si
C8F17 i Pr
i Pr
 287 
 
2-O-Acetyl-4-O-benzyl-3-O-{(1H, 1H, 2H, 2H-perfluorodecyl)-diisopropylsilyl}-α/β-L-
rhamnopyranosyl trichloroacetimidate (14) 
CDCl3, 400 MHz 
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2-O-Acetyl-4-O-benzyl-3-O-{(1H, 1H, 2H, 2H-perfluorodecyl)-diisopropylsilyl}-α/β-L-
rhamnopyranosyl trichloroacetimidate (14) 
CDCl3, 100 MHz 
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Pent-4-enyl 2-O-acetyl-4-O-benzyl-3-O-{(1H, 1H, 2H, 2H-perfluorodecyl) diisopropylsilyl}-
α-L-rhamnopyranosyl-(1→2)-3,4-di-O-benzyl-α-L-rhamnopyranoside (11) 
CDCl3, 400 MHz 
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Pent-4-enyl 2-O-acetyl-4-O-benzyl-3-O-{(1H, 1H, 2H, 2H-perfluorodecyl) diisopropylsilyl}-
α-L-rhamnopyranosyl-(1→2)-3,4-di-O-benzyl-α-L-rhamnopyranoside (11) 
CDCl3, 100 MHz 
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cis-4-(1H, 1H, 2H, 2H, 3H, 3H-Perfluoroundecyloxy)-2-butenyl 2-O-acetyl-4-O-benzyl-α-L-
rhamnopyranosyl-(1→2)-3,4-di-O-benzyl-α-L-rhamnopyranosyl-(1→3)-2-O-acetyl-4-O-
benzyl-α-L-rhamnopyranosyl-(1→2)-3,4-di-O-benzyl-α-L-rhamnopyranosyl-(1→3)-2-O-
acetyl-4-O-benzyl-α-L-rhamnopyranosyl-(1→2)-3,4-di-O-benzyl-α-L-rhamnopyranoside (10) 
CDCl3, 400 MHz 
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cis-4-(1H, 1H, 2H, 2H, 3H, 3H-Perfluoroundecyloxy)-2-butenyl 2-O-acetyl-4-O-benzyl-α-L-
rhamnopyranosyl-(1→2)-3,4-di-O-benzyl-α-L-rhamnopyranosyl-(1→3)-2-O-acetyl-4-O-
benzyl-α-L-rhamnopyranosyl-(1→2)-3,4-di-O-benzyl-α-L-rhamnopyranosyl-(1→3)-2-O-
acetyl-4-O-benzyl-α-L-rhamnopyranosyl-(1→2)-3,4-di-O-benzyl-α-L-rhamnopyranoside (10) 
CDCl3, 400 MHz 
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